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Introduction
Thyroid hormone (TH) is essential for normal development and cellular metabolism. Be-
cause of the importance of TH for the developing brain, hypothyroidism - a defi ciency 
of TH - during early development can lead to severe defects in motor and mental 
development as illustrated by patients with untreated congenital hypothyroidism.1,2 
In adults, hypothyroidism can result in symptoms such as cold intolerance, fatigue, 
constipation and depression. In contrast, an excess of thyroid hormone -hyperthyroid-
ism - can cause an upregulation of metabolism leading to heat intolerance, weight loss 
and tachycardia.3,4 Serum TH levels are regulated by the hypothalamic-pituitary-thyroid 
(HPT) axis. The hypothalamus produces thyrothropin releasing hormone (TRH), which 
stimulates the production of thyroid-stimulating hormone (TSH) by the pituitary. TSH 
stimulates the thyroid gland to produce TH, predominantly the prohormone T4 and a 
small fraction of the bioactive hormone T3.5,6 In turn, T3 and T4 negatively regulate TRH 
and TSH synthesis as part of a feedback control mechanism. TH action is regulated at the 
cellular level: i.e. the intracellular TH availability is dependent on membrane transport 
and TH metabolism is mediated by deiodinating enzymes in the cell. The importance 
of these regulatory steps is illustrated by the severe consequences in patients with 
defects in thyroid hormone transport or deiodination (see below). Ultimately, T3 binds 
to TH receptors (TRs) in the nucleus, thereby modulating gene expression of T3-target 
genes.7
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Figure 1. TH transport, metabolism and action in a T3 target cell (adapted from Visser T.J. et al, Horm Res 
2007)
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Thyroid hormone synthesis
TH is produced by the thyroid gland, which is composed of follicles, constituted of thy-
rocytes that surround the colloid lumen. Iodide is required for TH synthesis. Therefore 
the Na/I symporter (NIS; SLC5A5) transports iodide across the basolateral membrane 
of the thyrocyte, after which the transporter Pendrin (SLC26A4) facilitates the efflux 
of iodide to the colloid lumen. In the colloid, iodide is oxidized by thyroperoxidase 
(TPO), which subsequently incorporates the oxidized iodide into tyrosyl residues of 
thyroglobulin (TG). By this organification reaction, mono- and diiodotyrosines (MIT and 
DIT) are formed. TPO also catalyzes the coupling of two DIT residues to form T4 and 
the addition of a MIT to a DIT, which results in T3. After proteolysis of thyroglobulin in 
lysosomes T4 and T3 are secreted into the circulation by transporters, including the 
monocarboxylate transporter MCT8. Iodine is recycled by deiodination of iodothyro-
nines by iodotyrosine dehalogenase (DEHAL1).8–11
Figure 2. Main steps in TH synthesis. By A. Bizhanova and P. Kopp, Endocrinology 2009
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Thyroid hormone transport
Since TH metabolism and action take place intracellular, TH transport across the plasma 
membrane is required. Initially, it was believed that the transfer of TH across the cell 
membrane occurred via passive diffusion. This assumption was based on the fact that 
TH has a lipophilic structure and thus could easily cross the lipid bilayer of the plasma 
membrane. Then a number of studies showed that TH uptake was saturable, ATP- and 
Na+-dependent in certain cell types, providing evidence for transporter proteins being 
responsible for TH translocation over the cell membrane.12,13 During the last decade, 
several TH transporter families in different species have been identified, including 
monocarboxylate transporters (MCTs), organic anion transporter polypeptides (OATPs), 
L-type amino acid transporters (LATs) and Na+/taurocholate co-transporting polypep-
tides (NTCP).14–22
MCT8
MCT8 (SLC16A2) belongs to the MCT family of transporters, comprising 14 members. 
Because MCT1–4 showed transport of monocarboxylates such as lactate and pyru-
vate, the family was named after this class of substrates.16,23 MCTs are proteins with 
12 predicted transmembrane domains with intracellularly localized N- and C-terminal 
domains. In humans, the MCT8 gene is located on the X-chromosome (Xq13.2) and 
contains 6 exons. First, the rat Mct8 (rMct8) was identified as a specific thyroid hormone 
transporter,14 after which the human MCT8 (hMCT8) was functionally characterized.14,24 
Several studies confirmed that the expression of hMCT8 markedly increased intracellular 
T3 and T4, and modestly increased concentrations of the TH metabolites rT3 and 3,3’-T2. 
After 10–30 minutes, TH uptake by hMCT8 reached a plateau phase, suggesting that 
MCT8 facilitates both TH uptake and efflux. This is supported by the observation that 
co-transfection of µ-crystallin (CRYM), a high-affinity TH-binding protein in cytoplasm, 
showed a decrease in TH efflux and an increase in TH uptake by hMCT8.25 MCT8/ Mct8 
is expressed in liver, kidney, thyroid, heart, brain, and placenta during gestation.26–29 Mu-
tations in MCT8 are associated with the Allan-Herndon-Dudley syndrome (AHDS), an 
X-linked disorder leading to severe psychomotor retardation.30,31 The clinical phenotype 
of patients with AHDS comprises severe mental retardation, axial hypotonia, dystonia, 
defective speech development, low body weight and muscular hypoplasia. On brain 
MRI a delayed myelination is seen and thyroid function testing shows increased serum 
T3, low T4 levels and a normal to elevated TSH.32–34 The pathogenesis of AHDS is not 
yet completely understood, but it is hypothesized that inactivating mutations in MCT8 
result in a hypothyroid state of MCT8-expressing neurons.35–38 Different Mct8 knock-
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out (KO) mouse models have been studied to explore the molecular mechanisms 
underlying the neurological and endocrinological abnormalities in ADHS patients.26,39 
Mct8 KO mice have similar endocrine abnormalities as ADHS patients. However, Mct8 
KO mice lack an overt neurological phenotype despite low levels of T3 and T4 in the 
brain.26,38,39 Several explanations for this have been postulated. First, the consequences 
of hypothyroidism on brain development in mice may differ from humans. Second, 
hMCT8 may be important for the transport of other ligands, essential for normal brain 
development in humans. Third, Mct8 deficiency may sufficiently be compensated by 
other TH transporters in mouse brain, such as Oatp1c1, Lat1 or Lat2. Oatp1c1 KO mice 
indeed show decreased T3 and T4 levels in the brain together with downregulation 
of TH responsive genes.38,40–45 Mct8/Oatp1c1 double KO (dKO) mice have a significant 
neurological phenotype together with a clear hypothyroid state in brain.41
MCT10
Another member of the MCT family is MCT10 (SLC16A10), also known as a T-type 
amino acid transporter (TAT).25,46,47 The human MCT10 gene is located on chromosome 
6q21-q22 and is highly homologous to the MCT8 gene (49 % amino acid identity).48 
In humans, MCT10 is expressed in liver, kidney, intestine, muscle and placenta.46,47,49 
MCT10 is an effective iodothyronine transporter, and also facilitates the cellular uptake 
and efflux of aromatic amino acids.25,47,49,50 So far, no patients with mutations in MCT10 
have been identified and the polymorphism in the 3’-UTR region of MCT10 was not 
associated with TH levels.51 Although transport of TH across the plasma membrane has 
been clearly demonstrated, MCT8 and MCT10 also facilitate efflux of TH out of the cell. 
Therefore it remains unclear if MCT8/MCT10 transported T3 is preferentially directed 
towards the nucleus thereby increasing the availability of TH for the nuclear receptors, 
or that a rapid equilibrium is reached near the plasma membrane.
OATPs
OATPs belong to the superfamily of solute carrier organic anion transporters (SLCO). 
The OATPs identified in humans are classified into 6 families based on their amino acid 
identity. The proteins are named OATP (Oatp in rodents) followed by the family number, 
the subfamily letter and a number indicating the individual member within the family. 
The corresponding genes are named in a similar way: SLCO followed by the same num-
ber-letter-number combination.52 OATPs are proteins with 12 transmembrane domains 
that mediate sodium-independent transport of amphipathic organic compounds, 
13
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including TH, steroids, bile salts, drugs and anionic oligopeptides.48,53–56 Most OATPs are 
expressed at the basolateral membrane of polarized cells in multiple tissues, including 
liver, kidney, lung, heart, small intestine, placenta, testis, the blood-brain barrier (BBB) 
and choroid plexus.54,57–59 Certain transporters show a more restricted tissue expression 
pattern, as will be discussed below.
Liver: Oatp/OATPs
In humans, OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) are considered to be 
liver-specific and are localized at the sinusoidal membrane of hepatocytes. OATP1B1 
is expressed throughout the lobule, while OATP1B3 is mainly expressed around the 
central vein.52,57,60–62 The selective expression in human liver suggests that OATP1B1 
and OATP1B3 play an important role in the hepatic clearance of albumin-bound am-
phipathic organic compounds. When expressed in Xenopus laevis oocytes, OATP1B1 
and OATP1B3 show transport of bile salts (e.g. taurocholate (TCA)), conjugated and 
unconjugated bilirubin, bromosulfophthalein (BSP), steroid conjugates, several drugs 
and the thyroid hormones T3 and T4.55,61,62 OATP1B1 and OATP1B3 have a single rodent 
orthologue, Oatp1b2 (Slco1b2). In X. laevis oocytes, the transport properties of Oatp1b2 
are very similar to the transport characteristics of OATP1B1 and OATP1B3.57,62,63 In hu-
mans, the tissue distribution of OATP1A2 (SLCO1A2) includes the BBB, distal nephron, 
ciliary body and liver. In human liver, OATP1A2 is expressed in cholangiocytes and in X. 
laevis oocytes it transports T4, T3 and reverse T3 (rT3) beside bile salts, organic anions 
and cations.55,64–66 OATP1A2 has four mouse homologs, including Oatp1a1, Oatp1a4, 
Oatp1a5 and Oatp1a6. In mouse liver, Oatp1a4 is higher expressed in females than in 
males, the opposite of Oatp1a1.55,67–70 Hyperthyroidism downregulates mRNA expres-
sion of Oatp1a1, Oatp1a4 and Oatp1b2.16,71,72 Several Oatp-knockout mice have been 
generated to define the function of the transporter. Oatp1b2 null mice show a normal 
development. However, in adult mice serum bilirubin levels are increased.71,73,74 In 
addition, it was observed that in transporter-deficient mouse models compensatory 
changes in the expression of other transporters occur, that contribute to the pheno-
type of the model. To minimize the likelihood of compensatory function by another 
Oatp superfamily member, an Oatp1a/1b knockout mouse was generated. In these 
mice, serum levels of conjugated bilirubin and unconjugated bile acids are markedly 
increased indicating that Oatp1a/1b transporters are essential for the hepatic uptake of 
these substrates in mice.75
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SLC10
In humans, the solute carrier transporter family 10 (SLC10) represents 7 genes that en-
code proteins of 248–477 amino acids. The SLC10 family includes the sodium taurocho-
late cotransporting polypeptide (NTCP, SLC10A1), the apical bile salt transporter (ASBT, 
SLC10A2), SLC10A3–5, the Na+-dependent organic anion transporter (SOAT, SLC10A6) 
and SLC10A7. Only 3 members (SLC10A1, SLC10A2 and SLC10A6) show Na+-dependent 
transport of substrates, like bile salts. NTCP is expressed at the basolateral membrane of 
hepatocytes, while ASBT is expressed at the apical membrane of cholangiocytes, ileum 
and renal proximal tubules. SOAT, expressed in adrenal gland, testis and placenta, can 
transport sulfated steroid metabolites and sulfated taurolithocholate. SLC10A3–5 and 
SLC10A7 are considered orphan transporters, since they show no transport activity.22,76,77
Liver: Ntcp/NTCPs
Human NTCP and rodent Ntcp (SLC10A1/Slc10a1) show a 77 % amino acid identity and 
code for proteins of 349 and 362 amino acids with 7 putative transmembrane domains. 
NTCP/Ntcp plays an important role in the enterohepatic circulation of bile salts. Bile 
salts are the major constituents of bile and are required for systemic energy homeosta-
sis. In addition, bile salts are important for the intestinal digestion of fat and absorption 
of fat-soluble vitamins. NTCP mediates the uptake of bile salts into hepatocytes and 
the export of bile salts across the canalicular membrane occurs by the ATP-dependent 
canalicular bile salt export pump BSEP.22,78–80 Hepatocellular bile salt uptake by NTCP is 
driven by the Na+-gradient maintained by the basolateral Na+, K+-ATPase together with 
the negative intracellular potential.81,82
NTCP is capable of transporting both conjugated as unconjugated bile acids in a Na+-
dependent manner, while OATPs have a preference for (Na+-independent) transport 
of unconjugated bile acids. In mice, inactivation of the Slco1a/1b subfamily resulted in 
normal serum levels of conjugated bile salts and highly elevated levels of unconjugated 
bile acids. However, Slco1b2 KO mice have slightly elevated levels of unconjugated bile 
acids with normal bile salt levels in serum. These observations suggest that Ntcp is a 
poor transporter for unconjugated bile acids in mice.75,83 In conditions of hepatocel-
lular bile acids accumulation, such as cholestasis, the expression of Ntcp is strongly 
down-regulated. This is considered a hepatic defense mechanism to the overload of 
potentially toxic bile acids.79,84,85 Besides its role in bile acids homeostasis, Ntcp is also 
able to transport sulfated steroids, thyroid hormones, and xenobiotics.21,86
Beside their role in the enterohepatic circulation of bile salts, liver-specific transport-
ers such as OATPs and NTCP, are important in the maintenance of lipid and energy 
15
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homeostasis by TH. It is necessary to gain insight in the characteristics of these different 
transporters since liver-specific thyromimetics, of which Eprotirome and Sobetirome 
(GC-1) are the best studied in humans, are interesting compounds that can have great 
benefits on for example dyslipidemia, metabolic syndrome and hepatic steatosis with-
out systemic side effects.
PDZ domains
Many members of the OATP/Oatp family have a highly conserved PDZ consensus-
binding motif in their C-terminus. PDZ is an acronym combining the first letters of three 
proteins (Postsynaptic density protein PSD95, Drosophila septate junction protein 
discs-large Dlg1, and the epithelial zonula occludens-1 protein ZO-1), which were first 
described to share the domain. The PDZ domain is a structural domain of 80–90 amino 
acids found in signaling proteins. PDZ domains mediate specific protein-protein inter-
actions and proteins containing PDZ domains play a role in protein complex assembly, 
in particular at cellular membranes. Based on crystal structures of known PDZ domains, 
three classes of PDZ consensus binding sites have been defined. PDZ consensus sites 
that are present in the hepatic OATP/Oatps are all of Class 1, defined by the sequence 
X-S/T-X-φ, where X represents any amino acid and φ is a hydrophobic amino acid. De-
spite the large number of described PDZ proteins, it is hard to predict which if any will 
bind a particular protein with a PDZ consensus-binding site.87–89 It has been shown that 
expression of rat Oatp1a1 at the plasma membrane requires interaction with PDZK1, a 
70-kDa protein with 4 independent PDZ domains.89
Thyroid hormone metabolism: deiodination
Intracellular TH concentrations are accurately controlled by 3 deiodinating selenoen-
zymes, each with a distinct substrate preference, tissue expression and mode of action. 
Table 1 illustrates the specific characteristics of the deiodinases type 1 (D1), type 2 (D) 
and type 3 (D3).
D1 and D2 convert the prohormone T4 to bioactive T3 by outer ring deiodination, while 
D3 inactivates T4 to rT3 and T3 to 3,3’-T2 by inner ring deiodination.90,91
D1 is expressed in liver, kidney, thyroid and pituitary. In particular hepatic D1 activity is 
considered to contribute to serum T3 levels by converting T4 to T3. Evidence for this 
includes the observation that both hepatic D1 activity and plasma T3 levels decrease 
in conditions such as fasting and critical illness.92 On the other hand, D1 seems to be 
positively regulated by T3 and D1KO mice have normal serum T3 concentrations.93 In 
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addition, D1 shows a higher catalytic effi  ciency for rT3 compared to T4. These observa-
tions suggest that D1 could play a more important role in recycling iodide from inactive 
iodothyronines for reuse in the thyroid gland. No human mutations in DIO1 have been 
reported yet.
D2 is expressed in the central nervous system, pituitary, skeletal muscle, brown adipose 
tissue and the reproductive tract, where it regulates local TH homeostasis.94–96 D2 func-
Table 1. Characteristics of human iodothyronine selenodeiodinases. (Adapted from Bianco and Kim, J Clin 
Invest. 2006)
D1 D2 D3
Biochemical properties
Molecular weight (kDa) 29 30.5 31.5
Preferred substrate rT3 T4, rT3 T3, T4
Km 10-7 10-9 10-9
Half-life Hours ± 20 min Hours
Subcellular localization Plasma membrane Endoplasmic reticulum Plasma membrane
Susceptibility to PTU High Low Low
Tissues with high activity Liver, kidney CNS, pituitary, brown adipose 
tissue, placenta
CNS, placenta
Response to elevated T3 & T4
Transcriptional ↑↑ ↓ ↑↑
Translational ? ↓↓↓ (ubiquitination) ?
Physiological role rT3 clearance Thermogenesis, development, 
to provide intracellular and 
plasma T3
T3 and T4 clearance
Physiological regulation
Induction T3 Cold exposure, catecholamines Tissue injury, T3
Repression Fasting, illness T3 Glucocorticoids
	
	
	
D3,	D1	
D2,	D1	 D2,	D1	
D3	
T4	 rT3	
T3	 T2	
Figure 3. Deiodinase reactions. Adapted from Bianco and Kim, J Clin Invest. 2006
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tions as a TH activating enzyme, however it is unclear to what extent D2 contributes 
to serum T3 levels. The observation that D2 is upregulated by hypothyroidism and 
downregulated in hyperthyroidism, illustrates that thyroid status controls D2 activity 
and vice versa, changes in D2 activity contribute to the plasma and cellular levels of T3. 
The expression of D2 is inversely regulated by T4 and rT3, by induction of ubiquitination 
at the posttranslational level.97 However, D2KO mice show normal serum T3 concentra-
tions. Serum T4 and TSH levels in these mice are increased, suggesting that the pituitary 
of D2KO mice is resistant to the feedback effect of plasma T4.90,91,98 In addition, D2KO 
mice display only a mild neurological phenotype despite strongly decreased brain T3 
levels. This favors the suggestion that important compensatory mechanisms in brain 
must be involved in the absence of D2.99 To date, no mutations in the human DIO2 gene 
have been described. However, patients with mutations in the SECIS-binding protein 
SBP2, showed decreased DIO2 enzymatic activity in combination with decreased serum 
T3 concentrations and increased T4, rT3 and TSH levels. SBP2 is important for the syn-
thesis of selenoproteins, such as the deiodinases.100,101
D3 is an inactivator of TH and serves as a modulator of intracellular TH levels by catalyz-
ing the conversion of the bioactive T3 and T4 into the inactive T2 and rT3 metabolites. 
DIO3 is subject to genomic imprinting and is preferentially expressed from the paternal 
allele. D3 is highly expressed in fetal tissues, where it is responsible for low TH levels 
during early development. D3KO mice show neonatal mortality, growth retardation 
and abnormal serum TH concentrations. In adult life, D3 activity is only detectable in 
central nervous system, skin and placenta.102 In other tissues, e.g. liver, skeletal muscle, 
D3 can be re-activated in conditions of critical illness and injury.103,104 As for the other 
deiodinases, no mutations in DIO3 have been identified so far.
TH action
An optimal intracellular TH concentration is required for TH action, which is mediated 
by binding of the bioactive T3 to nuclear TH receptors (TRs). TRs belong to the nuclear 
receptor superfamily of ligand-inducible transcription factors. Preferentially, TRs bind to 
TH response elements (TREs) in target gene promoters as heterodimers with retinoid 
X receptors (RXRs), thereby regulating target gene expression. In the absence of TH, 
unliganded TRs recruit corepressors (e.g. nuclear receptor corepressor [NCoR], silencing 
mediator for retinoic acid and thyroid receptors [SMRT]) and histone deacetylase (HDAC), 
thereby repressing basal transcription of genes that are positively regulated by TH. Bind-
ing of T3 to TRs results in dissociation of the corepressor complex and recruitment of 
coactivator proteins (e.g. steroid receptor coactivator 1 [SRC-1], CREB-binding protein 
[CBP], and CBP-associated factor [pCAF]), which induce transcriptional activation.7,105–107 
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In humans, TRs are encoded by two genes (THRA and THRB) on chromosomes 17 and 3, 
respectively. By alternative splicing two different isoforms, which differ in their carboxy-
terminal regions, are generated from the THRA locus: TRα1 is ubiquitously expressed 
in the central nervous system (CNS), bone, heart, skeletal muscle and gastrointestinal 
tract while the non-T3 binding isoform TRα2 is more widely expressed (e.g. brain and 
testis). From the THRB locus two receptor proteins are generated: TRβ1 and TRβ2, which 
differ in their amino-terminal regions. TRβ1 is considered the major isoform in liver, 
kidney and thyroid. TRβ2 has a more restricted expression pattern regulating neuro-
sensory development as well as the HPT-axis.67,108,109 Since 1986 it has been known that 
heterozygous mutations within three hotspots of the ligand-binding domain (LBD) of 
TRβ result in resistance to thyroid hormone β (RTHβ), a clinical syndrome that was rec-
ognized two decades earlier as refractoriness to TH. The incidence of RTHβ is estimated 
1 in 40,000 and numerous mutations have been identified so far. Patients with RTHβ are 
characterized by elevated serum TH levels, a non-suppressed TSH, and a variable phe-
notype comprising goiter, tachycardia and increased energy expenditure.7,110 Human 
TRβ and TRα are highly homologous, in particular in their hormone binding domains, 
showing an overall 80 % amino acid identity. Taking into account the large number of 
different TRβ mutations associated with RTHβ, the identification of mutations in TRα 
had been anticipated. In an attempt to predict the clinical consequences of a defective 
TRα, several knockin and knockout mouse models have been generated. Interestingly, 
mice harboring different, heterozygous TRα mutations are viable and exhibit recogniz-
able abnormalities. However these mice have a near-normal thyroid function.111–114 Due 
to the absence of a clear biochemical thyroid phenotype, no human mutation in THRA 
was reported until 2012.
19
GENERAL INTRODUCTION
Outline of the thesis
The work in this thesis focuses on the molecular mechanisms of TH action at the level 
of transporters and receptors. Hereby, we report on various aspects of thyroid hormone 
and thyroid hormone analogs transport in liver. In addition, we describe a wide spec-
trum of RTHα phenotypes and elaborate on the role of TRα in human erythropoiesis.
In chapter 2 we investigated to what extent the thyroid hormone transporters MCT8 
and MCT10 modulate T3 availability for binding to its thyroid hormone receptor in the 
cell nucleus and its metabolism by type 3 deiodinase at the cell periphery.
In chapter 3 and chapter 4 we explored the characteristics of different human and 
mouse liver-specific thyroid hormone transporters (OATPs and NTCPs) and compared 
their role in the transport of thyroid hormone and thyroid hormone analogs such as 
Eprotirome and GC-1.
In Chapter 5 we report on the youngest patient identified with RTHα so far, which was 
treated with levothyroxine from very young age.
In chapter 6 we describe a total of 10 RTHα patients with three different mutations in 
TRα. This large case series enables us to report on the diversity in the RTHα phenotype 
and compare the phenotypes of both affected and non-affected individuals from a 
family with the same mutation.
In chapter 7 we report on the role of TRα in erythropoiesis and the pathogenesis of 
anemia, which seems to be a frequently appearing characteristic in RTHα.
In chapter 8 we present an overview of the clinical and biochemical characteristics of 
all patients identified with RTHα to date. Here we discuss the genetic basis and molecu-
lar pathogenesis of the disorder together with the effects of levothyroxine treatment.
In chapter 9 we discuss the findings presented in this thesis in view of the current 
literature and we explore possible implications of these studies.
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Abstract
Transport of thyroid hormone (TH) across the plasma membrane is necessary for the 
genomic action of T3 mediated by its nuclear T3 receptor. MCT8 and MCT10 have been 
identified as important TH transporters. Mutations in MCT8 result in severe psychomo-
tor retardation. In addition to TH transport into the cell, MCT8 and MCT10 also facilitate 
TH efflux from cells. Therefore, the aim of this study was to examine if MCT8 and MCT10 
increase the availability of T3 for its nuclear receptor rather than generate a rapid equi-
librium between cellular and serum T3.
T3 action was investigated in JEG3 cells co-transfected with TRβ1 and a T3 response el-
ement-driven luciferase construct, and T3 metabolism was analyzed in cells transfected 
with type 3 deiodinase (D3). In addition, cells were transfected with MCT8 or MCT10 
and/or the cytoplasmic T3-binding protein mu-crystallin (CRYM). Luciferase signal was 
markedly stimulated by incubating cells for 24 h with 1 nM T3, but this response was 
not augmented by MCT8 or MCT10 expression. Limiting the time of T3 exposure to 
1–6 hours and co-transfection with CRYM allowed for a modest increase in luciferase 
response to T3. In contrast, T3 metabolism by D3 was potently stimulated by MCT8 or 
MCT10 expression, but it was not affected by expression of CRYM.
These results suggest that MCT8 and MCT10 by virtue of their bidirectional T3 transport 
have less effect on steady-state nuclear T3 levels than on T3 levels at the cell periphery 
where D3 is located. CRYM alters the dynamics of cellular TH transport but its exact 
function in the cellular distribution of TH remains to be determined.
23
EFFECTS OF MCT8 AND MCT10 ON NUCLEAR ACTIVITY OF T3
Introduction
Lack of thyroid hormone (TH) in early life leads to severe neurological dysfunction.1,115,116 
TH regulates gene expression via binding of the biological active hormone T3 to its 
nuclear receptor (TR), which is bound to a T3 response element (TRE) in the promo-
tor region of target genes. To mediate its effects, TH must first be transported across 
the plasma membrane by specific transporters. Several TH transporters from different 
families have been identified, such as organic anion transporting polypeptides (OATP), 
bile acid transporters, L-type amino acid transporters (LAT) and monocarboxylate 
transporters (MCT).117 Two highly homologous monocarboxylate transporters, MCT8 
and MCT10, are so far the only identified transporters with a high activity and specificity 
for TH.14,24,25,118
MCT8 is expressed in neurons and at the blood-brain barrier.35,36,42,44,119–121 Other expres-
sion sites are the heart, placenta, kidney, liver and the adrenal glands.29,42 Inactivating 
mutations in MCT8 result in the X-linked Allan-Herndon-Dudley syndrome (AHDS) 
characterized by severe psychomotor retardation and abnormal serum TH levels (high 
serum T3, low T4 and normal TSH levels).30,31,122,123 Patients with AHDS also suffer from 
hypotonia, muscular hypoplasia, and a delayed development and myelination.122,124 The 
complete pathogenesis of AHDS is not yet completely understood, but it is hypoth-
esized that AHDS is due to a hypothyroid state of the MCT8-expressing neurons as a 
result of the inactivating mutations in MCT8.35–38,124 In contrast to humans, MCT8 KO 
mice do not show a neurological phenotype, although they have very similar abnormal 
serum TH levels as AHDS patients and low T3 levels in the brain.26,39,42 The absence of 
brain abnormalities in MCT8 KO mice may be explained by the more abundant expres-
sion of OATP1C1 at the blood-brain barrier in mice than in humans.44,125
MCT10, the highly homologous family member of MCT8, is expressed in multiple tis-
sues, including intestine, kidney, liver, muscle, and placenta37,47 (Nishimura and Naito, 
2008). There is little expression of MCT10 in the brain.126 In contrast to MCT8, no patients 
with mutations in MCT10 have been identified so far. Apart from TH, MCT10 is also 
capable of transporting amino acids.25
MCT8 and MCT10 facilitate not only the cellular uptake but also the efflux of TH from cells. 
It is therefore unclear if MCT8/MCT10 transported T3 is preferentially directed towards 
the nucleus, thereby increasing the availability of TH for its nuclear receptors, or that it 
results in a rapid equilibrium near the plasma membrane. We therefore investigated if 
the presence of MCT8 and MCT10 has an effect on directing T3 to the nucleus, thereby 
increasing the availability of T3 for its nuclear receptors. This was done by analyzing 
the effects of the overexpression of MCT8 or MCT10 on the TRβ1-mediated stimulation 
of a TRE-driven luciferase reporter by T3 in JEG3 human choriocarcinoma cells, which 
show low endogenous expression of TH transporters (Capri, Friesema, Kersseboom et 
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al., 2013). The findings were compared with the effects of MCT8 and MCT10 on the 
metabolism of T3 by type 3 deiodinase (D3) located in the plasma membrane.127 In ad-
dition, we studied the effects of the cytoplasmic TH-binding protein µ-crystallin (CRYM) 
on the availability of T3 for binding to its receptor in the cell nucleus and its metabolism 
by D3 at the cell periphery.
Material and methods
Materials
Unlabeled T3 was obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands [NL]). 
Na125I was obtained from Perkin Elmer (Groningen, NL). [3’-125I]T3 was prepared as previ-
ously described.128
Plasmids
Human MCT8,24 MCT10,25 CRYM,25 and D324 plasmids were obtained as previously 
described. hTRβ1 was cloned into the pcDNA3.1 expression vector by Dr. W.M. van der 
Deure (Erasmus MC, Rotterdam, NL). N-terminal Flag-tagged hTRβ1 with an optimized 
Kozak translation start site was also constructed in pcDNA3. The pdV-L1 construct con-
taining a T3 responsive firefly luciferase (LUC) reporter and a control renilla luciferase 
(REN) reporter was kindly provided by Dr. W.S. Simonides (VU Medical Center, Amster-
dam, NL).129 Both LUC and REN genes are driven by the SERCA1 minimal promoter, and 
two T3 response elements (TREs) are inserted in front of the minimal promoter of the 
LUC gene.
Cell culture
JEG3 cells were cultured at 37 C and 5 % CO2 in DMEM/F12 medium (Invitrogen, Ble-
iswijk, NL) supplemented with 9 % heat-inactivated fetal bovine serum (FBS) and 100 
nM Na2SeO3 (Sigma-Aldrich).
[125I]T3 transport
JEG3 cells were cultured in 24 or 96-well plates and transiently transfected with 
various combinations of pdV-L1, hTRβ1 or Flag-hTRβ1, hMCT8 or hMCT10, hCRYM, 
and/or hD3, and the total amount of plasmid was brought to 60–75 ng (96 wells) or 
200 ng (24 wells) with empty pcDNA3. Transfection was performed according to the 
manufacturer’s protocol using FuGene6 or X-tremeGENE9 (Roche, Almere, NL). In some 
experiments, cells were washed and incubated for 24 hours with 500 µl DMEM/F12 
containing charcoal-stripped FBS prior to transfection. Two days after transfection, cells 
were washed twice with 200 µl (96 wells) or 500 µl (24 wells) DMEM/F12 + 0.1 %BSA and 
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incubated for different time periods at 37 C and 5 % CO2 with 100 µl (96 wells) or 500 µl 
(24 wells) DMEM/F12 + 0.1 %BSA with 1 nM T3 and 10,000 cpm (96 wells) or 50,000 cpm 
(24 wells) [125I]T3. After incubation, the cells were again washed, lysed with 0.1 M NaOH, 
and counted for radioactivity.
Intact cell T3 metabolism
JEG3 cells were transfected as described above for the uptake assay in 96 well plates. 
Incubations were performed for different time periods at 37 C and 5 % CO2 with 1 nM 
T3 and 100,000 cpm [125I]T3 in 100 µl DMEM/F12 + 0.1 %BSA. Next, 100 µl medium was 
added to 100 µl ice-cold ethanol. The mixtures were incubated for 30 minutes on ice, 
and then centrifuged for 15 minutes at 3500 rpm and 4 C. Finally, 100 µl supernatant 
was mixed with 100 µl 0.02M ammonium acetate (pH 4.0), and the samples were ana-
lyzed by HPLC as previously described.24
Luciferase activity
Two days after transfection, cells were incubated for the different time periods with 
1 nM T3. After washing and replacement with medium without T3, incubations were 
continued for a total time of 24 hours. LUC and REN activities were determined as previ-
ously described.130 T3 has only a small effect on REN activity compared with its effect on 
LUC expression. Results are presented as LUC/REN ratio but are not essentially different 
from the absolute LUC activity.
Statistical tests
All experiments were performed in triplicate and presented as mean ± SEM.of n experi-
ments. Statistical differences were calculated using Student’s t-test or a 2-way ANOVA 
followed by Bonferroni post-hoc test, as indicated in the figure legends. P < 0.05 was 
considered significant.
Results
The transcriptional activity of T3 was studied using JEG3 cells transfected with human 
TRβ1 and a construct expressing LUC under control of a TRE-dependent promoter and 
REN under control of a constitutive promoter. Initial experiments were conducted under 
steady-state conditions, where cells were incubated for 24 hours without or with 1 nM 
T3. As demonstrated before using TRα1,130 this resulted in a marked stimulation of the 
LUC/REN ratio. To investigate if MCT8 or MCT10 increase the nuclear availability of T3, 
the effect of 24-hour incubation with 1 nM T3 was also studied in cells co-transfected 
with plasmids coding for MCT8 or MCT10. Remarkably, this did not result in any further 
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Figure 1.
(A, B) Functional analysis of JEG3 cells co-transfected with a TRE-regulated LUC and control REN construct 
and TRβ1 in combination with either empty vector, MCT8 or MCT10, without (A) or with (B) CRYM. Cells 
were incubated for 24 hours without or with 1 nM T3. Values represent means ± SEM of 5 experiments 
performed in triplicate. ns, not significant vs. cells without transporter.
(C, D) 24-hour uptake of 1 nM [125I]T3 in JEG3 cells in the absence (C) or presence (D) of CRYM. Cells were 
transiently transfected with empty vector, MCT8 or MCT10. Values represent means ± SEM of 3 experiments 
performed in triplicate. ns, not significant vs. cells without transporter.
(E, F) 24-hour metabolism in JEG3 cells of [125I]T3 in the absence (E) or presence (F) of CRYM. Cells were 
transfected with empty vector, MCT8 or MCT10, with or without D3. Values represent means ± SEM of 2 
experiments performed in triplicate; ** P < 0.01 vs. cells without transporter.
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increase in the T3-stimulated LUC/REN ratio compared with control cells transfected 
with empty plasmid (Figure 1A).
Cellular uptake of 1 nM [125I]T3 was determined in parallel 24-hour incubations, showing 
that transfection with MCT8 or MCT10 did not stimulate cellular T3 accumulation under 
these steady-state conditions (Figure 1C). This is in keeping with previous observations 
that MCT8 and MCT10 facilitate both cellular T3 influx and efflux. Therefore, expres-
sion of MCT8 or MCT10 has little effect on the steady-state cellular T3 concentration 
in the presence of other, endogenous transporters. It has also been shown previously 
that expression of the cytoplasmic T3 binding protein µ-crystallin (CRYM) markedly 
augments the cellular accumulation of T3 induced by MCT8 or MCT10 during short 
incubations. However, co-transfection with CRYM did not enable MCT8 or MCT10 to 
stimulate the transcriptional activity (Figure 1B) or cellular uptake (Figure 1D) of T3 in 
these prolonged incubations.
Little metabolism of T3 was observed during 24-hour incubation with JEG3 cells 
transfected with empty vector, MCT8 or MCT10 alone or in combination with CRYM 
(Figure 1E,F). About 25 % of added T3 was metabolized in parallel incubations with cells 
transfected with D3 alone or in combination with CRYM. Co-transfection of MCT8 or 
	
Figure 2.
Cellular accumulation of [125I]T3 in cells transfected with empty vector, MCT8 or MCT10 without or with 
CRYM as function of incubation time (0.5–24 hours). Interrupted lines indicate the loss of cellular T3 when 
[125I]T3-containing medium is replaced at the indicated time points with T3 deplete medium and the in-
cubation continued for a total period of 24 hours. Results are the means of 2 experiments performed in 
triplicate.
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MCT10 resulted in a similar, marked stimulation of T3 metabolism, amounting to ~75 % 
and ~90 % of added T3 in the absence or presence of CRYM, respectively (Figure 1E,F).
Since expression of MCT8 or MCT10 in the absence or presence of CRYM did not have 
a significant effect on the steady-state cellular and nuclear accumulation of T3 during 
prolonged incubations, we decided to test shorter incubation times. Therefore, JEG3 
cells transfected with the various constructs were incubated for 0.5–24 hours with 1 nM 
T3; after replacing the medium with T3 deplete medium the incubation was continued 
until a total period of 24 hours to allow sufficient synthesis of reporter activity. Figure 2 
shows that in the absence of CRYM, expression of MCT8 or MCT10 stimulated the cel-
lular accumulation of T3 only during the first 30 minutes of incubation.
However, in the presence of CRYM, expression of MCT8 or MCT10 resulted in the marked 
stimulation of T3 uptake during at least 6 hours of incubation. Therefore, we decided 
to test the effects of MCT8 and MCT10 in the absence or presence of CRYM on the 
uptake, nuclear activity and D3-mediated metabolism during a 4-hour incubation with 
T3. In addition, the effects of co-transfection with D3 were studied on the cellular ac-
cumulation and transcriptional activity of T3. Figure 3A shows that expression of MCT8 
or MCT10 in the absence of CRYM had no significant effect on the cellular accumulation 
of T3 during 4 hours of incubation.
Transfection of cells with CRYM alone did not markedly stimulate T3 uptake over the 
4-hour period (Figure 3B). However, transfection of CRYM-expressing cells with MCT8 
or MCT10 stimulated cellular T3 accumulation 2 and 3-fold, respectively. Expression 
of MCT8 or MCT10 in the absence of CRYM did not have a significant effect on the 
transcriptional activity induced by exposure of the cells for 4 hours to T3 (Figure 3C). 
Transfection of the cells with CRYM alone resulted in a significant decrease in nuclear 
T3 activity (Figure 3D). However, transfection of CRYM-expressing cells with MCT8 or 
MCT10 resulted in the stimulation of the transcriptional activity of T3 to levels at or 
above those observed in cells expressing MCT8 or MCT10 in the absence of CRYM.
In these short incubations, T3 metabolism was again negligible in cells transfected 
with empty vector, MCT8, MCT10 or CRYM alone (Figure 3E,F). About 5 % of added T3 
was metabolized during 4-hour incubation with cells expressing D3 in the absence or 
MCT8 or MCT10, and this was increased to about 30 % after co-transfection with MCT8 
or MCT10. The metabolism of T3 by D3 in MCT8 or MCT10-expressing cells was not 
affected by co-transfection of CRYM. Expression of D3 reduced the cellular uptake and 
transcriptional activity of T3 independent of the expression of CRYM and completely 
prevented the stimulation of T3 uptake and nuclear activity induced by MCT8 or MCT10 
observed in the presence of CRYM (Figure 3E,F).
Finally, the transcriptional activity induced by incubation of the variously transfected 
cells for different time periods with 1 nM T3 was studied as a function of time-integrated 
cellular T3 concentration. By plotting the percentage of T3 uptake against time, the 
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area under the curve represents the intracellular T3 concentration during the whole 
incubation period (Figure 2A). There was a good correlation between the integrated 
cellular T3 concentration and the luciferase response to T3, both in the absence and 
presence of CRYM. However, the intracellular T3 concentrations associated with similar 
T3 responses were higher in the presence than in the absence of CRYM (Figure 4).
	
Figure 3.
Cellular uptake (A,B), nuclear activity (C,D) and metabolism (E,F) of 1 nM T3 incubated for 4 hours with 
JEG3 cells co-transfected with reporter construct and Flag-TRβ1 plus MCT8, MCT10, CRYM and/or D3. In 
(C) and (D), incubations were continued with T3 deplete medium until 24 hours to allow sufficient time for 
luciferase synthesis. Results are the means ± SEM of 2–4 experiments performed in triplicate; * P < 0.05, ** 
P < 0.01, *** P < 0.001 vs. cells without transporter.
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Discussion
In the current study we demonstrate that transfection of JEG3 cells with MCT8 or MCT10 
has widely different effects on the binding of T3 to the nuclear receptor compared with 
its deiodination by D3 located in the cell membrane.
A schematic overview of the data is presented in Figure  5. Figure  5A represents a 
non-transfected JEG3 cell where cellular T3 uptake and efflux is mediated by endog-
enous transporters. In MCT8 or MCT10 overexpressing cells, both T3 influx and efflux 
are increased. Therefore, steady-state intracellular T3 levels and thus nuclear receptor 
binding are hardly affected (Figure 5B). In D3 expressing cells, T3 is degraded to 3,3-T2, 
resulting in decreased nuclear T3 receptor activation (Figure  5C). Transfection of D3 
expressing cells with MCT8 or MCT10 stimulates T3 metabolism but does not increase 
nuclear availability of T3 (Figure 5D). The cytoplasmic binding protein CRYM decreases 
T3 efflux and thus enhances the transient increase in cellular T3 accumulation in MCT8 
or MCT10 overexpressing cells. Consequently, nuclear receptor activation is stimulated 
by expression of MCT8 or MCT10 during short T3 exposure times (Figure 5E). However, 
co-transfection of D3 completely prevents T3 action even in the presence of CRYM and 
MCT8 or MCT10, suggesting that cellular T3 is degraded before it can reach the nuclear 
receptor (Figure 5F).
	Figure 4.
T3-stimulated reporter activity as a function of T3 accumulation in JEG3 cells transfected with reporter con-
struct and TRβ1 plus empty vector, MCT8, MCT10, and/or CRYM. Cells were incubated for 0.5–24 hours with 
1 nM T3 and subsequently until a total period of 24 hours in the absence of T3 to allow sufficient luciferase 
synthesis. The experiment was performed in triplicate. FC: fold change, AUC: area under the curve.
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Figure 5.
Schematic representation of a TH target cell with overexpression of MCT8/10, CRYM and/or D3. T3 respon-
sive gene expression is controlled by a positively regulated TRE.
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Inactivating mutations in MCT8 lead to AHDS.122,123 MCT10, the highly homologous 
family member of MCT8, has been studied in less detail and no patients with mutations 
in MCT10 have yet been identified.
Overexpression of MCT8 or MCT10 stimulates T3 uptake, resulting in a rapid rise in intra-
cellular T3 concentration, as we have shown previously.24,25 Nevertheless, the increased 
uptake results in only a modest increase in biological activity of T3. This is explained 
by the fact that both MCT8 and MCT10 are also capable of T3 efflux, leading to a rapid 
equilibrium between influx and efflux.24,25 Interestingly, some patients with AHDS have 
a milder phenotype, which has been ascribed to a greater impact of their mutations on 
the efflux than on the uptake of TH by MCT8.131,132
Co-transfection of either MCT8 or MCT10 greatly stimulates T3 metabolism by D3, con-
firming our earlier findings.24 Rapid degradation by D3 reduces the nuclear availability 
of T3, irrespective of the transfection with MCT8 or MCT10. D3 is mainly present in fetal 
tissues and its expression level declines after birth.133,134 A major site of action of D3 
is the central nervous system, where it acts primarily in neurons.102,135 It was recently 
shown in mice that D3 protects the cerebellum from high TH levels during fetal life and 
in the neonatal period.136 Our data suggest that TH transporters can only raise intracel-
lular T3 concentrations when D3 activity is low.
Expression of the intracellular binding protein CRYM inhibits the efflux of T3.137 This 
extends the period after addition of T3 during which MCT8 or MCT10 increase intra-
cellular T3 before equilibrium is reached between T3 influx and efflux. We utilized this 
property of CRYM in our in vitro testing system, but the possible physiological roles for 
CRYM are intriguing. It has homology to enzymes involved in glutamate and ornithine 
metabolism, and T3 binding to CRYM depends on NADPH and thiol cofactors.137,138 It 
has been hypothesized that CRYM may play a role in the delivery of TH to mitochondria 
or to the nucleus, depending on the redox state of the cytoplasm.138 CRYM has recently 
been identified as an enzyme with ketimine reductase activity regulated by TH.139 The 
apparent Kd value of T3 for CRYM amounts to 0.3 nM.140
CRYM is found in the inner ear, and mutations in CRYM have been associated with 
non-syndromic deafness.141 Furthermore, CRYM is abundantly expressed in the central 
nervous system; in the cerebral cortex predominantly in the cytoplasm of neurons.142 
Co-transfection of cells with MCT8, CRYM and D3 may thus mimic to some extent the 
handling of TH in central neurons. The co-transfection of CRYM in addition to D3 leads 
to a similar T3 metabolism as D3 alone. This suggests that the rapid degradation of T3 
prohibits an increase in cytoplasmic T3 levels, thus decreasing nuclear T3 availability.
The most remarkable finding in our study is the marked stimulation of intracellular 
metabolism of T3 by D3 if cells are co-transfected with MCT8 or MCT10. This is in con-
trast to the modest stimulation of T3 action as detected by the promoter-luciferase 
construct. D3 is located in the plasma membrane with its active center located on the 
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cytoplasmic surface.24,127,143 The biological activity of T3 is mediated by its nuclear recep-
tor. Therefore, the action of T3 requires a much greater penetration into the cell than 
its deiodination (Figure 5). The extent of T3 distribution within the cell depends on a 
number of factors, including the rate of T3 transport back to the extracellular milieu and 
its binding to intracellular proteins that may facilitate its further distribution. Our results 
suggest that in MCT8 over-expressing cells, efflux of T3 is much more rapid than its 
transport to the nucleus, explaining why accumulation of T3 in the nucleus is modest 
despite the strong stimulation of cellular T3 uptake.
In contrast, intracellular metabolism by D3 is greatly stimulated by co-transfection with 
MCT8 or MCT10 irrespective of the expression of CRYM. This suggests that the available 
T3 concentration at the D3 active center is much less affected by the rapid T3 efflux 
mediated by MCT8 or MCT10. We speculate that transporters such as MCT8 or MCT10 
that mediate both rapid uptake and efflux of T3 have a much greater effect on intracel-
lular T3 availability at the cell periphery than at the cell nucleus even in the presence of 
the cytoplasmic high-affinity T3-binding protein CRYM.
It should be realized that JEG3 cells express endogenous TH transporters, which is 
reflected by the steady increase in T3 uptake even during prolonged incubations with 
non-transfected cells. Of course, the effects of transfected MCT8 or MCT10 in cells 
already expressing endogenous transporters are quite different from cells devoid of 
other transporters. MCT8 may be the only significant TH transporter in certain popula-
tions of central neurons where it plays a crucial role in TH metabolism and action during 
critical periods of brain development.37 In addition to neurons, MCT8 is importantly 
expressed in endothelial cells of the blood-brain barrier (BBB). Perhaps, both TH uptake 
and efflux functions of MCT8 are involved in the transcellular transport of T4 and T3 
across the BBB. Indeed MCT8 has been localized in the apical (blood-facing) as well as 
the basolateral (brain-facing) membranes of the BBB endothelial cells.44
In conclusion, we demonstrated that over-expression of MCT8 or MCT10 in JEG3 cells 
induce only a transient increase in cellular T3 accumulation upon addition of T3, result-
ing in a modest increase in the nuclear activity of T3. In the presence of CRYM, the 
temporary effects of MCT8 or MCT10 on cellular accumulation and nuclear activity of 
T3 are enhanced. However, this effect is annulled in the presence of D3 due to rapid 
degradation of T3. MCT8 and MCT10 appear to have a much greater effect on the cel-
lular availability of T3 for D3 located in the plasma membrane than for the T3 receptor 
located in the nucleus. We hypothesize that this differential effect of MCT8 and MCT10 
on TH availability for processes located at the cell periphery or at the nucleus are inher-
ent to the rapid cellular TH efflux also mediated by these transporters. The implications 
of our findings for the pathogenic mechanism of AHDS remain to be explored.
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Abstract
The thyroid hormone (TH) analog eprotirome (KB2115; 3-[[3,5-dibromo-4-[4-hydroxy-
3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic acid) was developed to 
lower cholesterol through selective activation of the T3 receptor isoform TRβ1 in the 
liver. Interestingly, eprotirome shows low uptake in non-hepatic tissues, explaining its 
lipid-lowering action without adverse extra-hepatic thyromimetic effects. Clinical trials 
have shown marked decreases in serum cholesterol levels.
We explored the transport of eprotirome across the plasma membrane by members 
of three TH transporter families: monocarboxylate transporters MCT8 and 10, Na-
independent organic anion transporters OATP1A2, 1B1, 1B3, 1C1, 2A1 and 2B1, and 
Na-dependent organic anion transporters SLC10A1-7. Cellular transport was studied in 
transfected COS1 cells using [14C]eprotirome and [125I]TH analogs.
Of the 15 transporters tested initially, the liver-specific bile acid transporter SLC10A1 
(also known as Na/taurocholate co-transporting polypeptide, NTCP) showed the 
highest eprotirome uptake (>7 fold induction after 60 min) as well as TRβ1-mediated 
transcriptional activity. Uptake of eprotirome by SLC10A1 was Na+ dependent and 
saturable with a Km of 8 μM. Eprotirome transport was inhibited by known substrates 
for SLC10A1 (e.g. cholate and taurocholate), and by TH analogs such as triiodothyro-
propionic acid and triiodothyroacetic acid. However, no significant SLC10A1-mediated 
transport was observed of these [125I]TH analogs. To further explore the role of SLC10A1 
in the liver targeting of eprotirome, we studied the plasma disappearance and biliary 
excretion of [14C]eprotirome injected in control and Slc10a1 knockout mice. Although 
eprotirome is also transported by mouse Slc10a1, the pharmacokinetics of eprotirome 
were not affected by Slc10a1 deficiency.
In conclusion, we have demonstrated that the liver-specific bile acid transporter 
SLC10A1 effectively transports eprotirome. However, Slc10a1 does not appear to be 
critical for the liver targeting of this TH analog in mice. Therefore, the importance of 
SLC10A1 for liver uptake of eprotirome in humans remains to be elucidated.
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Introduction
Hypercholesterolemia is associated with atherosclerosis and thus represents a major 
health risk for ischemic heart disease and stroke, the foremost causes of death in middle 
and high income countries  144. Thyroid hormone (TH) plays an important role in the 
regulation of different steps in lipid metabolism such as lipolysis and hepatic cholesterol 
clearance  145. These effects are importantly mediated by the stimulation of the TRβ1 
receptor in the liver by T3 145. Therefore, reduction of serum cholesterol by TRβ-selective 
TH analogs without adverse thyromimetic effects has obvious therapeutic benefits. The 
TRβ specificity of such analogs would indeed prevent unwanted cardiovascular effects 
of TH analogs mediated by TRα1. However, it would not prevent the suppression of 
the hypothalamus-pituitary-thyroid (HPT) axis by such analogs via the TRβ2 receptor 
expressed in hypothalamus and pituitary. TH receptors are located in the nucleus and 
the action of T3 and analogs requires their cellular uptake by plasma membrane trans-
porters. This makes it possible to target lipid-lowering TH analogs to the liver through 
liver-specific transporters.
One of the TH analogs developed to lower cholesterol is eprotirome (KB2115; 3-[[3,5-di-
bromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic 
acid) 146. It differs from T3 by the presence of two bromines instead of iodine substituents 
in the inner ring, an isopropyl group instead of an iodine substituent in the outer ring, 
and a 3-amino-3-oxopropionic acid instead of an alanine side chain (Supplemental Fig-
ure 1). It has two characteristics which makes it an attractive candidate as lipid lowering 
drug: 1) modestly higher affinity for TRβ than for TRα, and 2) minimal non-hepatic tissue 
uptake. Interestingly, recent rodent studies demonstrated reduction of cholesterol 
by T3 and eprotirome through a LDL receptor independent pathway  147, indicating a 
mechanism distinct from other lipid lowering agents. In a 12-week clinical trial where 
the TH analog was given in addition to statin therapy, eprotirome produced a marked 
decrease in serum cholesterol levels without adverse extra-hepatic thyromimetic ef-
fects 146. However, phase III clinical trials were discontinued because long-term studies 
in dogs resulted in cartilage damage 148.
It is important to gain insight in eprotirome’s mechanism of action and its pronounced 
liver-selective uptake for future development of lipid-lowering TH analogs. As men-
tioned above, TH action is dependent on cellular uptake by plasma membrane trans-
porters, which may also apply to TH analogs. Therefore, the objective of our study was 
to get a better understanding of the tissue-specific actions of eprotirome by exploring 
the role of TH transporters in tissue uptake of eprotirome. Because of the presence of 
a negatively charged side chain in eprotirome, we focused primarily on the possible 
involvement of organic anion transporters. Different (Na-independent) organic anion 
transporting polypeptides (OATPs) as well as Na/taurocholate co-transporting polypep-
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tide (NTCP; SLC10A1) are capable of transporting TH 20,21,61. Therefore, we concentrated 
on the OATP and SLC10 families in our search for transporters facilitating cellular uptake 
of eprotirome. For comparison, we also tested possible eprotirome transport by MCT8 
(SLC16A2) and MCT10 (SLC16A10), the most effective TH transporters identified to 
date 37.
Materials and methods
Materials
Eprotirome and [14C]eprotirome were obtained from Karo Bio AB (Huddinge, Sweden); 
iodothyronine derivatives, D-glucose, bovine serum albumin (BSA), Na2SeO3, cholate, 
taurocholate, bromosulfophthalein (BSP), dehydroepiandrosterone 3-sulfate (DHEAS), 
estrone 3-sulfate (E3S), fetal bovine serum (FBS) from Sigma Aldrich (Zwijndrecht, The 
Netherlands [NL]); cell culture dishes from Corning (Schiphol, NL); DMEM/F12-Gluta-
MAX, Dulbecco’s phosphate buffered saline (DPBS) and penicillin/streptomycin from 
Invitrogen (Bleiswijk, NL); X-tremeGENE 9 transfection reagent from Roche (Almere, NL); 
SYBR Green from Eurogentec (Maastricht, NL); and Na125I from Perkin-Elmer (Groningen, 
NL). 125I-labeled T3, 3,3′,5-triiodothyroacetic acid (Triac; TA3), 3,3’,5-triiodothyropropionic 
acid (TP3), T4 and 3,3′,5,5′-tetraiodothyroacetic acid (Tetrac; TA4) were produced as 
previously described 128.
Plasmids
Human (h) OATP1A2 in pSPORT1 was kindly provided by Prof. Dr. Peter J. Meier (Institute 
of Clinical Pharmacology and Toxicology, University Hospital Zürich, Zürich, Switzer-
land), and subcloned into pSG5 (Stratagene, La Jolla, USA). hOATP1B3 in pcDNA3.1-
Hygro was kindly provided by Prof. Dr. Dietrich Keppler (German Cancer Research 
Center, Heidelberg, Germany), and subcloned into pSG5. hOATP1B1 in pCMV6-XL4 149, 
hOATP1C1 in pcDNA3.1  150, hSLC10A1, hSLC10A2 and hSLC10A3 in pcDNA3, rat (r) 
Slc10a4, hSLC10A5, hSLC10A6, and hSLC10A7 in pcDNA5  21, hMCT8 in pcDNA3  24 
and hMCT10 in pcDNA3.1  25 were obtained as described previously. hOATP2A1, and 
hOATP2B1 in pCMV.SPORT6 were purchased from Open Biosystems (Huntsville, AL). 
hSLC10A1 and mSlc10a1 were subcloned into pSG5 with a 5’-FLAG tag and an opti-
mized Kozak sequence as previously described 151.
Cell culture and transfection
Most transport assays were done using transfected COS1 (African green monkey kidney) 
cells but some experiments were also done with JEG3 (human choriocarcinoma) cells. 
Cells were maintained in culture medium (DMEM/F12+glutamax, 9% FBS, 1% penicillin/
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streptomycin, 100 nM Na2SeO3) at 37 C and 5% CO2. Cells were seeded in 6-well or 
24-well culture dishes in culture medium without antibiotics. At 70% confluence, cells 
were transfected with 200 ng (24-well dishes) or 500 ng (6-well dishes) transporter plas-
mid or empty vector using X-tremeGENE 9 transfection reagent in a 3:1 ratio, according 
to the manufacturer’s protocol.
Transport studies
Time-dependent uptake assays were done in 6-well dishes. All other transport stud-
ies were performed in 24-well dishes, producing similar results as in 6-well dishes. 
Experiments were carried out 48 h after transfection. Cells were rinsed with incubation 
medium (DPBS/0.1% BSA/0.1% D-glucose or DMEM/F12-GlutaMAX with 0.1% BSA) and 
incubated for 2-60 minutes at 37 C and 5% CO2 with 0.5 µM (6x104 or 12x104 cpm) [14C]
eprotirome in 0.5 or 1 ml incubation medium in 24-well or 6-well dishes, respectively. 
After incubation, cells were rinsed with incubation medium, lysed in 0.5 ml 0.1 M NaOH, 
mixed with 4 ml scintillation fluid (Pico-Fluor 15, Perkin-Elmer), and counted for radio-
activity in a β-counter (Perkin-Elmer). Experiments exploring the kinetics of eprotirome 
transport, and competition by alternative substrates were carried out in incubation 
medium without BSA.
To study the Na+ dependence of [14C]eprotirome transport by SLC10A1, experiments 
were carried out in Na+ replete medium (142.9 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 
1.2 KH2PO4, 1.8 mM CaCl2, 20 mM HEPES, 0.1% BSA, pH 7.4) or in Na+ deplete medium 
where NaCl was replaced by an equimolar amount of choline chloride.
To study efflux of [14C]eprotirome, cells transfected with SLC10A1 or empty vector were 
loaded for 30 minutes with [14C]eprotirome in incubation medium. Immediately after 
removing the loading medium, cells were incubated for 2-30 minutes in efflux medium, 
consisting of the Na+ replete or Na+ deplete medium described above containing 1% 
BSA to increase the binding of [14C]eprotirome released from the cells. In some experi-
ments, 100 µM cholate was added to the efflux medium to block the SLC10A1 transport 
channel.
To explore the specificity of eprotirome transport by SLC10A1, transfected COS1 cells 
were incubated for 30 minutes with 0.5 µM [14C]eprotirome in the absence or presence 
of 50 µM of the SLC10A1 substrates cholate, taurocholate, BSP, DHEAS or E3S, or the 
iodothyronine derivatives T4, TA4, T3, TA3, TP3, or 3,5-diiodothyropropionic acid (DP2) 
(Supplemental Figure 1) in incubation medium without BSA. In addition, possible trans-
port of iodothyronine derivatives by SLC10A1 was tested by incubation of transfected 
COS1 cells for 30 minutes with 1 nM (5x104 cpm) [125I]T3, [125I]TA3, [125I]TP3, [125I]T4 or [125I]
TA4, and cellular radioactivity was measured as described above using a γ counter 152.
Kinetics of eprotirome transport by SLC10A1 were explored by incubation of trans-
fected COS1 cells for 30 minutes with 0.5 µM [14C]eprotirome and 0.5-200 µM unlabeled 
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eprotirome in incubation medium without BSA. SLC10A1-mediated uptake was calcu-
lated by subtracting uptake in cells transfected with empty vector from uptake in cells 
transfected with SLC10A1, and expressed as nmol/min. Km values were calculated by 
Michaelis-Menten analysis using GraphPad Prism 5.01 (GraphPad Software, San Diego 
CA).
Effect of liver transporters on nuclear activity of eprotirome
To explore the effect of SLC10A1 on the nuclear availability of eprotirome, we used a 
TRβ1-dependent transactivation assay as described previously with minor modifica-
tions 153. COS1 and JEG3 cells were cultured in 96-well plates, and co-transfected with 
15 ng pcDNA3.1-hTRβ1, 15 ng of the pdV-L1 plasmid containing a T3 response element 
(TRE)-dependent firefly luciferase reporter and a control renilla luciferase reporter  129, 
and 15 ng pcDNA3-SLC10A1 or empty pcDNA3 vector. Two days after transfection, cells 
were incubated for 24 hours with 0, 0.1 or 1 nM eprotirome in DMEM/F12-GlutaMAX 
containing 0.1% BSA. Firefly luciferase and renilla luciferase activities were determined 
using the Dual-Glo Luciferase Assay (Promega), and the luciferase/renilla ratio was 
calculated as a read-out for eprotirome transcriptional activity.
Quantitative RT-PCR of tissue SLC10A1 mRNA levels
cDNA prepared from human liver, cartilage, bone marrow, sternum, and chondrosar-
coma was kindly provided by Dr. Bram van der Eerden (Erasmus University Medical 
Center). SLC10A1 qPCR was carried out using 5’-GGTTCTCATTCCTTGCACCA-3’ as the 
forward primer, 5’-ATGGCAGAGAGAACTGTGACG-3’ as the reverse primer, SYBRgreen as 
the probe, and universal master mix (Roche). SLC10A1 expression levels were expressed 
relative to the expression of the HPRT1 housekeeping gene measured using a com-
mercial primer-probe mix (Applied Biosystems).
Immunoblotting
Expression of FLAG-hSLC10A1 and FLAG-mSlc10a1 protein in COS1 cells was deter-
mined by immunoblotting using anti-FLAG antibody as previously described  154. In 
brief, transfected COS1 cells were lysed in ice-cold RIPA buffer supplemented with 
the Complete Protease Inhibitor cocktail (Roche Diagnostics). Lysates were cleared 
by centrifugation for 5 minutes at 700xg, and protein concentration of the superna-
tant was determined using the bicinchoninic assay (Fisher Scientific). Proteins were 
separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes, which 
were blocked in TBST/5% milk and probed overnight with a 1:1000 dilution of mouse 
FLAG M2-antibody (F1804; Sigma-Aldrich) at 4 C. Bound antibody was detected with 
a horseradish peroxidase-conjugated goat anti-mouse antibody (#172-1011; Bio-Rad) 
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and visualized by enhanced chemiluminescence using the Alliance 4.0 Uvitec platform 
(Uvitec Ltd).
Eprotirome pharmacokinetics in wild-type and Slc10a1 deficient mice
Male Slc10a1 knockout mice (C57Bl6/J background), and wild-type or heterozygous 
littermates were housed and bred in the Academic Medical Center, Amsterdam. As 
heterozygote littermates have almost 90% of normal NTCP expression and indistin-
guishable from wild-type 155, these were used as control.
To investigate eprotirome transport in control and Slc10a1 knockout mice, the gall 
bladder was cannulated and bile was collected after distal ligation of the common bile 
duct, as described 156. After a 30 minutes depletion-phase, a single bolus of 14C-labeled 
eprotirome was administered intravenously in 100 µL 0.9% NaCl per 20 g mouse. 
Blood and bile samples were collected at the indicated time points after eprotirome 
administration. Mice were sacrificed and liver, kidney, heart and brain were dissolved in 
Solvable (Perkin Elmer). Radioactivity in plasma and bile was measured by liquid scintil-
lation counting. Total blood volume was estimated based on the mouse body weight 
(58.5 uL/g mouse).
Statistical analysis
The results are shown as means ± SEM of usually 3 experiments carried out at least in 
duplicate. GraphPad Prism 5.01 was used for statistical analysis. To test the significance 
of the difference between background and transporter-mediated eprotirome uptake, 
a 1-way ANOVA with Bonferroni post-test was used. A paired t-test was used to test 
the difference in uptake of different substrates between cells transfected with empty 
vector or with SLC10A1. P<0.05 was considered significant.
Results
In addition to the TH transporters MCT8 and MCT10, 6 members of the OATP family and 
all 7 members of the SLC10 family were tested for [14C]eprotirome uptake in transfected 
COS1 cells (Figure 1A). Of all 18 transporters tested, SLC10A1 showed a robust increase 
in eprotirome uptake compared with empty vector. OATP1A2, OATP1B1, OATP1B3, 
SLC10A6, and SLC10A7 produced a modest, insignificant increase in eprotirome uptake.
Figure 1B shows a strong time-dependent increase in eprotirome uptake by COS1 cells 
transfected with SLC10A1, whereas no increase in eprotirome uptake with time was ob-
served in cells transfected with empty vector. The latter suggests that COS1 cells do not 
express endogenous transporters for eprotirome. The fold stimulation of eprotirome 
uptake induced by SLC10A1 vs. empty vector increased from 1.4 at 2 minutes to 7.1 at 
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60 minutes. Even after 24 hours, a 4.6-fold induction in eprotirome uptake was seen in 
COS1 cells expressing SLC10A1 (Figure 1C). In contrast to COS1 cells, control JEG3 cells 
showed a significant time-dependent uptake of eprotirome, representing expression 
of endogenous transporter(s) that facilitate eprotirome uptake (Figure 1D). Transfection 
of JEG3 cells with SLC10A1 produced a time-dependent increase in eprotirome uptake 
up to 1.7-fold at 60 minutes. However, no significant induction of eprotirome uptake by 
SLC10A1 was found anymore after 24 hours in JEG3 cells (Figure 1C).
SLC10A1 (NTCP) transports its substrates in a Na+-dependent manner 20,85. To assess if 
eprotirome transport by SLC10A1 is also a Na+-dependent process, parallel incubations 
were carried out with Na+ replete medium or with Na+ deplete medium where all Na+ 
was replaced by choline. In both COS1 and JEG3 cells, eprotirome transport by SLC10A1 
was found to be strictly dependent on the presence of Na+ in the medium (Figure 
2A). Interestingly, eprotirome uptake by control JEG3 cells was not affected by Na+ 
depletion, indicating the involvement of Na+-independent endogenous transporter(s) 
Figure 1. (A) 0.5μM [14C]Eprotirome uptake (30 min) by MCT, OATP and SLC10 transporters in COS1 cells. 
(B) Time-dependent uptake of 0.5μM [14C]eprotirome by COS1 cells transfected with empty vector (EV) 
or SLC10A1. (C) 0.5μM [14C]Eprotirome uptake (24 h) by EV or SLC10A1 transfected COS1 and JEG3 cells. 
(D) Time-dependent uptake of 0.5μM [14C]eprotirome by EV or SLC10A1 transfected JEG3 cells. Results are 
presented as means ± SEM (n=3). Significance of difference between control and transporter-expressing 
cells (1-way ANOVA with Bonferroni post-test): * P<0.05; ** P<0.01; *** P<0.001.
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and thus distinct from SLC10A1. Because of the considerable endogenous uptake by 
JEG3 cells, further transport characteristics of eprotirome by SLC10A1 were investigated 
using COS1 cells.
Next, we examined if, in addition to eprotirome uptake, SLC10A1 also facilitates 
eprotirome efflux. COS1 cells were loaded during incubation for 30 minutes with [14C]
eprotirome in incubation medium. Efflux of cellular [14C]eprotirome was subsequently 
analyzed by incubation with medium containing 1% BSA to minimize re-uptake of 
[14C]eprotirome released from the cells. Also, the effects of Na+ depletion from the 
efflux medium and/or the addition of the SLC10A1 substrate cholate (100 µM) were 
tested on eprotirome efflux. Apparently, SLC10A1-transfected cells showed the slowest 
eprotirome efflux in Na+ replete efflux medium without cholate (Figure 2B). Eprotirome 
efflux from SLC10A1-transfected cells was similarly increased by Na+ depletion and by 
addition of cholate to Na+ replete medium. Eprotirome efflux from SLC10A1-expressing 
Figure 2. (A) 0.5μM [14C]Eprotirome uptake by control (EV) or SLC10A1-expressing COS1 or JEG3 cells dur-
ing 30 min incubation in Na+ replete (sodium) or Na+ deplete (choline) medium. (B) Time-dependent efflux 
of eprotirome from EV or SLC10A1-transfected COS1 cells preloaded during 30 min with 0.5μM [14C]eproti-
rome. Efflux was studied using Na+ replete or Na+ deplete medium containing 1% BSA without or with (+) 
100 µM cholate. Results are presented as means ± SEM (n=3).
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cells was not further increased by addition of cholate to Na+ deplete medium. These 
data suggest that the presence of 1% BSA in the efflux medium does not completely 
prevent eprotirome re-uptake, and that this is only accomplished by depletion of Na+ 
or addition of cholate. The findings that Na+ depletion and cholate do not inhibit epro-
tirome efflux suggest that this is not mediated by SLC10A1, although efflux from cells 
transfected with empty vector followed different kinetics. The uptake of eprotirome by 
control cells is much lower than the uptake in SLC10A1-transfected cells and plateaus 
after a very short incubation time (~10 minutes). It cannot be excluded that a part of 
the eprotirome is associated with but not internalized by the control cells, which then 
shows a rapid dissociation from the cells. Na+ depletion and cholate also did not affect 
efflux of eprotirome from control cells.
The kinetics of eprotirome transport by SLC10A1 were studied by incubation of trans-
fected cells with 0.5-200 µM eprotirome, and subtraction of eprotirome uptake by 
control cells from uptake by SLC10A1-expressing cells. The results clearly demonstrate 
saturation of eprotirome transport by SLC10A1 (Figure 3). Based on these data a Km 
value of approximately 10 µM was estimated.
We examined if SLC10A1 increases the nuclear availability of eprotirome using COS1 
and JEG3 cells co-transfected with TRβ1 and a construct coding for a TRE-dependent 
luciferase reporter and a control renilla reporter. The luciferase/renilla ratio was used as 
a measure of the transcriptional activity of eprotirome. In the absence of SLC10A1, 0.1 
nM eprotirome was inactive while 1 nM eprotirome induced a modest increase in tran-
scriptional activity (Figure 4A). In contrast, a marked, dose-dependent transcriptional 
activity was observed in JEG3 cells (Figure 4B). Expression of SLC10A1 resulted in a 5.7- 
and 4.3-fold increase in transcriptional activity in COS1 cells exposed to 0.1 and 1 nM 
eprotirome, respectively. In JEG3 cells, SLC10A1 expression enhanced transcriptional 
activity of 0.1 nM but not of 1 nM eprotirome, where the latter already shows maximum 
activity in the absence of SLC10A1.
As SLC10A1 also mediates transport of bile acids, steroid sulfates and cholephilic com-
pounds such as BSP 20,21,85, we studied the inhibitory effects of 50 µM taurocholate, cho-
late, DHEAS, E3S and BSP on eprotirome transport by SLC10A1 (Figure 5A). Eprotirome 
transport was inhibited in decreasing order of potency by taurocholate ~ cholate > BSP 
~ E3S > DHEAS.
The preceding experiments indicate that eprotirome is an excellent substrate for the 
organic anion transporter SLC10A1. Therefore, we investigated if other TH analogs with 
a negatively charged side chains could also be substrates for SLC10A1. This was studied 
indirectly by measuring the effects of TA4, TA3, TP3 and DP2 on eprotirome uptake by 
SLC10A1 in comparison with the effects of T4 and T3. As expected, minimal effects 
on eprotirome uptake were seen by addition of 50 µM T3 or T4 (Figure 5B). However, 
eprotirome uptake was markedly inhibited in decreasing order of potency by 50 µM 
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Figure 3. Inhibition of uptake of 0.5 µM [14C]eprotirome in COS1 cells transfected with SLC10A1 or empty 
vector (EV) by 0.5-200 µM unlabeled eprotirome (30 min incubation). Results are presented as means ± 
SEM (n=3).
Figure 4. Effects of SLC10A1 on nuclear activity of eprotirome. COS1 (A) or JEG3 (B) cells co-transfected 
with TRβ1, TRE-luciferase/control renilla construct, and SLC10A1 or empty vector (EV) were incubated for 24 
h with 0, 0.1 or 1 nM eprotirome. The luciferase/renilla ratio was determined as a measure of TRE-mediated 
transcriptional activity. Results are presented as means ± SEM (n=3).
Figure 5. Effects of 50 µM alternative substrates (A) and of 50 µM iodothyronine derivatives (B) on uptake 
of 0.5 µM [14C]eprotirome (30 min) by SLC10A1 in COS1 cells. Uptake by SLC10A1-transfected cells is cor-
rected for uptake in control (EV) cells, and expressed relative to uptake in the absence of competitor. Re-
sults are presented as means ± SEM (n=3-4). Significance of difference between uptake in the presence vs. 
absence of competitor (1-way ANOVA with Bonferroni post-test): * P<0.05; ** P<0.01; *** P<0.001.
CHAPTER 3
46
TP3 > TA3 > TA4 > DP2. Dose-dependent inhibition of eprotirome uptake by SLC10A1 
in the presence of increasing concentrations of TA4, TA3, TP3 and DP2 is presented in 
Supplemental Figure 2, indicating near-complete inhibition at the highest concentra-
tion of the analogs tested (100 µM).
To explore if the TH analogs were also substrates for SLC10A1, transport was directly 
measured in transfected COS1 cells using [125I]T3 (Figure 6A), [125I]TA3 (Figure 6B), [125I]
TP3 (Figure 6C), [125I]T4 (Figure 6D) and [125I]TA4 (Figure 6E). Although the TH analogs 
with acidic side chains strongly inhibit eprotirome uptake by SLC10A1, no significant in-
crease in uptake of the [125I]TH analogs was observed in cells transfected with SLC10A1. 
In agreement with previous results, SLC10A1 showed minimal transport of T4 and no 
significant transport of T3.
Because of the cartilage damage observed in dogs during long-term treatment with 
eprotirome, we investigated if this side effect could be explained by SLC10A1 expres-
sion in cartilage. Quantitative RT-PCR of SLC10A1 in human tissues showed pronounced 
expression in liver but negligible expression in cartilage and cartilage-related tissues 
(Supplemental Figure 3). These findings indicate that SLC10A1 is not involved in the 
possible targeting of eprotirome to human cartilage.
Figure 6. (A-E) Uptake of 1 nM [125I]T3 (A), [125I]TA3 (B), [125I]TP3 (C), [125I]T4 (D) and [125I]-TA4 (E) during 10 
min incubation with EV or SLC10A1 transfected COS1 cells. Results are presented as means ± SEM (n=3). 
Significance of difference between EV vs. SLC10A1 (paired t-test): * P<0.05; ** P<0.01; *** P<0.001.
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Our findings suggest that SLC10A1 is an important transporter for hepatic uptake of 
eprotirome. To test this hypothesis, we studied the pharmacokinetics of eprotirome 
in Slc10a1 knockout mice and control littermates 155, assuming that eprotirome is also 
effectively transported by mouse Slc10a1. To compare the expression and activity of 
mouse and human SLC10A1, COS1 cells were transfected with FLAG-tagged constructs 
and tested for protein expression by immunoblotting using anti-FLAG antibody and for 
eprotirome uptake.
Protein expression levels (Figure 7A) and cellular uptake of taurocholate and eprotirome 
(Figure 7B) were somewhat lower for FLAG-tagged mouse Slc10a1 than for the human 
SLC10A1 construct. Surprisingly, plasma clearance and biliary excretion of injected [14C]
Figure 7. Eprotirome kinetics in NTCP knockout mice and controls. (A) Immunoblot of lysates of COS cells 
transfected with Flag-tagged human SLC10A1 or mouse Slc10a1. (B) Uptake of radioactive taurocholate 
(0.1 μM) or eprotirome (0.5 μM) by COS1 cells transfected with empty vector (EV) or Flag-tagged human 
SLC10A1 or mouse Slc10a1. Results are presented as means ± SEM (n=3-5). (C) Plasma clearance in NTCP 
knockout mice (grey lines) and control littermates (black lines) was assessed after cannulation of the gall-
bladder and jugularis vein. Radiolabeled eprotirome was injected into the jugularis vein and tritium radio-
activity was measured in plasma (left figure, data from 4 knockout and 6 control mice) and bile (middle 
figure, data from 3 knockout and 5 control mice) at the indicated time points, and in tissues at 60 minutes 
(right figure, data from 2 knockout and 5 control mice). (D) Same data as shown in panel C but now sepa-
rated by sex. Male mice are depicted as black lines and females as grey lines. Plasma data were obtained in 
4 males and 5 females (left figure), bile data in 4 males and 4 females (middle figure), and tissue data in 4 
males and 3 females.
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eprotirome were not significantly different between control and Slc16a1 knockout 
mice (Figure 7C). However, we noted a strong sex dependence of the data obtained, 
indicating that both plasma clearance and biliary excretion of eprotirome were mark-
edly higher in male than in female mice irrespective of Slc10a1 status (Figure 7D). The 
amount of eprotirome present at the end of the experiment was markedly higher in 
liver than in kidney, heart and brain (Figure 7C,D). However, there was no significant 
difference between the amounts of eprotirome finally present in the tissues comparing 
male with female mice or Slc10a1 knockout with control mice.
Discussion
This study shows that transporters are required for transport of eprotirome across the 
plasma membrane, a necessary step to enable its activation of nuclear T3 receptors. 
We also demonstrate that eprotirome is effectively transported into cells by the liver-
specific transporter SLC10A1. However, the importance of SLC10A1 for the liver target-
ing of eprotirome in humans remains to be determined.
Since an intact alanine side chain is required for effective transport of iodothyronines 
by MCT8 and MCT10  157,158, it is not surprising that eprotirome is not transported by 
these TH transporters. In view of the negatively charged side chain of eprotirome, we 
hypothesized that cellular uptake of this TH analog is facilitated by an organic anion 
transporter. We showed that of the 13 organic anion transporters tested in our first 
experiments, the bile acid transporter SLC10A1 markedly stimulated cellular uptake of 
eprotirome. SLC10A1 is known to transport bile acids, steroid sulfates 85 and iodothy-
ronine sulfates 20,21 in a Na+-dependent manner. This was also found to be the case for 
eprotirome uptake by SLC10A1, since this was completely blocked under Na+ deplete 
conditions. Consistent with previous findings of the unidirectional transport of other 
substrates 21, SLC10A1 does not appear to mediate cellular efflux of eprotirome.
Experiments using control COS1 cells transfected with empty vector indicate that very 
little if any eprotirome is taken up by cells through simple diffusion across the plasma 
membrane. The amount of radioactive eprotirome associated with control COS1 cells 
does not increase with time after 2 minutes, suggesting that this largely represents 
binding of eprotirome to the cell surface. This may also explain the rapid release of 
labeled eprotirome from control COS1 cells in the efflux experiments. The negligible 
endogenous uptake of eprotirome by COS1 cells permits their use to study the charac-
teristics of eprotirome transport by SLC10A1. Considering the lack of eprotirome trans-
port into control COS1 cells, the 7-fold increase in cell-associated eprotirome after 30 
minutes incubation with SLC10A1-transfected cells represents an underestimation of 
the increase in cellular uptake induced by SLC10A1. These findings indicate that eproti-
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rome is effectively transported by SLC10A1, which is further supported by the marked 
stimulation of the TR-mediated action of eprotirome induced by this transporter. This 
confirms that cellular uptake of eprotirome by SLC10A1 also results in a prominent 
increase in the nuclear availability of this T3 analog.
SLC10A1 has a relatively high affinity for eprotirome with an apparent Km value of 7.8 
µM, compared with Km values reported for other substrates such as taurocholate (6-
34 µM), E3S (27-60 µM) and BSP (3.7 µM)  85. As expected, transport of eprotirome by 
SLC10A1 is inhibited by the alternative substrates cholate, taurocholate, E3S, DHEAS 
and BSP, suggesting that they compete for the same translocation pathway in SLC10A1. 
The strongest competition was observed with the bile acids cholate and taurocholate.
Obviously, the presence of a negative charge in the substrate is important for its 
transport by SLC10A1. This is also the case for sulfonated T4 and T3 derivatives (sulfates 
and sulfamates), which appear to be transported better by SLC10A1 than T4 and T3 
themselves 20,21. The presence of the negatively charged 3-amino-3-oxopropionic acid 
side chain of eprotirome probably contributes importantly to the effective transport of 
this T3 analog by SLC10A1. For this reason, we also expected that other iodothyronine 
derivatives with an anionic side chain, such as TA4, TA3, TP3 and TP2, are also effec-
tively transported by SLC10A1. Although these compounds strongly inhibit eprotirome 
transport by SLC10A1, studies using 125I-labeled TA4, TA3 and TP3 failed to demonstrate 
significant transport by SLC10A1. T4 and T3 are poor inhibitors of eprotirome transport 
by SLC10A1, while they are also poorly transported by SLC10A1. In agreement with 
previous studies 21, T4 showed minimal uptake by SLC10A1, whereas T3 transport was 
undetectable. This difference in transport between T4 and T3 may be explained by the 
presence of a negative charge due to dissociation of the phenolic hydroxyl group of 
T4 at neutral pH and the absence of such charge on T3. The observation that iodo-
thyronine derivatives with anionic side chains (e.g. TA3, TP3) are potent inhibitors but 
poor substrates for SLC10A1 in contrast to eprotirome may suggest that the presence 
of larger iodine vs. bromine and isopropyl substituents interferes with the passage of 
substrate through SLC10A1.
Our studies in mice confirm that eprotirome is largely targeted to the liver. Despite the 
effective transport of eprotirome by both human and mouse SLC10A1 in transfected 
cells, its plasma disappearance and biliary clearance were not distinctly different be-
tween WT and Slc10a1 KO mice. Instead, a marked influence of sex was observed since 
both plasma disappearance and biliary clearance of eprotirome were markedly higher 
in male than in female mice. These differences are most likely explained by a more rapid 
hepatic uptake of eprotirome in male vs. female mice, although the liver eprotirome 
content at the end of the experiment was not obviously different between males and 
females.
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Many hepatic genes are expressed sex-dependently in mice, including the liver-
specific transporters Oatp1a1 and 1a4. Oatp1a1 is expressed at higher levels in male 
mice, whereas Oatp1a4 shows higher expression in female mice 159. The expression of 
another liver-specific transporter, Oatp1b2, is not clearly sex-dependent 160. Therefore, 
Oatp1a1 may also be an important transporter for liver uptake of eprotirome. We were 
unable to test this hypothesis as we failed to obtain functional expression of Oatp1a1 
in transfected mammalian cells. This may be due to the absence of proteins required 
for expression of Oatp1a1-dependent transport activity, such as Atp11c, Cdc50a, Pdzk1 
and perhaps other factors  89,161. This may also apply to our findings of a low uptake 
of eprotirome by human OATP1B1 and 1B3, although we previously demonstrated 
significant transport activity using other substrates 48,149. We are now exploring optimal 
conditions for functional expression of OATP1B1 and 1B3, and preliminary results show 
that this is cell-dependent.
Finally, the lack of an obvious defect in liver eprotirome uptake in Slc10a1 deficient 
mice may be due to increased expression of other transporters. However, expression of 
Oatp1a1 and 1b2 is not increased in Slc10a1 KO mice, while expression of Oatp1a4 is 
only increased in hypercholanemic Slc10a1 KO mice 155.
The small decrease in serum T4 combined with unaffected TSH levels in patients treated 
with eprotirome suggests some extra-hepatic activity 146,162. The modest decrease in T4 
may be explained by an increase in liver D1 activity, and the lack of an increase in TSH 
may represent a modest activity of eprotirome at the hypothalamus and/or pituitary 146.
MCT8 is known to be widely expressed in cartilage-forming chondrocytes, while MCT10 
appears to be the preferentially expressed transporter in the growth plate 163. However, 
these two transporters do not show any eprotirome uptake. The lack of expression of 
SLC10A1 in human cartilage does not exclude that eprotirome is targeted to cartilage 
through another transporter, producing the unwanted side effects of eprotirome on 
this tissue as observed in long-term studies in dogs. Our studies in human cartilage 
also do not negate that SLC10A1 may be expressed in dog cartilage. More studies are 
required to resolve this issue.
Finally, clinical studies with eprotirome indicate good oral availability of this T3 ana-
log 146, indicating the presence of transporters for eprotirome in the intestinal mucosa. 
Our studies demonstrate that the SLC10A2 intestinal bile acid transporter is not involved 
in the absorption of oral eprotirome.
SLC10A1 transports a broad range of substrates, in particular bile acids 85,164, that may 
interfere with hepatic eprotirome uptake in vivo. In addition to physiological substrates, 
certain drugs may also be transported by SLC10A1, and thus also interfere with eproti-
rome uptake. Recent studies have indicated that uptake of statins into the liver is partly 
mediated by SLC10A1 165-168. This is of particular interest since statins and eprotirome 
have the same therapeutic goal, that is, reduction of serum cholesterol. A recent clinical 
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trial has indicated that the combined therapy with statins and eprotirome produces a 
greater reduction in serum cholesterol than treatment with statins alone  146. Despite 
this positive clinical outcome, our results suggest that the effectiveness of combined 
TH analog and statin therapy may be limited by drug-drug interaction at the level of 
hepatic transport.
In conclusion, the liver-specific bile acid transporter SLC10A1 effectively transports 
eprotirome into cells. The high expression of this transporter in liver may explain the 
liver-selective action of this TH analog. However, hepatic eprotirome uptake is not 
affected in Slc10a1 knockout mice, suggesting an important contribution of other 
liver-specific transporters. Our findings support the hypothesis that TH analogs may be 
targeted to specific tissues depending on the transporters they express.
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Supplemental Figure 1. Chemical structures of T3, T4 and analogs.
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Supplemental Figure 2. Effects of 0.1-100 µM DP2 (A), TP3 (B), TA3 (C) or TA4 (D) on uptake of 0.5 µM 
[14C]eprotirome during 30 min incubation with COS1 cells transfected with SLC10A1 or empty vector (EV). 
Results are presented as means ± SEM (n=3).
Supplemental Figure 3. Expression of SLC10A1 relative to the HPRT1 housekeeping gene in different tis-
sues. Results are presented as means ± SEM (n=2). For liver and cartilage the results of two different samples 
are shown.

4
TRANSPORT OF THE THYROID 
HORMONE ANALOG GC-1 BY 
LIVER-SPECIFIC TRANSPORTERS
A.L.M. van Gucht, S. Farina, G. Brigante, B. Carlsson, 
M.E. Meima, T.S. Scanlan, R.P. Peeters, T.J. Visser
To be submitted
CHAPTER 4
56
Abstract
Sobretirome (GC-1) is a thyroid hormone (TH) analog that was developed in the 1990s 
to lower cholesterol levels through selective binding to the thyroid hormone receptor 
TRβ1 and preferential accumulation in the liver. GC-1 has been tested in several animal 
models and clinical trials, all showing significant reduction of serum lipid levels without 
unwanted thyrotoxic side effects.
We studied the cellular transmembrane transport of GC-1 by the Na-independent 
organic anion transporters OATP1A2, 1B1, 1B3 and the Na-dependent organic anion 
transporter SLC10A1 (also known as Na/taurocholate co-transporting polypeptide, 
NTCP). Cellular transport was studied in transfected COS1 and HEK293 cells using [3H]
GC-1, [3H]taurocholate (TCA), and [125I]TH analogs. In addition, we explored the effect 
of the transporters on the nuclear availability of GC-1 and other analogs, using a TRβ1-
dependent transactivation assay.
In transfected HEK293 cells, uptake of GC1 was stimulated 3.8-fold by OATP1B1, 2.0-fold 
by OATP1B3 and 1.8-fold by NTCP, but not by OATP1A2. Also the uptake of eprotirome 
was stimulated by NTCP, OATP1B1 and OATP1B3, whereas no significant eprotirome 
transport was seen with OATP1A2. NTCP was clearly most effective in facilitating 
transport of TCA. Regarding TH transport, T3 uptake was higher than T4 uptake, and 
the percentage uptake of both T4 and T3 was higher at 1 nM than at 10 µM substrate 
concentration for all transporters. In our hands, co-transfection of PDZK1 (a 70 kDa 
protein with 4 PDZ-domains, necessary for proper expression of OATPs at the plasma 
membrane) or the cytoplasmic TH binding protein CRYM had little or no effect on T3 
and T4 transport. Transfection of OATP1B1 and NTCP increased transcriptional activity 
in HEK293 cells incubated with 1 nM GC-1, while OATP1A2 showed no stimulation. With 
eprotirome incubation, OATP1B3 also stimulated transcriptional activity in HEK293 cells.
In conclusion, we have demonstrated that liver-specific transporters OATP1B1, 1B3, and 
NTCP can transport the TH analog GC-1 across the plasma membrane, a crucial step 
to enable its activation of nuclear TRβ1 receptor. However, other transporters for both 
GC-1 and eprotirome seem to be present in liver, which should be further elucidated 
before TH analogs can safely be targeted to specific tissues.
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Introduction
Elevated serum cholesterol and/or triglyceride levels trigger the onset of atheroscle-
rosis, ischemic heart disease, stroke and peripheral vascular abnormalities leading to 
high cardiovascular mortality in developed countries (http://www.who.int/healthinfo/
global_burden_disease/projections/en/). Treatment with statins has achieved striking 
cholesterol reducing effects; however, there remains a need for new cholesterol-
lowering drugs.169 In the past years, much research has been done focusing on thyroid 
hormone (TH) signaling with the aim of developing new cholesterol-lowering thera-
pies, since it is known that TH plays an important role in lipid metabolism.
Increased TH levels result in both positive and negative outcomes. On the negative 
side, hyperthyroidism can cause tachycardia, arrhythmias, bone and muscle catabolism, 
and mood disturbances. However, reduction of serum cholesterol levels and body fat 
can be considered as beneficial effects, particularly in patients with dyslipidemia and 
metabolic syndrome.145,170 The effects of T3 on the heart, muscle and bone are due to 
the stimulation of the predominant TH receptor isoform TRα1 in these tissues, while the 
lipid-lowering effects are mediated by TRβ1 in the liver.105
From this perspective, TRβ-selective ligands without undesirable effects via TRα are 
of great interest for the therapeutic control of serum cholesterol. However, analogs 
targeting TRβ will suppress the hypothalamus-pituitary-thyroid (HPT) axis, since TRβ2 
is highly expressed in hypothalamus and pituitary. Therefore, lipid-lowering TH analogs 
should ideally be directed to the liver only. TRs are located in the nucleus and the action 
of T3 and analogs requires their cellular uptake by plasma membrane transporters. This 
makes it possible to target lipid-lowering TH analogs to the liver through liver-specific 
transporters without unwanted effects on the HPT-axis or other TRβ-dominant tissues.
In a 12-week clinical trial in patients with hypercholesterolemia, where the TH analog 
eprotirome (KB2115) was given in addition to statin therapy, eprotirome produced a 
marked decrease in atherogenic lipoproteins without adverse extra-hepatic thyromi-
metic effects.146
In our previous work,171 we explored the tissue-selectivity of eprotirome by investigat-
ing its transport across the plasma membrane. Our study showed that in particular 
expression of the liver-specific bile acid transporter Na-taurocholate co-transporting 
polypeptide (NTCP, SLC10A1) stimulates cellular eprotirome uptake as well as TRβ1-
mediated transcriptional activity.
In the current work, we extended our analyses by studying cellular transmembrane 
transport of another TH agonist, sobetirome (GC-1). Because of the presence of a 
negatively charged side chain in GC-1, we studied its possible transport by NTCP as 
well as the organic anion transporting polypeptides OATP1A2, 1B1 and 1B3. Of the 
latter, OATP1B1 and 1B3 are also selectively expressed in liver.
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GC-1 was synthesized in the 1990s and differs structurally from T3 by having methyl 
and isopropyl substituents instead of the three iodines, a methylene instead of a biaryl 
ether linkage, and an oxyacetic acid side chain instead of the alanine side chain. GC-1 is 
reported to preferentially bind TRβ1 with a high affinity and to accumulate selectively 
in liver.170,172
GC-1 has been tested in several animal models including mice, rats and monkeys, 
and reached Phase 1b human clinical trials. In all models, GC-1 treatment resulted in 
significantly reduced LDL cholesterol levels and in primates additional reduction of 
serum triglycerides and lipoprotein a was observed. The used GC-1 doses in these stud-
ies did not elicit unwanted thyrotoxic side effects on heart rate and muscle and bone 
catabolism, except for a weak suppression of the HPT-axis.173–175
Unfortunately, long-term eprotirome treatment led to unexpected cartilage defects in 
dogs after which phase III clinical trials with eprotirome were discontinued (Karo Bio. 
Karo Bio terminates the eprotirome program. [Press release]. www.karobio.com; 2012 [14 
February 2012]. Available from: http://www.karobio.com/investormedia/pressreleaser/
pressrelease?pid = 639535). It is important to clarify the occurrence of these harmful 
effects before future clinical trials with lipid-lowering TH agonists can be considered. 
In addition, it is necessary to gain more insight in the mechanisms of tissue-specific 
targeting of TH analogs, such as GC-1, and their interactions with different transporters.
Materials and methods
Materials
GC-1 and [3H]GC-1 were prepared as described.172 Iodothyronines, bovine serum albu-
min (BSA), Na2SeO3, [3H]taurocholate (TCA), and fetal bovine serum (FBS) were obtained 
from Sigma Aldrich (Zwijndrecht, The Netherlands [NL]); cell culture dishes from Corn-
ing (Schiphol, NL); DMEM/F12-GlutaMAX, Dulbecco’s phosphate buffered saline (DPBS) 
and penicillin/streptomycin from Invitrogen (Bleiswijk, NL); X-tremeGENE 9 transfection 
reagent from Roche (Almere, NL); and Na125I from Perkin-Elmer (Groningen, NL).125I-
labeled T3, T4 and were produced as previously described.128
Plasmids
Human OATP1A2, OATP1B1, OATP1B3 and NTCP cDNA were all subcloned in the pSG5 
expression vector with an optimized Kozak translation start site and an N-terminal 
FLAG-tag as previously described.151,171 In addition, we used an N-terminal FLAG-tagged 
TRβ1 construct in pcDNA3, and a pdV-L1 reporter construct, expressing firefly luciferase 
(LUC) under control of a T3 responsive promoter and renilla luciferase (REN) under con-
trol of a constitutive promoter as described.129,176 The constructs for human cytoplasmic 
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T3 binding protein μ-crystallin (CRYM)25 and for PDZK189,177 were obtained as previously 
reported.
Cell culture and transfection
COS1 (African green monkey kidney) and HEK293 (human embryonic kidney) cells were 
used in the experiments, as these cell lines show relatively high transfection efficiency. 
Cells were maintained in culture medium (DMEM/F12 + glutamax, 9 % FBS, 1 % penicil-
lin/streptomycin, 100 nM Na2SeO3) at 37 C and 5 % CO2. Cells were seeded in 24-well 
(transport and luciferase studies) or 6-well (immunoblotting) culture dishes in culture 
medium without antibiotics 24 hours before transfection. At 70 % confluence, the 
medium was changed to DMEM/F12 containing charcoal-stripped FBS and the cells 
were transiently transfected with 200 ng (24-well) or 500 ng (6-well) plasmid in 0.5 ml 
(24-well) or 2 ml (6-well). Transfection was performed using X-tremeGENE 9 transfection 
reagent in a 3:1 ratio, according to the manufacturer’s protocol.
Transport studies
Transport studies were performed in cells transfected with 200 ng of transporter 
plasmid (Flag-OATP1A2, 1B1 or 1B3 or Flag-NTCP) or empty pSG5 vector (EV) with or 
without addition of 100 ng CRYM or PDZK1 plasmid. Two days after transfection, cells 
were washed with DMEM/F12 + 0.1 % BSA and incubated for 30 minutes at 37 C and 5 % 
CO2 with 1 nM or 10 μM T3 or T4 and 50,000 cpm [125I]T3 or [125I]T4, or 0.5 μM [3H]GC-1, or 
1 μM [3H]TCA in 0.5 ml incubation medium (DMEM/F12 + 0.1 % BSA). After incubation, 
cells were washed with incubation medium, lysed in 0.5 ml 0.1 NaOH, and counted 
for radioactivity in a γ-counter ([125I]T3 or [125I]T4) or mixed with 4 ml scintillation fluid 
(Pico-Fluor 15, Perkin-Elmer), and counted for radioactivity in a β-counter ([3H]GC-1 or 
[3H]TCA). In some experiments, uptake studies were also performed done using DMEM/
F12 without BSA.
Luciferase activity
To study the effect of the transporters on the nuclear availability of GC-1 and eprotirome, 
we used a TRβ1-dependent transactivation assay. COS1 and HEK293 cells were cultured 
in 24-well dishes and co-transfected with 60 ng transporter plasmid (Flag-OATP1A2, 
1B1 or 1B3 or Flag-NTCP) or empty pSG5 vector together with 60 ng pdV-L1 reporter 
construct and 60 ng Flag-hTRβ. Two days after transfection, cells were incubated for 
24 hours without or with 1 nM GC-1 or eprotirome in DMEM/F12 + 0.1 % BSA. Firefly 
luciferase and renilla luciferase activities were determined as previously described,178 
and the LUC/REN ratio was calculated as a read-out for transcriptional activity.
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Immunoblotting
The expression of the FLAG-tagged transporters OATP1A2, 1B1, 1B3 and NTCP was 
determined by immunoblotting using an anti-FLAG antibody as previously reported.179
Statistical analysis
All experiments were performed in triplicate and are presented as ± SEM of usually 
3 experiments. Statistical differences were calculated using Student’s t-test or 2-way 
ANOVA with Bonferroni post-hoc test. P < 0.05 was considered significant.
Results
Initial experiments were performed to compare the efficacy of transporter expression 
between COS1 and HEK293 cells. To this end, cells transfected with the Flag-tagged 
OATP and NTCP constructs were analyzed for transporter protein expression by immu-
noblotting and for functional expression by determining the uptake of the bile acid TCA 
(Figure 1). Expression of the OATP1A2 protein was clearly less than the expression of the 
OATP1B1 and 1B3 proteins in both COS1 and HEK293 cells. Surprisingly, NTCP protein 
could only be visualized in COS1 cells (Figure  1A). Among the different transporters 
tested, NTCP was clearly most effective in facilitating transport of TCA. Compared with 
control empty vector-transfected cells, TCA uptake was increased 13.2-fold in COS1 
cells and 48.5-fold in HEK293 cells. Modest stimulation of TCA uptake was observed 
with OATP1B1 and OATP1B3, which again was greater in HEK293 than in COS1 cells. 
Stimulation of TCA uptake by OATP1A2 was negligible in both COS1 and HEK293 cells 
(Figure 1B). However, significant stimulation of estrone-3-sulfate (E3S) uptake was ob-
served with all three OATPs, declining in the order OATP1B1 >> 1A2 > 1B3 (Figure 1C). 
Based on the functional activities of the different transporters in the two cell systems, 
all further experiments were done using HEK293 cells.
Previous studies have indicated that OATP1A2, 1B1 and 1B3 and NTCP are capable of 
transport TH. Therefore, we studied T3 and T4 uptake by the Flag-tagged OATPs and 
NTCP in HEK293 cells, and this was done using a low (1 nM) or a high (10 µM) substrate 
concentration (Figure 2). In general, T3 uptake was higher than T4 uptake, which may be 
related to the higher affinity of T4 than of T3 for the BSA (0.1 %) present in the medium. 
Also in general, the percentage uptake of both T4 and T3 was higher at 1 nM than at 
10 µM substrate concentration, suggesting saturation of the different endogenous and 
exogenous transporters. Apparently, endogenous transporters are saturated by 10 µM 
substrate to a greater extent than the exogenous transporters, resulting in a greater fold 
induction of TH uptake by transfected transporters compared with 1 nM substrate. At 
the high substrate concentration, uptake of T3 and T4 was stimulated 1.6- and 1.2-fold 
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by OATP1A2, 3.5- and 2.6-fold by OATP1B1, 2.3- and 3.1-fold by OATP1B3, and 2.4- and 
2.7-fold by NTCP, respectively.
Since it has been reported that diff erent OATPs require interaction with PDZK1, a 70 
kDa protein with 4 PDZ-domains,87–89 for proper expression at the plasma membrane, 
we have explored the eff ect of co-transfection of PDZK1 with OATP1A2, 1B1 or 1B3. In 
our hands, co-transfection of PDZK1 had little or no eff ect on T3 and T4 transport by 
OATP1A1, 1B1 and 1B3 (not shown)
In addition, it has been shown previously that expression of the cytoplasmic TH bind-
ing protein CRYM augments the cellular accumulation of T3 and T4 induced by the 
TH transporters MCT8 and MCT10.137 This is explained by the property that MCT8 and 
MCT10 facilitate both cellular uptake and effl  ux of iodothyronines. To investigate if this 
also applies to OATP1A2, 1B1, 1B3, and NTCP, we tested the eff ect of co-transfection of 
CRYM with these transporters on T3 and T4 uptake. CRYM was found to have little or 
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Figure 1. (A) Immunoblot of lysates of COS1 and HEK293 cells transfected with Flag-tagged OATPs and 
NTCP. Flag/HA-tagged TRα1 was used as a positive control.
Uptake of radioactive taurocholate (B) and estrone-3-sulfate (C) by COS1 and HEK293 cells transfected 
with empty vector (EV) or Flag-tagged OATPs and NTCP. Results are presented as means ± SEM (n = 3). 
Highest stimulation of TCA uptake was observed with NTCP, while OATP1B1 showed the most eff ective E3S 
transport.
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no effect on the cellular accumulation of T4 and T3 when incubated at low (1 nM) or 
high (10 µM) substrate concentration with cells transfected with empty vector or the 
different transporters (not shown). These findings suggest that OATP1A2, 1B1, 1B3 and 
NTCP primarily facilitate the uptake rather than the efflux of TH.
In a previous study using transfected COS1 cells, we have demonstrated effective trans-
port of eprotirome by NTCP and modest transport by OATP1B1, whereas OATP1A2 and 
OATP1B3 appeared to be inactive. However, these studies were done with untagged 
constructs and the level of transporter expression was unknown. Therefore, we decided 
to study the transport of eprotirome in HEK293 cells transfected with the Flag-tagged 
OATP and NTCP constructs. The results indicated that uptake of eprotirome is stimu-
lated not only by NTCP and OATP1B1 but also by OATP1B3, whereas still no significant 
eprotirome transport was seen with OATP1A2 (Figure 3A).
We also examined the transport of the other liver-selective T3 analog GC-1 by the 
different Flag-tagged transporters in transfected HEK293 cells. Compared with control 
empty vector-transfected cells, uptake of GC1 was stimulated 3.8-fold by OATP1B1, 2.0-
fold by OATP1B3 and 1.8-fold by NTCP, but not by OATP1A2 (Figure 3B).
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Figure 2. Uptake of radioactive T3 and T4 (1 nM vs 10 µM) by HEK293 cells transfected with empty vector 
(EV) or Flag-tagged OATPs and NTCP in medium containing 0.1 % BSA. The highest uptake by endogenous 
transporters was seen for 1 nM T3. With 10 µM T3 transfected OATP1B1 showed the greatest fold induction 
of TH uptake, while for 10 µM T4 transfected OATP1B3 stimulated the uptake most effectively.
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Next, we examined to what extent OATP1A2, 1B1, 1B3 and NTCP increase the nuclear 
availability of eprotirome and GC-1 using HEK293 cells co-transfected with Flag-TRβ1 
and pdV-L1, a construct coding for a TRE-dependent luciferase reporter and a control 
renilla reporter. The luciferase/renilla ratio was used as a measure of the transcriptional 
activity of eprotirome and GC-1.
Incubation of control HEK293 cells with 1 nM eprotirome resulted in a 2.8-fold increase in 
transcriptional activity, which was further stimulated 2.5-fold by expression of OATP1B1, 
1.8-fold by OATP1B3 and 1.9-fold by NTCP but not by OATP1A2 (Figure 3C). Incubation 
of control cells with 1 nM GC-1 resulted in a 3.1-fold increase in transcriptional activity, 
which was further stimulated 1.8-fold by OATP1B1 and 1.2-fold by NTCP but not by 
OATP1A2 or OATP1B3 (Figure 3D).
EV 1A
2
1B
1
1B
3
10
A1
0
1
2
3
4
5
 
Epro (fold uptake)
EV 1A
2
1B
1
1B
3
10
A1
0
1
2
3
4
 
Epro (fold TR activation)
EV 1A
2
1B
1
1B
3
10
A1
0
1
2
3
4
5
 
GC-1 (fold uptake)
EV 1A
2
1B
1
1B
3
10
A1
0
1
2
3
4
 
GC-1 (fold TR activation)
A	 B	
C	 D	
Figure 3. Uptake of radioactive eprotirome (A) and GC-1 (B) by HEK293 cells transfected with empty vector 
(EV) or Flag-tagged OATPs and NTCP. Highest stimulation of eprotirome uptake was seen by NTCP, while 
OATP1B1 facilitated GC-1 uptake most effectively. OATP1A2 did not show eprotirome or GC-1 uptake.
Expression of OATP1B1 stimulated transcriptional activity the most in HEK293 cells, incubated with 1 nM 
eprotirome and GC-1.
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Discussion
In this study, we demonstrate that liver-specific transporters OATP1B1, 1B3, 1A2 and 
NTCP are capable of transporting the TH analog GC-1 across the plasma membrane, a 
crucial step to enable its activation of nuclear TRβ1 receptor. This supports the hypoth-
esis that transporters may be used to target TH analogs to specific tissues.
In our previous study, we showed that mainly OATP1B1, 1B3 and NTCP facilitate the cel-
lular uptake of the TH agonist eprotirome. Because GC-1 showed similar lipid-lowering 
effects as eprotirome in both animal studies and human clinical trials146,162,170 and high 
structure similarity to eprotirome, we extended our experiments by testing the same 
transporters in their uptake of GC-1. Besides their ability to facilitate the cellular uptake 
of GC-1, the transporters OATP1B1, 1B3, 1A2 and NTCP also induced the transport of 
(mainly high concentrations) T3 and T4 into the cells.
OATP1B1 and OATP1B3 are considered to be liver-specific and are localized at the 
sinusoidal membrane of hepatocytes where they play an important role in the he-
patic clearance of albumin-bound amphipathic organic compounds and also mediate 
sodium-independent transport of TH, steroids, drugs and bile salts. The expression of 
OATP1A2 in humans includes the liver but also the brain, kidney and intestine.48,53,54,180,181 
NTCP is expressed at the basolateral membrane of hepatocytes, where it transports bile 
acids, steroid sulfates and iodothyronine sulfates in a sodium-dependent manner.20,21,85
In experiments using COS1 cells transfected with empty vector, very little GC-1 was 
taken up by the cells suggesting a negligible presence of endogenous transporters 
for GC-1 in this cell line. In HEK293 cells, the endogenous expression of OATP1A2, 1B1, 
1B3, and NTCP is reported to be low182 however, more endogenous uptake of GC-1 
was observed in these cells compared to COS1 cells. This points towards the presence 
of other, yet unidentified, transporters for GC-1 in HEK293 cells. This is confirmed by a 
marked stimulation of the TRβ1-mediated action of GC-1 in control HEK293 cells. In 
contrast, expression of the transporter constructs in COS1 cells effectively increased 
the nuclear availability of GC-1, confirming cellular GC-1 uptake by these transport-
ers. In addition, in our previous study171 we showed cellular uptake of eprotirome in 
HEK293 and JEG3 cells transfected with empty vector. This supports the existence of 
other transporters for both GC-1 and eprotirome in liver and other tissues. Possible 
expression of such transporters in cartilage could explain the unwanted side effects of 
eprotirome in long-term studies in dogs.
Since it has been reported that the tested transporters facilitate the transport of bile 
acids, we tested the uptake of TCA by these transporters in both COS1 and HEK293 
cells. Expression of OATP1B3 and 1B1 resulted in mild cellular uptake of TCA, especially 
in HEK293 cells, while NTCP showed much more convincing TCA transport into the cells 
(13.2 vs 48.5 fold in COS1 vs HEK293 cells). Despite the pronounced functional activity 
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of NTCP in HEK293 cells, we were unable to visualize the expression of the NTCP protein 
in this cell line by immunoblotting. A clear expression of NTCP in COS1 cells, supports 
the proper function of our NTCP transporter plasmid and suggests that HEK293 cell-
specific factors could interfere with the stability of the used Flag-epitope attached to 
the NTCP transporter. Possibly, Flag-NTCP undergoes sulfation or ubiquitin-mediated 
degradation in HEK293 cells, which enables visualization of the protein on Western 
blot.183,184 We tested inhibition of Flag sulfation using sodium chlorate and inhibition of 
ubiquitin-mediated degradation using the proteasome inhibitor MG132 and bortezo-
mib however, this did not improve the expression of Flag-NTCP on immunoblot nor the 
uptake of TCA by NTCP (data not shown).
In addition, we explored the effect of co-transfecting the ancillary protein PDZK1 since 
it has been shown that interaction with PDZK1 is necessary for functional expression of 
many members of the OATP transporters at the plasma membrane.87–89 Unfortunately, 
this did not change the uptake capacity nor the protein expression of the tested trans-
porters suggesting that endogenous levels of PDZK1 are sufficient for proper function 
of the transfected transporter proteins or that other, likely liver-specific factors neces-
sary for OATP-PDZK1 interaction, were lacking in our used cell models. We studied GC-1 
transport in vitro under conditions that may not represent the in vivo situation. Thereby, 
it is likely that in vivo OATP1A2, 1B1, 1B3 and NTCP transport other physiological sub-
strates or drugs, that can interfere with GC-1 transport.
It has been shown in animal studies that TH analogs can lower cholesterol via induc-
tion of the LDL-receptor, which promotes cholesterol reabsorption, and CYP7A1, which 
catalyzes the main step of cholesterol to bile acid conversion. These mechanisms could 
work additively with statins, which also increase liver LDL-receptor expression and ad-
ditionally suppress liver HMG-CoA reductase activity.185–187 From this perspective, it is 
very intriguing to study liver-specific targeting of cholesterol reducing thyromimetics. 
However, it is necessary to fully understand whether these TH analogs are exclusively 
transported to the liver and if these analogs only show TRβ1 selectivity. Our current 
study unraveled a small piece of the large puzzle regarding the mechanisms of how TH 
analogs can be targeted to specific tissues depending on the transporters they express.
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Abstract
Background
Recently, the first patients with resistance to thyroid hormone (RTHα) due to inacti-
vating mutations in the thyroid hormone receptor alpha (TRα) were identified. These 
patients are characterized by growth retardation, variable motor and cognitive defects, 
macrocephaly and abnormal thyroid function tests. Our objective was to characterize a 
young girl (18 months) with a mutation in both TRα1 and TRα2, and study the effects of 
early levothyroxine (LT4) treatment.
Methods
The patient was assessed clinically and biochemically before and during 12 months of 
LT4 treatment. In addition, we studied the consequences of the mutation for TRα1/2 
receptor function in vitro.
Results
At 18 months of age, the patient presented with axial hypotonia, delayed motor de-
velopment, severe growth retardation and abnormally elevated T3/T4 ratios. RTHα was 
suspected and concomitantly a c.632A>G/p.D211G missense mutation was identified, 
affecting both the TRα1 and TRα2 proteins. This mutation was also found in the girl’s 
father. LT4 treatment was started, resulting in a marked improvement of her hypoto-
nia, motor skills and growth. Functionally, the missense mutation led to a decreased 
transcriptional activity of TRα1, which could be overcome by higher T3 levels in vitro. 
The mutant TRα1 showed a moderate dominant negative activity on WT TRα1. In con-
trast, WT TRα2 and mutant TRα2 had negligible transcriptional activity and showed no 
dominant-negative effect over TRα1.
Conclusions
This report describes the phenotype of a young RTHα patient with a mild TRα mutation 
before and during early LT4 treatment. Treatment had beneficial effects on her muscle 
tone, motor development and growth.
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Introduction
Thyroid hormone (TH) is essential for normal development and metabolism. The 
majority of TH actions is mediated by binding of triiodothyronine (T3), the bioactive 
form of TH, to nuclear thyroid hormone receptors (TRs). TRs bind as heterodimers with 
Retinoid X Receptors (RXRs) to TH response elements (TREs), thereby regulating target 
gene expression.1,105,108 TRs are encoded by 2 genes (THRA and THRB), from which dif-
ferent isoforms are generated, with TRα1, TRβ1 and TRβ2 being highly homologous T3 
binding isoforms. TRα1 is preferentially expressed in the CNS, bone, heart and intestine 
while the non-T3 binding isoform TRα2 is more widely expressed. TRβ1 is considered 
the major isoform in liver, kidney, and thyroid. TRβ2 has a more restricted expression 
pattern regulating neurosensory development as well as the hypothalamus-pituitary-
thyroid (HPT) axis.67,108,109
For over 20 years it has been known that heterozygous mutations within 3 hotspots 
of the ligand-binding domain (LBD) of TRβ result in resistance to thyroid hormone 
β (RTHβ), a clinical syndrome characterized by elevated serum TH levels, a non-sup-
pressed TSH, and a variable phenotype comprising goiter, tachycardia and increased 
energy expenditure. Recently, the first patients with RTHα due to mutations in the LBD 
of TRα1 have been identified. These patients are characterized by growth retardation, 
variable motor and cognitive defects, macrocephaly and abnormal thyroid function 
tests (elevated T3/T4 and T3/rT3 ratios with normal TSH levels).151,153,178,188–191 Recently, 
Moran et al. identified the first family with a mutation in both TRα1 and TRα2.192 Patients 
in this family displayed a similar clinical and biochemical phenotype as patients with a 
mutation in TRα1 alone, suggesting that the mutation in TRα2 does not contribute to 
the nature or severity of the phenotype.192,193 Although only a few patients with RTHα 
have been identified so far, the severity of the phenotype appears to be related to the 
location and type of the mutation in TRα1. Considering the crucial role of TH during 
development, RTHα patients may benefit differently from levothyroxine (LT4) treatment 
depending on the severity of the mutation and the timing of treatment.151,153,178,188,190–192
In this study, we describe the youngest patient identified with RTHα so far. She was 
diagnosed with a mild mutation in both TRα1 and TRα2 and was treated with LT4 from 
the age of 18 months onwards. Beneficial effects of treatment on different parameters 
such as motor development, growth and thyroid function tests are supported by in 
vitro data showing that the reduced sensitivity of the mutant TRα1 towards T3 could be 
overcome by higher T3 concentrations.
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Patients, materials and methods
Index patient
Because of suspected central hypothyroidism, the index patient was referred to a pe-
diatric endocrinologist, who conducted extensive thyroid function tests showing low 
FT4 and rT3 levels, with a high T3 and a normal TSH concentration. Based on the clinical 
phenotype and this typical biochemical profile, a mutation in THRA was suspected.
Clinical and biochemical assessment
Written informed consent was obtained from the parents of the index patient. The study 
was approved by the Medical Ethics Committee of the Amsterdam Medical Center.
From the age of 18 months onwards, the girl underwent detailed physical examinations 
(growth parameters, head circumference) by the pediatric endocrinologist once every 
2–3 months. In addition, biochemical measurements (T4, FT4, T3, rT3, TSH, thyroglobu-
lin, TBG, IGF-1, IGFBP-3, SHBG, ferritin, complete blood count), imaging (skeletal X-ray) 
and motor developmental tests (Alberta Infant Motor Scale (AIMS)194 and the Bayley 
Scales of Infant and Toddler Development (Bayley III-NL))195 were performed at specific 
time points.
Genetic analysis
Sequencing of exons 6–9 of THRA [GenBank: NM_199334.3] was performed as previ-
ously described.178 The sequence results were compared to the reference sequence of 
THRA. To exclude PCR errors, the amplification and sequencing of the exon carrying the 
mutation was repeated.
Functional characterization of the mutant TRα1 and TRα2
DNA constructs and mutagenesis
The mammalian expression vector pcDNA3-FLAG-TRα1 was used, containing the full 
length coding sequence of human TRα1 with a 5’-FLAG tag and optimized Kozak 
sequence as previously described.151 The pcDNA3-FLAG-TRα2 expression vector was 
generated according to the same methods (see Supplemental Table 1 for primers). The 
RXRα plasmid was generated by cloning the full length coding sequence of human 
RXRα into the EcoRI and XbaI sites of the pcDNA3 expression vector (see Supplemental 
Table 1 for primers).
Mutations in TRα1 and TRα2 were generated by site directed mutagenesis using the 
QuickChange II Mutagenesis kit (Agilent Technologies, Amstelveen, NL) according to 
the manufacturer’s instructions. The presence of the introduced mutations was con-
firmed by sequencing.
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To study the transcriptional activity of WT and mutant TRα1 and TRα2, a construct was 
used containing a DR+4 TRE-dependent firefly luciferase reporter and a control renilla 
luciferase reporter (pdV-L1; gift from Dr. W.S. Simonides, VUMC, NL129).
Cell culture and transfection
JEG3 cells were maintained in Dulbecco’s modified Eagle’s/F12 medium supplemented 
with 9 % FBS and 100 nM Na2SeO3 at 37˚C and 5 % CO2. To deplete cells of TH, charcoal-
treated FBS (CT-medium) was used instead during 48 hours. Cells were transfected at 
80–90 % confluence with 100 ng pdV-L1 luciferase-renilla reporter construct together 
with 100 ng WT or mutant TRα1, or the combination of 50 ng WT and 50 ng mutant 
TRα1 using Xtreme Gene 9 transfection reagent (Roche Diagnostics, Almere, NL) ac-
cording to the manufacturer’s protocol. To explore the possible effect of the mutation 
on TRα2 function, WT TRα1 was co-transfected with WT or mutant TRα2 in different 
ratios (1:1, 1:10, 1:50).
Luciferase assays
Transcriptional activity of WT and mutant receptors was determined using the Dual-
Glo Luciferase kit (Promega, Leiden, NL), as described before.153 The luciferase activity 
was normalized to the renilla activity to adjust for transfection efficiency. The results 
are presented as the means ±SEM of at least three or more independent experiments, 
carried out in triplicate.
Immunoblotting
To determine expression of WT and mutant TRα1 and TRα2, transfected cells were 
lysed in ice-cold RIPA buffer supplemented with the Complete Protease Inhibitor 
cocktail (Roche Diagnostics, Almere, NL). The lysates were cleared by centrifugation for 
5 min at 3000 rpm and the protein concentration of the supernatant determined by 
bicinchoninic assay (BCA) (Fisher Scientific, Landsmeer, NL). Proteins were separated 
by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. The mem-
branes were blocked in TBST / 5 % milk and probed overnight at 4˚C with a 1:1000 
dilution of the FLAG M2-antibody (F1804 Sigma-Aldrich). Bound antibody was detected 
with a HRP-conjugated goat-anti mouse antibody ((#172–1011 Bio-Rad Life Science, 
Veenendaal, NL) and visualized by enhanced chemiluminescence using the Alliance 4.0 
Uvitec platform (Uvitec Limited, Cambridge, UK).
Electrophoretic Mobility Shift Assays (EMSA)
Direct binding of WT and mutant TRα receptors to DNA was tested by EMSA, using a double 
stranded overlapping oligonucleotide probe labelled with a fill-in reaction using Klenow 
fragment in the presence of32P-labeled dCTP.196 The sequences of the oligonucleotides 
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used for the synthesis of the DR+4 TRE-containing probe are listed in the Supplemental 
Table 1. The32P-labeled probe was purified using NucAway Spin Colums (Life Technolo-
gies, Bleiswijk, NL). Receptor proteins were transcribed and translated in vitro using the 
TnT Quick Coupled Transcription/Translation System (Promega, Leiden, NL), according to 
the manufacturer’s protocol. The binding assays were performed according to previously 
described methods.197,198 Radioactive spots were visualized by autoradiography.
Statistical tests
Statistical differences between WT and mutant receptors were calculated using Stu-
dent’s t-test. P-values < 0.05 were considered statistically significant.
Results
Case report and clinical assessment of the index patient at baseline
The girl was born at term by vacuum extraction after an uncomplicated pregnancy. 
Birth weight was 4000 g, and Apgar scores 5, 7 and 9 after 1, 5 and 10 minutes, re-
spectively. After an uneventful neonatal period, including a normal neonatal congenital 
hypothyroidism screening result (T4 62 nmol/L [-1,3 SD], TSH 1 mIU/L), the girl displayed 
hypotonia and slow motor development, whereupon she was referred to a pediatric 
physical therapist. At first consultation at the age of 8.5 months the hypotonia was 
found to be predominantly “axial”. Motor developmental testing,194 yielded an AIMS 
score below the 5th percentile, indicating severe delay in motor development.
At the age of 10.5 months, the girl was referred to a pediatric neurologist for lack of 
progression in motor development and persisting hypotonia. In the absence of “alarm” 
signs suggestive of serious neuromuscular disease, and because cognitive develop-
ment was judged normal, diagnostic testing was postponed and frequent physical 
therapy (PT) was continued. At the age of 12 months, the girl rolled over from tummy 
to back and vice versa for the first time, a milestone normally occurring at 9 months199), 
but she was still unable to crawl or pull herself up to a standing position, characteristic 
milestones for 12 months199). Although the AIMS was not routinely performed after the 
first PT consultation the physical therapist reported no clear improvement up to the 
age of 18 months (based on home video fragments filmed between the ages of 17 and 
18 months the physical therapist estimated the AIMS score at that age between 20 and 
30, still far below the 5th percentile; Figure 2D).
Because of persistent hypotonia, lack of improvement in motor development and 
mild speech delay (babbling and the use of only one word), additional investigations 
were performed around the age of 17 months. A full blood count and blood chemistry 
(including liver enzymes and creatine kinase), and electromyography were normal. 
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However, repeated laboratory testing revealed FT4 concentrations (9.0–9.8 pmol/L) 
just below the lower limit of the reference interval (10.0–20.0 pmol/L) in the presence 
of normal TSH concentrations (2.0–5.6 mIU/L; reference interval 0.48–4.6 mU/L). At 
this point, she was referred to a pediatric endocrinologist, at the age of 18 months for 
suspicion of central hypothyroidism. The medical history revealed mild constipation 
from the age of 6 months onwards, but no other problems. The family history revealed 
primary hypothyroidism in the maternal grandmother, but no thyroid or pituitary disor-
ders in other family members or in the father’s family.
On physical examination height was 73 cm (-2.77 SD), weight 10.6 kg (+2.11 SD), BMI 
19.89 (+2.17 SD) and head circumference 47 cm (0 SD) (Figures 2A-2B). The face and 
nasal bridge were broad, but there was no macroglossia. Skin tags were absent. Neu-
rological examination showed impaired trunk balance with axial hypotonia and more 
pronounced hypotonia in the arms than in the legs. Repeated, but more extensive 
thyroid function testing showed low FT4, T4 and rT3, high T3 and normal TSH concen-
trations, and increased T3/T4 and T3/rT3 ratios (Table 1), supporting clinical suspicion 
of a mutation in THRA.
Genetic assessment
Sequencing of THRA indicated that the index patient and her father were heterozygous 
for a nucleotide substitution (c.632A>G), resulting in an aspartic acid to glycine substi-
tution at codon 211 (p.D211G) in both TRα1 and TRα2 (Figure 1). This mutation is not 
present in public databases.
Clinical assessment of the index patient during LT4 treatment
Because of the presumptive diagnosis of central hypothyroidism, awaiting the results 
of THRA mutation analysis, treatment with LT4 was started with a daily dose of 3.5 μg/
kg body weight. The dose was gradually increased to a final dose of 62.5 μg (5.25 μg/
kg body weight). After 6 months of LT4 treatment (chronological age of 24 months), 
the index patient showed clear improvement in motor development: her hypotonia 
had almost disappeared and she was able to crawl, sit and walk independently, albeit 
with a broad gait. Repeat assessment by the referring pediatric neurologist showed no 
clear abnormalities. AIMS testing by the same physical therapist yielded a score of 54, 
corresponding to the 50th percentile at 12 months of age (Figure 2C). In addition, the 
parents found their daughter to be livelier, less tired, and her bowel movements had 
normalized to once daily. Her speech was still slightly delayed (use of a few words, but 
not yet two-word phrases (milestone: 24 months199)). Length had increased to -1.98 SD 
and head circumference +0.76 SD (Figure 2A,B). Bone age was delayed (9 months at 
chronologic age of 21 months). On LT4 treatment, plasma FT4 normalized and TSH was 
suppressed (Table 1).
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Figure 1. Molecular analysis of THRA in the index patient and her father.
(A) Sequence analysis of exon 7 of THRA shows the nucleotide substitution (c.632A>G), corresponding to 
an aspartic acid to glycine substitution at codon 211 (D211G) in both the index patient and her father, 
which is absent in her mother (B).
Table 1. Biochemical characteristics of the index patient before and on levothyroxine treatment.
Biochemical measurements in the index patient
Variable Reference values Before treatment On treatment
(6 months)
On treatment
(12 months)
T4 70 – 150 nmol/L 110 145 165
FT4 10 – 23 pmol/L 9.0 15.5 19.1
T3 1.3 – 2.7 nmol/L 3.6 3.9 5.0
rT3 0.11 – 0.44 nmol/L 0.09 0.18 0.19
TSH 0.5 – 5.0 mE/L 4.40 < 0.01 0.01
T3/T4 (x100) 1.42 – 3.05 3.27 2.69 3.03
T3/rT3 3.1 – 13.0 40 21.67 26.32
Thyreglobulin 0.0 – 45 pmol/L 19.0 5.0 6.0
TBG 200 – 650 nmol/L 800 400 420
IGF-1 3.0 – 20 nmol/L 1.0 8.0 8.0
Hemoglobin 6.0 – 9.0 mmol/L 6.2 6.7  
MCV 70 – 85 fL   85.1  
Ferritin 15 – 150 μg/L   312  
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After one year of LT4 treatment, still at a dose of 62.5 μg per day, the now 30 months 
old girl showed further progress in motor development, with Bayley III-NL scores195 for 
gross and fine motor skills of 50 and 41, corresponding to developmental ages of 19 
and 25 months, respectively. Speech development had also improved: the girl was now 
able to say two-word phrases (milestone: 24 months199). Formal neurological examina-
tion at the age of 32 months revealed only very mild hypotonia, which disabled her to 
A B
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Figure 2. Phenotypic characteristics of the index patient.
(A) The index patient’s growth chart showing deflecting growth between the ages of 6 and 18 months, but 
clear catch-up growth after the start of levothyroxine treatment at the age of 18 months. (B) Chart showing 
the index patient’s head circumference between the ages of 18 and 30 months. (C) The index patient had a 
severe delay in motor development, as measured by the Alberta Infant Motor Scale (AIMS), which improved 
after the start of treatment.
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change from lying to sitting position. In order to compensate, she rolled over to her 
tummy and pushed herself to a sitting position. Further assessment showed normal 
gross and fine motor skills and symmetric reflexes. In addition, length had increased to 
-1.92 SD, head circumference to +1.84 SD, and bone age to 21 months (chronological 
age 30 months), respectively.
Clinical assessment of the girl’s father
The father of the patient has the same mutation and has not been treated to date. 
No detailed data on childhood development are available, but he reported delayed 
puberty. At the age of 15 years he had four epileptic episodes for which he was treated 
with valproic acid. Furthermore, he suffered from constipation (hard stools 2 – 3 times 
a week). Physical examination showed coarse facies, macrocephaly (+ 2.5 SD), a short 
stature (-1.19 SD) and, an increased body mass index (28.3 kg/m2). Blood pressure 
(135/85 mmHg) and bone mineral density (femoral head: Z-score -0.3, T-score -0.5; 
lumbar spine: Z-score 0.9, T-score 0.9) were normal. In addition, neuropsychological 
evaluation showed normal performances on memory, language, attention and execu-
tive function tests together with a normal processing speed. Lastly, his biochemical 
profile (abnormal T3/T4 and T3/rT3 ratios with a normal TSH and a mild anemia; Table 2) 
fitted well with the previous patients identified with RTHα.151,153,178,188,189,192
Table 2. Biochemical characteristics of the girl’s father.
Biochemical measurements in the girl’s father
Variable Reference values  
T4 70 – 150 nmol/L 85
FT4 10 – 23 pmol/L 10.1
T3 1.3 – 2.7 nmol/L 2.25
rT3 0.11 – 0.44 nmol/L 0.12
TSH 0.5 – 5.0 mE/L 1.60
T3/T4 (x100) 1.42 – 3.05 2.65
T3/rT3 3.1 – 13.0 18.75
Thyroglobulin 0 – 45 pmol/L 13
TBG 200 – 650 nmol/L  
IGF-1 8 – 41 nmol/L 24
Hemoglobin 8.5 – 10.5 mmol/L 7.3
MCV 80 – 100 fL 98.2
Ferritin 25 – 300 μg/L 272
Functional analysis of mutant TRα1 and TRα2
To determine the effect of the mutation on TRα1 function, we expressed FLAG-tagged 
WT or D211G-TRα1 in JEG3 cells and determined T3-dependent transcriptional activity. 
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In luciferase assays, the D211G mutant TRα1 showed a reduced apparent affinity for 
T3 compared to WT TRα1 (EC50 10.1 nM T3 for D211G TRα1 vs. 0.49 nM T3 for WT TRα1, 
     A B
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Figure 3. Functional analysis of D211G mutant TRα1 and TRα2.
(A) The transcriptional activity of WT and D211G TRα1 was tested in JEG3 cells transfected with a T3-depen-
dent promoter-reporter construct. Mutant TRα1 had a reduced affinity for T3 compared to WT TRα1 at low 
T3 concentrations, while at higher T3 concentrations the maximal transcriptional activity was similar. When 
co-expressed, mutant TRα1 showed no dominant-negative effect on WT TRα1. Results are the means ± SEM 
of 3–5 experiments. (B) The biological activity of TRα2 and the possible interaction with TRα1 was studied 
by transfecting cells with an increasing amount of WT TRα1 (1–50ng) and increasing ratios (1:1 – 1:50) of 
WT or D211G TRα2. WT TRα2 and mutant TRα2 showed no transcriptional activity and both TRα2 recep-
tors hardly had any dominant-negative effect over TRα1. Results are the means ± SEM of 3–8 experiments. 
(C) Expression of the TR proteins was verified by western blot analysis, showing a similar expression of 
WT and mutant TRα1 and TRα2. (D) Electrophoretic mobility shift assay showing the binding of hormone 
bound or unbound WT and D211G TRα1 to a direct repeat (DR+4) thyroid response element.
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p < 0.001). However, the D211G mutant had a similar maximal transcriptional activity 
as WT TRα1 (Figure 3A). When co-expressed, the D211G mutant TRα1 had a moderate 
dominant-negative effect on WT TRα1 function (Figure 3A).
Independent of the T3 concentration, WT TRα2 and D211G TRα2 showed no transcrip-
tional activity. Co-transfection of WT TRα1 with increasing amounts of WT or mutant 
TRα2 (1:1, 1:10, 1:50) suppressed transcriptional activity, but the same was the case after 
increasing the amount of WT TRα1 plasmid alone (Figure 3B). This indicates that both 
WT and mutant TRα2 exert little or no dominant-negative effect over TRα1.
A similar expression of WT TRα1, WT TRα2 and D211G TRα2 proteins was confirmed by 
immunoblotting lysates for FLAG (Figure 3C).
In addition, we tested the binding capacity of WT and mutant TRα1 and TRα2 to a32P-
labeled DR+4 TRE probe by EMSA in the absence or presence of RXRα and T3. WT and 
mutant TRα1 bound similarly to the TRE as heterodimers with RXRα independent of T3, 
whereas no binding of WT TRα2 or mutant TRα2 to the probe was detected under any 
of the conditions tested (Figure 3D). In the absence of RXRα both WT and mutant TRα1 
still bound to the TRE, but the binding was less pronounced (data not shown).
Overall, these results suggest that D211G TRα1 has a reduced affinity for T3, while DNA 
binding and expression levels are similar to WT TRα1. At high concentrations of T3, 
maximal transcriptional activity of the mutant is the same as for WT TRα1. In contrast 
to TRα1, both WT TRα2 and D211G TRα2 show no transcriptional activity nor binding to 
the DR+4 TRE.
Discussion
In the current study we describe the effects of early LT4 treatment in a very young girl 
with a mild missense mutation in TRα1/2. We report beneficial effects during treatment 
on her muscle tone, motor development and growth. This is in line with our in vitro 
data showing that the reduced transcriptional activity of the mutant receptor could be 
overcome by higher T3 concentrations, and that D211G TRα1 has a moderate dominant 
negative effect on WT TRα1. The D211G mutation in TRα2 does not influence the func-
tion of WT TRα1 or TRα2 and does not seem to contribute to the phenotype of the 
patient.
Although the index patient had some clinical characteristics associated with hypothy-
roidism (growth retardation, and a broad face and nasal bridge), her hypotonia and 
delay in motor development were the prime reasons for referral and consultation. 
Because of presumed central hypothyroidism, based on normal TSH with low-normal 
FT4 levels, LT4 treatment was started at the age of 18 months. LT4 treatment had a 
beneficial effect on the girl’s development: her muscle tone improved and her motor 
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development accelerated. In addition, during treatment she showed catch up growth 
and a normalization of her FT4 and rT3 levels. The suppressed TSH concentrations 
upon LT4 treatment are in line with previous reports153 and indicate an intact HPT-axis 
feedback, which is predominantly regulated via TRβ2.200 Our in vitro data support the 
developmental benefit of LT4 treatment, since transcriptional activity of the mutant 
TRα1 could be restored in vitro by higher T3 concentrations.
The fact that the girl’s father reached adulthood without major complications as-
sociated with the TRα1 D211G mutation supports the relatively mild character of this 
mutation with a decreased but not absent affinity for T3. The difference in severity 
between the developmental phenotype of the father and the daughter is remarkable, 
but similar to RTHβ in which the severity of the phenotype also varies among different 
subjects carrying the same mutation.7 The reasons for this variability are not yet fully 
understood, but may result from genetic variability in other genes, such as cofactors 
involved in TH action.
Anemia is a frequent characteristic in RTHα and was only present in the father of the 
index patient. Usually, it concerns a normocytic normochromic anemia however, in 
three cases the MCV was raised.151,188,193 Several studies in humans have indicated an 
association between hypothyroidism and anemia.201,202 In addition, data from animal 
models point towards an important role for TRα in erythropoiesis.203–206 The molecular 
mechanisms underlying the anemia in RTHα patients remain to be elucidated.
The phenotype of the girl shows similarities with that of heterozygous TRα1-R384C mu-
tant mice, having a mutant receptor with a 10-fold reduced affinity for T3.207 Affected 
animals show delayed postnatal development together with locomotor dysfunctions. 
Interestingly, treatment with supra-physiological TH doses in the postnatal period, but 
not in adulthood, substantially improved motor function.208 These TRα1-R384C mutant 
mice also suffer from growth retardation, which is overcome in adulthood since they 
reach a near-normal size.111,207
The phenotype of the index patient and her father resemble the clinical characteristics 
of previously described RTHα patients with a mutation in TRα1 alone.151,153,178,188–190 The 
D211G mutation in TRα2 does not seem to contribute to this phenotype, which is in line 
with what has been described in three patients with the A263V mutation, also affecting 
TRα1 and TRα2.191,192 Our findings are also in line with the phenotype of the TRα2KO 
mice, since the phenotypic changes in these mice are most likely not attributable to 
the loss of TRα2, but to a compensatory overexpression of TRα1 in that particular mouse 
model.209 In contrast, a recently described patient193 with a N359Y mutation in TRα1/2 
showed a distinct clinical phenotype consisting of severe bone malformation, chronic 
diarrhea, macrocytic anemia and hypercalcemia. To date it remains unclear whether this 
phenotype is the result of the mutation in THRA alone. Our in vitro results support a lack 
of effect of the mutation in TRα2, since WT and D211G TRα2 showed no transcriptional 
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activity both in the absence or presence of T3. Co-transfection of WT TRα1 with large 
amounts of WT or D211G mutant TRα2 suppressed the function of WT TRα1 in the same 
way as when we increased the concentration of WT TRα1 plasmid alone. This suggests 
that the suppressive effect is caused by an increased amount of transfected plasmid 
and not by a dominant-negative effect of the TRα2 receptors towards WT TRα1.
The lack of effect of WT or mutant TRα2 on the transcriptional activity of TRα1 is ex-
plained by the observation that TRα2 does not bind to the TRE (DR+4) we used in our 
luciferase assays, independent of the absence or presence of RXRα. Under the condi-
tions of our experiments, competition for binding to the TRE is therefore absent and 
so is a suppressive effect of TRα2 on TRα1 function. These findings are supported by 
the study of Liu et al., describing that the possible dominant-negative effect of TRα2 
on TRα1 is not attributable to competitive binding to TREs or inadequate formation of 
heterodimers with RXRα.210
The fact that the girl’s father has RTHα with a relatively mild phenotype, which was 
detected only because of severe developmental delay of his daughter, supports the 
hypothesis that the incidence of RTHα could be much higher than currently estimated. 
Suggestively, the RTHα incidence could correspond to the incidence of RTHβ (1:40,000),7 
given the strong homology between the TRα1 and TRβ1 receptors. Moreover, although 
so far only a few mutations in TRα have been reported, they seem to cluster in a few 
hotspots similar to the pattern of TRβ mutations.211 Lastly, the paternal inheritance of 
the TRα mutation in this family, and maternal and paternal inheritance of TRα muta-
tions in three other families,153,178,189,192 suggests that transmission of TRα mutations from 
parents to offspring is less impaired in humans than in mice.112
This case study illustrates that RTHα patients with mild mutations, especially when 
diagnosed at a young age, are likely to benefit from LT4 treatment. This is supported by 
a previous case192 as well as by studies in TRα mutant mice.207,212
Since the index patient was initially suspected of having central hypothyroidism, we 
advocate a low threshold to measure T3 (and rT3) in the work-up of children with unex-
plained growth retardation or developmental delay who have a low or low-normal FT4 
in combination with a normal TSH.
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Supplementary Table 1. Primers used for generation of pcDNA3-FLAG-TRα2 expression vector, RXRα plas-
mid and DR+ TRE-containing probe.
  Forward primer (5’-3’) Reverse primer (5’-3’)
pcDNA3-FLAG-
TRα2
GTAGAATTCTGGCCGCAGAAATGGA 
CTACAAAGACGATGACGACAAGATG 
GAACAGAAGCCAAGCAAGG
GTACTCGAGACTCACTTTCAGGGAGAGGC 
TGCATTGCC
RXRα GTAGAATTCTGGCCGCAGAAATGGA 
CACCAAACATTTCCTGCC
CTATCTAGACTAAGTCATTTGGTGCGGCGC
DR+4 TRE
(half sites underlined)
ATCCCCGGGCGAGCTCTTCAGGTCA 
CTTCAGGTCACCGGG
GAAGAGCTCGCCCGGTGACCTGAAGTG 
ACCTGAAGAGCTC
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Abstract
Context
Recently, several patients with RTHα due to T3 receptor alpha (TRα) mutations were 
identified. The phenotype of these patients consists of varying degrees of growth im-
pairment, delayed bone, mental and motor development, constipation, macrocephaly, 
and near-normal thyroid function tests.
Objective
To describe the clinical phenotype of three new families with RTHα and thereby gain 
more detailed knowledge on this novel syndrome.
Design, setting, participants
RTHα was suspected in 3 index patients from different families. Detailed clinical and 
biochemical assessment, imaging and genetic analyses were performed in the patients 
and their relatives. In addition, functional consequences of TRα mutations were inves-
tigated in vitro.
Results
We studied 22 individuals from 3 families, and identified 10 patients with heterozygous 
TRα mutations: C380fs387X, R384H, and A263S, respectively. The frame-shift mutation 
completely inactivated TRα, whereas the missense mutations produced milder defects. 
These mutations were associated with decreasing severity of the clinical phenotype: 
the patient in family 1 showed severe defects in growth, mental and motor develop-
ment, whereas the 7 patients in family 3 only had mild clinical features. The most 
frequent abnormalities were anemia, constipation, and a delay in at least one of the 
developmental milestones. Serum (F)T3 ranged from high-normal to high, and serum 
(F)T4 and rT3 from normal to low. TSH levels were normal in all patients.
Conclusions
This large case series underlines the variation in the clinical phenotype of RTHα patients. 
RTHα should be suspected in subjects when even mild clinical and laboratory features 
of hypothyroidism are present along with high/high-normal (F)T3, low/normal (F)T4, 
and normal TSH.
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Introduction
Genetic disorders associated with impaired sensitivity to thyroid hormone (TH) include 
1) resistance to TH (RTHβ) due to mutations in THRB which codes for the T3 recep-
tor TRβ1 and TRβ2 isoforms, 2) the Allan-Herndon-Dudley syndrome (AHDS), a severe 
neurological disorder caused by mutations in the TH transporter MCT8, and 3) a multi-
system disorder caused by mutations in SBP2, a protein essential for the production 
of selenoproteins, including the TH activating and inactivating deiodinases.7,106,107,213 
Until 2012, no mutation was reported in THRA encoding T3 receptor subtypes TRα1 and 
TRα2. Products of the THRB and THRA genes show differential tissue expression.214–218 
TRβ1 is the predominant T3 receptor in liver, kidney, and thyroid, and TRβ2 is exclusively 
expressed in hypothalamus, pituitary, retina and cochlea. On the other hand, growth, 
development, and function of brain, bone, heart, and intestine are mainly dependent 
on interaction of T3 with TRα1. TRα2 does not bind T3 and its function is enigmatic.
Since 2012, 15 patients from 10 families have been reported with the RTHα syndrome 
due to mutations in THRA.130,151,153,188,193,219–221 The clinical pictures and TH profiles as-
sociated with RTHα and RTHβ are consistent with the expression patterns of THRA and 
THRB. Elevated serum T3 and T4 with non-suppressed TSH levels are typical for RTHβ. 
Symptoms are usually mild but may include goiter, tachycardia, atrial fibrillation, mild 
mental retardation, hyperactivity, and increased resting metabolic rate.7,106,107 Patients 
with RTHα have varying degrees of developmental retardation, growth impairment, 
and constipation, with low to low-normal (F)T4, normal to high (F)T3, and normal to 
mildly elevated TSH levels.107,130,151,153,188,191,219–221
Here, we present the clinical and laboratory characteristics of the largest case series so 
far with 3 novel THRA mutations in a total of 10 patients resulting in a wide spectrum of 
RTHα phenotypes. More awareness of the variation in the clinical presentation of RTHα 
is likely to result in the identification of additional RTHα patients.
Patients and Methods
Patients
Three index patients with symptoms and signs suggestive of hypothyroidism associ-
ated with near-normal TH levels and their families were included. Detailed information 
regarding developmental milestones and symptoms of hypothyroidism were collected. 
The subjects underwent physical examination, including anthropometric measure-
ments, biochemical tests, imaging, genetic studies, and neurodevelopmental tests. The 
study was approved by the Medical Ethics Committee of Dokuz Eylül University. Written 
informed consent was obtained from all subjects and/or their parents.
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Neurodevelopmental and neuropsychological evaluation
Developmental state was evaluated with the Bayley Scales of Infant and Toddler Devel-
opment, Second Edition (Bayley II) in children < 3 years.222 Older children were tested 
with Wechsler Intelligence Scale for Children-Revised (WISC-R) intelligence tests.223 
Adult patients were assessed with Wechsler Adult Intelligence Scale to determine 
their IQ score and classification was done based on Wechsler classification system.224 
A neuropsychological test battery composed of Mini-Mental State Examination for 
general cognitive functioning, Oktem Auditory-Verbal Learning Test, Rey-Osterreith 
Complex Figure Tests for memory and visuospatial skills, and Stroop and Trail Making 
Tests for executive functioning were applied.225–227 Each test has been shown to be 
reliable and valid in the Turkish population and the details of the procedures can be 
found elsewhere.228–230 In addition, adult patients were examined for lifetime psychiatric 
diagnoses and family history.
Laboratory and imaging studies
The thyroid status of all subjects was initially evaluated using measurements of FT4, FT3 
and TSH in İzmir (Roche Diagnostics, Mannheim, Germany). Total cholesterol, creatinine 
kinase (CK), complete blood count, ferritin, SHBG, IGF-1, and IGFBP-3 were measured 
from blood samples obtained between 8 AM and 10 AM after an overnight fast using 
routine laboratory methods. Available serum samples were also assayed for TSH, FT4, 
T4, T3 (Vitros ECI technology, Ortho-Clinical Diagnostics, Beerse, Belgium), and rT3 (ra-
dioimmunoassay, Zentech, Angleur, Belgium) levels in Rotterdam. Hip and skull X-rays 
were obtained.
Identification and functional analysis of THRA mutants
THRA was analyzed for mutations as described.221 FLAG-tagged WT and mutant TRα1 
and TRα2 cDNA clones in pcDNA3 were obtained as described.221 Transcriptional 
activity of WT and mutant TRα1 was assessed using a reporter construct expressing 
firefly luciferase (LUC) under control of a T3 responsive promoter and renilla luciferase 
(REN) under control of a constitutive promoter as described.221 Expression of WT and 
mutant TRα1 and TRα2 was determined by immunoblotting using anti-FLAG antibody 
as described.221
Statistical tests
Statistical differences between WT and mutant receptors were calculated using a Stu-
dent’s t-test. P-values < 0.05 were considered statistically significant.
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Results
Clinical Assessment
Among 3 families, 10 patients were identifi ed with THRA mutations: 6 children and 4 
adults, 4 males and 6 females, age range 8 months – 56 years. The pedigrees, pho-
tographs and mutations of the patients are shown in Figure  1. Table  1 presents an 
overview of the clinical data, and Table 2231 summarizes the laboratory data. Results of 
neurological and neuropsychological tests are provided in Supplemental Table 2. Skull 
X-ray photographs are presented in Supplemental Figure 2. The families are presented 
in chronological order of diagnosis and evaluation of cases.
Figure 1. Pedigree and molecular analysis of THRA in the three index patients.
(A) Sequence analysis of exon 9 of THRA shows a deletion of 4 nucleotides (c.1138–1141delTGCC), resulting 
in a deletion and frameshift at codon 380 and an early stop at codon 387 (p.C380fs387X). This mutation is 
only present in the index patient (1.II.1). (B) In both the index patient (2.III.1) and his mother (2.II.1) a nucleo-
tide substitution (c.1151G>A) lead to an arginine to histidine substitution at codon 384 in TRα1 (p.R384H). 
(C) The index patient (3.III.6) and 6 other members of this family (3.III.1, 3.III.3, 3.III.5, 3.II.1, 3.II.3, 3.I.2) were 
heterozygous for a nucleotide substitution in THRA (c.G787T), leading to an alanine to serine substitution 
at codon 263 (p.A263S).
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Family 1
Patient 1.II.1(index case). The index patient was born at term (birth weight 3200 g) fol-
lowing an eventless pregnancy. First evaluation was made at the age of 16 months 
due to prominent developmental delay: she could not control her head until the age 
of 8 months (normal milestone < 2 months232), at 16 months she was not able to sit 
(normal milestone < 8 months,232) and had no teeth eruption (normal milestone before 
13 months (233). In addition, she suffered from constipation and she was noted to have a 
hoarse-sounding cry, coarse facies, macroglossia, and an umbilical hernia. Normocytic 
anemia, normal TSH, low FT4, high T3, and a normal TSH response to TRH (31.8 mU/L 
at 20 min) were found. At the age of 2, she was started on LT4 (4.5 µg/kg/day), and she 
has been treated since with various LT4 doses (1–3.7 µg/kg/day), with normalization of 
FT4 levels and suppression of TSH for most of the time. Despite treatment with LT4, she 
still had a delay in reaching several developmental milestones: sitting occurred at 26 
months (normal milestone < 8 months, ), resolution of umbilical hernia at 3 years, and 
closure of the anterior fontanelle at 5 years (normal milestone < 24 months,234). Men-
arche was at 12 years of age (normal range: 12.2 ± 0.9 years235). Hypertrophic obstructive 
cardiomyopathy, pericardial effusion, and nephrolithiasis developed during follow-up.
At her most recent visit at the age of 12.7 years, she was severely handicapped, was 
not able to walk, and had mild scoliosis. Her height was 127 cm (SD score [SDS] -3.49), 
weight 43.3 kg (SDS 0.04), body mass index (BMI) 26.85 (SDS 1.81), and head circumfer-
ence 57.4 cm (SDS 3.12). Serum TSH was suppressed but, despite LT4 treatment, serum 
T4 and FT4 levels were at the lower limit of normal, serum rT3 was decreased, T3 and FT3 
levels were increased, and the T3/T4 and T3/rT3 ratios were markedly elevated. General 
thickening of skull vault was demonstrated on cranial X-ray while femoral epiphyses 
were normal.
The mother (1.I.1) and father (1.I.2) of the index patient were not affected.
Family 2
Patient 2.III.1(index case). This boy was born after an eventless pregnancy with a birth 
weight of 3400 g. Macroglossia was evident at birth and was reported to ameliorate 
with time. He was first evaluated at the age of 8 months due to frequent upper respira-
tory tract infections. High FT3, low FT4 and a normocytic normochromic anemia were 
detected. A TRH test revealed a delayed TSH peak (24.3 mU/L) at 60 minutes. Physical 
examination revealed an anterior fontanelle of 5x3 cm [> 90th percentile (2.5 cm)],234 a 
decreased height (-0.63 SDS), increased BMI (1.25 SDS) and head circumference (2.02 
SDS). However, umbilical hernia and constipation were absent. Bone age corresponded 
to 6 months at the chronological age of 8 months. Lateral skull radiograph showed 3–4 
wormian bones at the conjunction of lambdoid and sagittal sutures and thickening of 
skull at the frontal and occipital region.
91
DIVERSE GENOTYPES AND PHENOTYPES OF THREE NOVEL THYROID HORMONE RECEPTOR ALPHA MUTATIONS
At 16 months of age the boy was tested for neuromotor and neuropsychological de-
velopment. His cognitive ability was only moderately impaired but his motor develop-
ment was more severely impaired.
Patient 2.II.1. The 35 years old mother of the index patient also showed delay in reaching 
several developmental milestones (Table 1). She had her first menstruation at the age 
of 13 and she became pregnant naturally despite a history of irregular menses requiring 
treatment. In adulthood, a number of characteristics associated with hypothyroidism 
were present, such as constipation and a slow speech. In addition, she showed several 
features of RTHα, borderline intellectual functioning, impaired executive functioning 
and mild deficits in memory. No psychiatric pathology according to DSM-IV was evi-
dent and, the patient did not have a history of a psychiatric disorder. Her parents (2.I.1 
and 2.I.2) and only sibling (2.II.2) were not affected.
Comparison of the two patients with the unaffected members indicates that elevated 
serum T3 and T3/rT3 ratio and anemia are distinctive features of RTHα in this family. Short 
stature is not a distinctive characteristic, although the affected mother (2.II.1) shows 
marked disproportionate growth. Head circumference and thickening of the skull are 
increased and serum IGF-1 is decreased in both patients but these abnormalities are 
also observed in the unaffected father (2.II.2) and grandfather (2.I.2) of the index patient.
Family 3
Patient 3.III.6 (index case). The index case was born at term with a birth weight of 3000 
g. He was evaluated first at the age of 13 months due to frequent infections, and low 
FT4, normal FT3 and TSH levels were detected. He frequently suffered from constipation 
and had a delay in tooth eruption (normal milestone < 13 months233 and his anterior 
fontanelle had closed at 2 years and 4 months (normal milestone < 24 months234). Mac-
roglossia, umbilical hernia and anemia were not present. Physical examination at the 
age of 2 years and 7 months showed mild growth retardation with a disproportionate 
body habitus and a mildly increased head circumference. Skull radiographs showed 
thickening of the skull at the occipital region. Neurological and neuropsychological 
examination at the age of 2 years and 8 months yielded scores for cognition and motor 
development in the normal range.
The index patient has two older sisters, one of whom is also affected. The affected sister 
(3.III.5) showed relatively mild growth retardation but otherwise normal development. 
Her serum T3 levels were higher and hemoglobin was lower than in her unaffected 
sister. Also, her global IQ, verbal and performance scores were lower than those of her 
older unaffected sister (3.III.4) but they were all in the normal range.
The index patient has three cousins, two of whom are also affected. One cousin (3.III.3) 
had clearly more clinical features of RTHα than his oldest sister (3.III.1), including delayed 
developmental milestones and constipation. Like the index patient, he showed a de-
CHAPTER 6
92
creased serum IGF1 level. He also revealed low average global, verbal and performance 
IQ scores. Both affected cousins had anemia.
The two mothers of the above children (3.II.1, 3.II.3) were affected. Both patients suffered 
from constipation and had anemia. In addition, radiological evaluation of the patients’ 
skull X-rays showed a thickening of the skull vault in combination with wormian bones. 
The mother of the index patient (3.II.3) demonstrated low-average intellectual func-
tioning, with a more prominent decrease in performance than in verbal IQ. The patient 
reported a period of antidepressant therapy after the suicide of her younger brother, 
but no psychiatric pathology was evident at the time of the interview. We were not 
able to evaluate any biological samples from the deceased (3.II.5), but his psychiatric 
story was insignificant before he committed suicide. Patient 3.II.1 had also received 
treatment for depression and panic attacks.
The index patient’s grandfather (3.1.2) was also affected and showed several RTHα 
characteristics during development as well as short stature and marked macrocephaly. 
He displayed low-average intellectual and verbal memory and executive functioning. 
The patient reported a depressive episode, where he used antidepressant medication 
for a year, after the suicide of his son (3.II.5).
The grandparents are consanguineous. The grandmother (3.I.1) is not affected although 
she has long-standing hypothyroidism from an unknown cause for which she receives 
LT4 therapy. Remarkably, she also has a short stature and macrocephaly.
An overview comparing the clinical and biochemical characteristics in this family is 
presented in Figure  3. Comparing the phenotypes of the affected and unaffected 
members, there are remarkably few distinctive RTHα characteristic in this family. Con-
stipation and mild developmental delays are seen in most but not all affected subjects. 
There appears to be no significant difference in TH levels, although the T3/rT3 ratio is 
higher in affected than in unaffected subjects. The most distinct feature of RTHα in this 
family is the low/borderline low hemoglobin level in 6 of the 7 affected subjects but in 
none of the unaffected relatives.
Genetic and molecular analyses
Family 1. Sequencing of genomic DNA indicated that the index patient was heterozy-
gous for a deletion of 4 nucleotides in exon 9 of THRA (c.1138–1141delTGCC), resulting 
in a deletion and frameshift at codon 380 and an early stop at codon 387 of TRα1 
(p.C380fs387X) (Figure 1). The mutation was absent in the parents of the patient, sug-
gesting a de novo mutation in patient 1.II.1.
Family 2. Sequence analysis showed that the index patient and his mother were het-
erozygous for a nucleotide substitution in THRA (c.1151G>A), leading to an Arg to His 
substitution at codon 384 in TRα1 (p.R384H) (Figure  1). Remaining members of the 
family did not carry the mutation.
93
DIVERSE GENOTYPES AND PHENOTYPES OF THREE NOVEL THYROID HORMONE RECEPTOR ALPHA MUTATIONS
Family 3. DNA sequencing indicated that the index patient, his middle sister, mother, 
grandfather, maternal aunt, oldest niece and cousin were heterozygous for a nucleo-
tide substitution in THRA (c.G787T), leading to an Ala to Ser substitution at codon 263 
(p.A263S) common to both TRα1 and TRα2 (Figure  1). The deceased member of this 
family (3.II.5) was not analyzed for THRA mutations; remaining members were negative.
All three mutations have not been detected in public databases.
Figure 2. Functional analysis of the C380fs387X, R384H and A263S TRα1 mutants.
(A) The transcriptional activity of WT and mutant TRα1 was tested in JEG3 cells transfected with a T3-depen-
dent promoter-reporter construct. The C380fs387X mutant had a negligible affinity for T3 compared to WT 
TRα1 at all T3 concentrations. When co-expressed, the C380fs387X mutant suppressed WT TRα1 function 
in a dominant negative manner. Results are the means ± SEM of 3–5 experiments. (B) At concentrations 
of 1–10 nM T3, the R384H mutant showed a reduced transcriptional activity, but at higher T3 levels the 
maximal transcriptional activity was similar to WT TRα1. Co-transfection of WT TRα1 with the R384H mutant 
resulted in a moderate dominant-negative effect. (C) The A263S mutant showed a comparable biological 
activity to WT TRα1, and co-expression of the A263S mutant hardly changed the function of WT TRα1.
Figure 3. Clinical and biochemical parameters of family 3 (A263S TRα).
(A) The height, body mass index (BMI), head circumference (HC) and sitting-to-total height (S/T height) 
of both affected (MT) and unaffected (WT) individuals are expressed in SDS values. Heart rate (HR) is ex-
pressed in beats per minute and the mean arterial blood pressure (BP) is expressed in mm Hg. (B) TSH 
(mU/L), FT4 (pmol/L), T3 (nmol/L), rT3 (nmol/L), T3/rT3, CK (U/L), ΔHb (Hb vs. the lower limit of normal, g/dL) 
and cholesterol (mg/dL) values of both WT and MT family members are presented.
CHAPTER 6
94
Functional analysis of the mutant receptors
To assess the effects of the mutations on the transcriptional activity of TRα1, luciferase 
assays were performed. In addition, the expression of all the receptor proteins was con-
firmed by Western blotting with an antibody against the N-terminal Flag epitope tag 
added to the receptor constructs. The C380fs387X, R384H and A263S mutant receptors 
showed similar expression levels as WT TRα1 (Figure 1).
Family 1. Analysis of JEG3 cells co-transfected with WT or mutant TRα1 and a DR+4 
TRE-luciferase reporter gene showed negligible activation of the C380fs387X mutant 
by up to 100 nM T3 in contrast to marked activation of WT TRα1 (EC50 0.4 nM T3). When 
co-expressed, the C380fs387X mutant suppressed WT TRα1 function in a dominant 
negative manner (Figure 2).
Family 2. The R384H and A263S mutations showed much milder effects on the function 
of TRα1. At concentrations of 1–10 nM T3, the R384H mutant TRα1 showed a reduced 
transcriptional activity, but at higher T3 levels the R384H mutant approached the activ-
ity of WT TRα1. EC50 values were 22-fold higher for the R384H mutant than for WT TRα1 
(8.7nM vs 0.4 nM T3; p < 0.05). Co-transfection of WT TRα1 with the R384H mutant did 
result in a moderate dominant-negative effect (Figure 2).
Family 3. The biological activity of the A263S mutant was comparable to that of WT 
TRα1 at most T3 concentrations, except at the lowest concentration (0.1 nM) T3 where 
WT TRa1 was stimulated 3.6-fold and the A263A mutant 1.5-fold. EC50 values of A263S 
mutant and WT TRα1 differed scarcely (0.83 nM vs 0.33 nM T3; p < 0.05). Co-expression 
with the A263S mutant hardly changed the function of WT TRα1, except that 0.1 nM 
T3 produced an intermediate response compared with cells transfected with WT TRa1 
alone or the A263S mutant alone (Figure 2). To investigate the biological activity of TRα2 
and its possible interaction with TRα1, we co-transfected cells with WT TRα1 together 
with WT TRa2 or the A263S mutant in various ratio’s (1:1–50). Independent of the T3 
concentration, WT and A263S mutant TRα2 showed neither transcriptional activity 
nor dominant-negative activity towards WT TRα1 when overexpressed (Supplemental 
Figure 1).
Discussion
In the current study we describe a total of 10 RTHα patients with three different muta-
tions in TRα. This large case series enables us to report on the diversity in the phenotype 
of patients with different mutations and compare the phenotypes of both affected and 
non-affected individuals from a family with the same mutation.
So far, 4 patients from 3 families have been described with frame-shift mutations in the 
C-terminal domain of TRα1: the F397fs406X mutation found in two patients from the 
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same family by van Mullem et al.,130,153 the A382fs388X mutation found in one patient 
by Moran et al.,188 and the C380fs387X mutation in patient 1.II.1 in the present study. 
Although only 3 frameshift mutations have been identified yet, the more upstream 
the shift of these mutations occurs, the more severe the clinical phenotype appears 
to become. The father and daughter with the most downstream F397fs406X mutation 
showed marked short stature and mild delay of motor and mental development but 
had normal IQ.130,153 They had been treated with LT4 from the age of 6 and 42 years, 
respectively. The 45-year-old female with the A382fs388X mutation, who had been 
treated with LT4 from the age of 3 months, presented with more severe cognitive 
impairment and constipation, but she was still able to walk and talk, and had only mild 
short stature.188 Patient 1.II.1 with the most upstream C380fs387X mutation has a more 
severe phenotype than the above cases. Late initiation of LT4 treatment at 2.5 years 
of age cannot be the only cause for her global developmental delay as LT4 treatment 
of the patients with the F397fs406X mutation was started even much later.130,153 Also 
growth did not ameliorate with LT4 treatment, and cardiac and renal problems that 
may reflect tissue hypothyroidism developed during treatment. All three frame-shift 
mutations result in a clear dominant-negative effect on WT TRα1 in in vitro assays, 
explaining the marked pathogenic activity of these heterozygous mutations in the 
patients. At present it is unknown if this dominant-negative activity increases with the 
more upstream location of the frame-shift mutation.
So far, 3 nonsense THRA mutations have been reported. Bochukova et al.151 found 
an E403X mutation in a 6-year-old girl with developmental delay, clumsiness, severe 
constipation, disproportionate short stature, macrocephaly, and femoral epiphyseal 
dysgenesis. Tylki-Szymanska et al.220 reported the same E403X mutation in a 15-year-old 
female who demonstrated similar features without femoral epiphyseal dysgenesis. Sim-
ilar to the patients with frame-shift THRA mutations, they also found a more upstream 
mutation (C392X) leading to a more severe phenotype,.220 There were no nonsense 
mutations in our case series.
Different missense THRA mutations have previously been reported in RTHα patients 
with milder clinical phenotypes,219–221 and such mutations were also identified in 
families 2 and 3 in the present study. We report for the first time that spontaneous 
conception and eventless pregnancy can occur in untreated females with RTHα (2.II.1, 
3.II.1 and, 3.II.3) despite varying signs of hypothyroidism. Furthermore, it is noteworthy 
that case 2.II.1 had a similar and even more remarkable delay in developmental mile-
stones compared to her affected son (patient 2.III.1). However, as an adult, she had a 
milder intellectual deficit, no cardiac problems, and normal FT3, FT4, and TSH levels, 
suggesting amelioration of the clinical phenotype with time. Similar observations were 
made in a mouse model with a heterozygous TRα1 mutation at the same position as in 
family 2, i.e. R384C.111,207 These mice showed severe but transient impairment of post-
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natal development and growth. Alterations in TH levels were also only evident during 
the juvenile period. The mechanisms underlying the amelioration of deficits caused by 
TRα1 mutations with age are unknown.
The third family is the largest pedigree with RTHα reported so far, and includes patients 
with the mildest phenotype in terms of growth, body habitus, and cognitive functions 
as well as the oldest untreated patient (3.I.2). This large family allowed us to observe the 
heterogeneous clinical consequences of the same THRA mutation in a single family, 
which is very similar to what has been described for RTHβ.7,236 Both affected and non-
affected family members showed appreciable variation in the clinical and biochemical 
characteristics (Figure 3). Overall, patients with the A263S TRα1 mutation differed from 
healthy individuals by a higher serum T3/rT3 ratio and lower hemoglobin levels. Af-
fected individuals also displayed a shorter body stature in combination with a larger 
head circumference, although there was a large overlap with the unaffected subjects.
The A263S mutation in this family is located at the same location as the A263V mutation 
found recently in a 60-year-old woman and her 2 young adult sons with RTHα.219 The 
A263V mutation resulted in poor linear growth, delayed developmental milestones, 
constipation, and macroglossia during infancy, and they had been treated with LT4 
since 2–3 years of age.219 Their final height and body habitus were normal but all had 
increased head circumference. Two of them had numerous skin tags while only one 
skin tag was present in a single individual in our series (patient 3.I.2). The functional 
analysis of the A263V mutant also indicated a greater defect in transcriptional activity 
of TRα1 than that induced by the A263S mutation,219 in further support of some degree 
of genotype–phenotype correlation for THRA mutations.
The Ala263 mutations are present in both TRα1 and TRα2. In line with previous studies 
of patients with the A263V or D211G (also affecting TRα1 and TRα2) mutation, we did 
not find any evidence for additional abnormalities caused by consequences of the 
mutation on TRα2.219,221 In vitro studies did not provide any evidence for a dominant-
negative effect of WT or mutant TRα2 over TRα1, in agreement with findings that the 
TRα2 protein is located in the cytoplasm and thus cannot interfere with the interaction 
of TRα1 with genomic elements and other nuclear factors.237,238
The A263S mutation in this family and the A263V mutation mentioned above219 are 
present at the corresponding position as a mutation in THRB (A317V) recently identi-
fied in a family with RTHβ.239 It is also of interest to note that the R384H and R384C 
mutations have been identified repeatedly at the corresponding positions R438H and 
R438C, respectively, in THRB in patients with RTHβ,240 suggesting that this is also a hot 
spot for mutations in RTHα. As in RTHβ, the identified mutations in TRα are mostly 
located within three CpG-rich hot spots in the ligand-binding domain of the recep-
tor. Considering the strong homology between the TRα1 and TRβ1 receptors and the 
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comparable localization pattern of mutations in both receptors, the incidence of RTHα 
could be similar to that of RTHβ (1:40,000).7
Despite T3 resistance at the receptor level, (F)T3 levels are not always high. In all previ-
ously reported RTHα patients, (F)T4 levels were low or at the lower limit of normal. 
In the current study, we observed that (F)T4 levels were initially low in index cases 
initially but increased into the normal range during follow-up. Accordingly, none of 
the affected adults had low serum (F)T4, suggesting attenuation in time. If rT3 levels 
were measured in previous cases, they were all low which may be explained by lower 
precursor (F)T4 levels and down-regulation of type 3 deiodinase activity. In the present 
study, pretreatment rT3 levels were in the normal range except for two moderately 
affected patients (2.II.1, 3.III.1). TSH levels were normal in all patients with THRA muta-
tions, including our cases, except for the 45-year-old female patient reported by Moran 
et al., who showed a slightly increased TSH of 5.8 mU/L (N 0.35–5.5) after stopping LT4 
following long-term treatment.
Despite the fact that (usually normocytic normochromic) anemia is not present in all 
RTHα patients, it seems to be a frequently appearing characteristic. Several studies in 
humans have indicated an association between hypothyroidism and anemia.201,202 In 
addition, data from animal models point towards an important role for TRα in eryth-
ropoiesis.203–206 This supports the hypothesis that mutations in TRα contribute to the 
pathogenesis of anemia seen in RTHα patients.
In conclusion, this study shows that the clinical consequences of mutations in THRA are 
heterogeneous. This is the case for patients with different TRα mutations, but also for 
family members with the same mutation. Common characteristics in almost all patients 
comprise a delay in reaching developmental milestones, constipation, and anemia. 
Growth retardation and macrocephaly are less consistent. The clinical phenotype varies 
from severe to very mild, in part depending on the type and location of the mutation. 
Therefore, mutations in THRA should be suspected in subjects with even mild develop-
mental delays, anemia, and a high serum T3/rT3 ratio.
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Supplemental Figure 1. Functional analysis of WT and A263S mutant TRα2.
(A) JEG3 cells were transfected with a T3-dependent promoter-reporter construct and increasing amounts 
of WT TRα1 (1–50 ng plasmid). Higher plasmid concentrations (≤ 10 ng) resulted in a decreasing transcrip-
tional activity. (B) Co-transfection of WT TRα1 with increasing amounts of WT or A263S mutant TRα2 (1–50 
ng) resulted in a decreased transcriptional activity, comparable to the effect of increasing amounts of WT 
TRα1 (1–50 ng) alone. (C) JEG3 cells were transfected with WT TRα1, WT TRα2 or A263S mutant TRα2 (1 ng) 
and incubated with increasing T3 concentrations (1–1000 nM). At all T3 concentrations, WT TRα2 and A263S 
mutant TRα2 showed negligible transcriptional activity. (D) and (E) Co-transfection of WT TRα1 (1 ng) with 
increasing amounts WT or A263S mutant TRα2 (1–50 ng) produced mildly reduced transcriptional activity, 
similar to the effect of increasing the WT TRα1 concentration (1–50 ng) alone (panel B).
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1.II.1 
2.II.1 2.III.1 
3.III.1 3.III.3 3.III.5 3.III.6 
3.II.1 3.II.3 3.I.2 
Supplemental Figure 2. Radiological investigation of the patients.
Skull X-rays of the patients demonstrating features noted in Table 1. White arrows indicate frontal promi-
nence, black arrows wormian bones, and grey arrows thickened skull vault.
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Supplementary Table 1. Primers used for PCR amplification and sequencing of THRA
Exon Forward primer (5’-3’) Reverse primer (5’-3’)
6 TTCTCCAACCTGTACTCTAGGAAGA TCCTGGAGGAGGCAAGACT
7 CTTGGAGCTCCCCCTGGT TCCTTGTCCAGAGAACCTCAG
8 GGCTCCCGTAGGACACTCTA ATTCAGGAGGGAGTTGAGCA
9 TCCCCTCTAGTCCTTTCTTCC TGTGTGTGTGGGAGCTGAAT
Supplementary Table 2. Neuropsychological and neuromotor development of affected and unaffected 
individuals tested.
Case Test Score Corresponding age Classification
2.III.1 index (M, 16mo, R384H) Cognition 82 14 mo Moderately impaired
Motor development 57 10 mo Severely impaired
2.II.1 (F, 35y, R384H) Global IQ 75   Borderline
Verbal IQ 77   Borderline
Performance IQ 74   Borderline
3.III.6 index (M, 32mo, A263S) Cognition 85 27 mo Average
Motor development 94 30 mo Average
3.III.5 (F, 7.4y, A263S) Global IQ 91   Average
Verbal IQ 92   Average
Performance IQ 92   Average
3.III.4 (F, 10.1y, WT) Global IQ 104   Average
Verbal IQ 98   Average
Performance IQ 108   Average
3.III.3 (M, 8.8y, A263S) Global IQ 83   Low average
Verbal IQ 89   Low average
Performance IQ 72   Borderline
3.II.3 (F, 31y, A263S) Global IQ 85   Low average
Verbal IQ 93   Average
Performance IQ 76   Borderline
3.I.2 (M, 55y, A263S) Global IQ 89   Low average
Verbal memory 84   Low average
Executive functions 86   Low average
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Abstract
Context
Patients with Resistance to Thyroid Hormone alpha (RTHα) are characterized by vary-
ing degrees of growth retardation, macrocephaly, constipation, and abnormal thyroid 
function tests. In addition, almost all RTHα patients have mild anemia, the pathogenesis 
of which is unknown. Animal studies suggest an important role for TH and TRα in eryth-
ropoiesis.
Objective
Our objective was to investigate whether a defect in TRα affects the maturation of red 
blood cells in RTHα patients.
Design, setting and patients
Cultures of primary human erythroid progenitors (HEPs), from peripheral blood of RTHα 
patients (n = 11) harboring different inactivating mutations in TRα (P398R, F397fs406X, 
C392X, R384H, A382fs388X, A263V, A263S) were established and compared to healthy 
controls (n  =  11). During differentiation, erythroid cells become smaller, accumulate 
hemoglobin, and express different cell surface markers. We therefore assessed cell 
number and cell size, and used cell staining and FACS analysis to monitor maturation 
at different time points.
Results
After ~14 days of ex vivo expansion, both control and patient-derived progenitors 
differentiated spontaneously. However, RTHα-derived cells differentiated more slowly. 
During spontaneous differentiation, RTHα-derived HEPs were larger, more positive for 
c-Kit (a proliferation marker), and less positive for GPA (a differentiation marker). The 
degree of abnormal spontaneous maturation of RTHα-derived progenitors did not cor-
relate with severity of underlying TRα defect. Both control and RTHα-derived progeni-
tors responded similarly when differentiation was induced. T3 exposure accelerated 
differentiation of both control and RTHα patient-derived HEPs.
Conclusions
Inactivating mutations in human TRα affect the balance between proliferation and dif-
ferentiation of progenitor cells during erythropoiesis, which may contribute to the mild 
anemia in most RTHα patients.
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Introduction
Erythropoiesis is the process that involves the maturation of hematopoietic progenitor 
cells to differentiated red blood cells (erythrocytes). Erythrocytes are of fundamental 
importance for all vertebrates, since they provide cells with oxygen in exchange for 
carbon dioxide.241,242 The site of erythropoiesis changes throughout human develop-
ment. During early embryonic development, erythropoiesis occurs in the yolk sac. By 
the 3rd-4th month of gestation this primitive function is taken over by the liver. From 
the 7th month of gestation onwards and throughout adulthood, the bone marrow is the 
predominant erythropoietic organ.243–246
The production of sufficient numbers of mature red blood cells requires a fine balance 
between proliferation and differentiation of progenitor cells. The cytokine erythro-
poietin (Epo) plays a key role in this process, along with other growth factors such as 
interleukin 3 (IL3), stem cell factor (SCF), and insulin-like growth factor I (IGF-I).242,247,248 
In addition, thyroid hormone (TH) is also important for erythropoiesis. Patients with 
hypothyroidism frequently have anemia201 and mice with congenital primary hypothy-
roidism are also anemic.249 The action of TH is mediated via binding of the active ligand 
(T3) to nuclear TH receptors (TRs), TRα and TRβ. TRs are ligand-inducible transcription 
factors that regulate target gene expression by binding to TH response elements (TREs) 
in promoters of T3-responsive genes.7,105,106
Interestingly, the presence of v-ErbA, an oncogenic homologue of TRα, disturbs the bal-
ance between proliferation and differentiation of immature avian erythrocytes during 
erythropoiesis, contributing to fatal erythroleukemia.250–252 Additional evidence for the 
involvement of T3 and TRα in erythropoiesis is provided by observations in mice lack-
ing TRα (TRα-/-), showing compromised fetal and adult erythropoiesis with a decreased 
number of erythroid progenitors in TRα-/- fetal livers and impaired transit of TRα-/- eryth-
roblasts through further stages of maturation.204 Other studies with TRα knockout mice, 
displaying defective spleen erythropoiesis, confirm that T3 via TRα stimulates late steps 
of erythroid development.203
In 2012, the first patients with resistance to thyroid hormone alpha (RTHα) due to 
inactivating mutations in THRA were discovered. All patients identified since then have 
monoallelic mutations in the ligand-binding domain of TRα. The phenotype of RTHα 
patients is characterized by growth restriction, varying degrees of neurodevelopmental 
retardation, macrocephaly, constipation, and abnormal thyroid function tests (low/
low-normal FT4 and high/high-normal T3 levels with a normal TSH).107,130,151,153,188,189,192
,193,221,253 In addition, a mild, usually normochromic and normocytic, anemia is a virtu-
ally universal finding in RTHα patients. However, in three cases the mean corpuscular 
volume was raised.151,188,193
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Given the observations that most RTHα patients have anemia and that aberrant TRα 
signaling affects erythropoiesis in animal models, we hypothesized that mutations in 
TRα affect the balance between proliferation and differentiation in the later stages of 
human erythropoiesis.
Patients, materials and methods
Cells and cell culture
Peripheral blood (5–10 mL) was obtained by venesection and collected into heparin or 
EDTA tubes from 11 RTHα patients, who have been described previously,153,188,189,192,253 
and 11 healthy donors (n = 3 related and n = 8 non-related). The study was approved 
by the Medical Ethics Committee of the Erasmus Medical Center. Written informed 
consent was obtained from all subjects and/or their parents. Mononuclear cells (PBMC) 
were purified from peripheral blood by density gradient centrifugation using Ficoll 
(Axis-Schield, Oslo, Norway).
Human erythroid progenitor cells (HEPs) were expanded in StemSpanTM SFEM medium 
(Stem Cell Technologies, Grenoble, France) supplemented with lipids (40 μg/mL cho-
lesterol-rich lipid mix; Sigma), penicillin-streptomycin (1:100, Lonza, Basel, Switzerland), 
recombinant human erythropoietin (Epo, 2 U/mL, Janssen-Cilag, Baar, Switzerland), 
recombinant human Stem Cell Factor (SCF, 100 ng/ml, R&D Systems, Minneapolis, MN, 
USA), human IL-3 (1 ng/ml, R&D systems), human IGF-1 (40 ng/ml, R&D systems), and 
dexamethasone (Dex, 1 μM, Sigma, St. Louis, MO, USA).254,255 After 4–5 days, HEPs were 
purified by density purification (Percoll, GE Healthcare, Little Chalfont, UK), and further 
expanded in StemSpan containing Epo, SCF, and Dex.
After sufficient expansion (10–15 days), 10 nM T3 (Sigma) was added to part of the HEPs, 
cultured under proliferation conditions. To induce differentiation, HEPs were washed 3 
times with PBS (Lonza) and switched to StemSpan medium containing Epo (10 U/mL), 
human serum (3 %, Sigma), and iron-saturated transferrin (1:100, Scipac, Kent, UK).
HEPs were maintained at 1–1.5 x106 cells/mL during proliferation and at 1.5–2 x106 
cells/mL during differentiation by daily partial medium changes. To confirm that these 
cells are a good TRα-expressing model, RNA was extracted using TRI Reagent (Sigma) 
and deep sequencing was performed (using the Illumina Hiseq2500 platform (single 
read43bp)) in a subset of control HEPs during late proliferation (Supplemental Figure 1).
Cell count and morphology
The number of HEPs was daily monitored by cell count (CASY® INNOVATIS TTC Cell 
Counter, Omni Life Science, Raynham, MA, USA). To analyze cell morphology at various 
stages of proliferation and differentiation, 105 HEPs were centrifuged onto glass slides, 
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and stained with Benzidine (Sigma) to detect hemoglobin-expressing cells, and with 
Diff-Quick staining (Medion Diagnostics, Miami, FL, USA). Images were made using an 
Olympus BX40 microscope (40x objective, NA 0.65, Olympus, America Inc., Valley, PA, 
USA) equipped with an Olympus DP50 CCD camera (Olympus, America Inc., Valley, PA, 
USA) and Viewfinder lite 1.0 acquisition software (Better light, Inc., San. Carlos, CA, USA). 
The images were processed using Adobe Photoshop SC6 (Adobe, San Jose, CA, USA).
Flow cytometry
HEPs (3 x105 cells) were briefly centrifuged after which the pellet was resuspended in 
PBS supplemented with 0.1 % bovine serum albumin and 1 mM EDTA (FACS buffer) and 
stained for 30 minutes at RT with fluorescently labeled antibodies against the following 
cell surface markers (all BD Pharmingen antibodies, San Diego, CA, USA): CD117 (stem 
cell factor receptor c-Kit, dilution 1:100), CD71 (transferrin receptor, dilution 1:100) and 
CD235a (glycophorin A, GPA, dilution 1:1000) in a final volume of 100 μl. To exclude 
non-viable cells, 7-AAD (A1310, Thermo Fisher Scientific, Waltham, MA, USA, dilution 
1:1200) was added to all samples. Fluorescence was measured on a FACS Fortessa 
instrument (BD Biosciences, Oxford, UK) and data were analyzed using FlowJo v.10.1 
software (FlowJo, Ashland, OR, USA).
Results
Genotypic and phenotypic characterization of RTHα patients
All 11 patients were heterozygous for a mutation in the C-terminal, ligand-binding 
domain of TRα1. In patients 5 to 9 (P5–9) the mutation (A263S/V) also affected TRα2. 
When studied in vitro, the mutant receptors showed defective hormone-dependent 
activation and inhibited WT TRα1 function in a dominant negative manner when co-
expressed.130,188 The severity of mutant receptor dysfunction varied depending on the 
type of the mutation. Patients 1 to 3 (P1-P3) have frameshift/premature stop and P4 
a nonsense mutation, all generating a truncated receptor with negligible T3-induced 
transcriptional activity and marked dominant-negative activity. In contrast, P5–11 have 
missense mutations that cause reduced T3 sensitivity.
All RTHα patients with a severe mutation (P1 to P4), as well as most patients with milder 
mutations (P5 to P7 and P9 to P11), exhibited mild anemia. There was no correlation 
between the severity of the mutations and hemoglobin levels or red blood cell count 
(Table 1). Except for P4, P9 and P11, RTHα patients were treated with levothyroxine (LT4).
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Delayed spontaneous differentiation in HEPs of RTHα patients
Peripheral blood mononuclear cells were isolated from RTHα patients and healthy 
controls, and cultured in conditions permissive for proliferation. The population of 
expanding human erythroid progenitors (HEPs) was purified by Percoll density cen-
trifugation after 4–5 days, depending on the number of cycling progenitor cells at day 
0. Once homogenous HEP populations were established (after 10–15 days), cultures 
were monitored daily for cell number and cell size.
After approximately 2 weeks of proliferation, normal HEPs start to differentiate spon-
taneously, a process characterized by a decrease in proliferation rate, reduced cell size, 
cytoplasmic acidification, hemoglobin production, and nuclear condensation followed 
by enucleation.256 This reduction in growth rate and cell size was delayed in the RTHα 
cells, suggesting reduced spontaneous differentiation capacity in these cells. This was 
further studied by Benzidine/Diff-Quick staining of cytospin preparations. Proliferat-
ing, hemoglobin-negative, HEPs appear as large cells with blue cytoplasm, while dif-
ferentiating, hemoglobin-positive HEPs are smaller with brown cytoplasm203 (Figure 1 
flowchart254). Consistent with our hypothesis, at a late phase of proliferation (culture 
day ~ 14), cytospin preparations from control cultures (n = 11), showed a substantial 
number of cells with differentiated morphology, marked by smaller and dark-stained 
cells. In contrast, preparations from RTHα patients (n = 11) showed predominantly large 
light-stained cells, indicating that most cells had not yet entered the differentiation 
program (Figure 2A).
The difference in cell size was confirmed by flow cytometry analysis. To distinguish 
large cells from small cells a cut-off of ≥ 100K was used, measured with forward scatter 
(FSC-A). The forward scatter (FSC-A) showed that cells from RTHα patients (n = 11) had 
a larger mean size compared to cells of controls (n = 11) (41.7 % of cells in patients vs 
Figure 1. Flowchart of methods.
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23.6 % in controls had a forward scatter index larger than 100K, p = 0.001), indicating 
that many RTHα HEPs were still expanding, whereas the majority of control HEPs had 
started their differentiation program (Figure 2B).
HEPs express stage-specific cell surface proteins during different phases of erythropoi-
esis. CD-117 (c-Kit) is a marker of immature erythroblasts, CD71 (transferrin receptor) 
Figure 2. Spontaneous differentiation is delayed in HEPs from RTHα patients.
(A) Benzidine and Diff-Quick stained cytospins of RTHα-derived (P4; C392) and control HEPs. After 2 weeks 
of proliferation (day 14), control HEPs start to differentiate spontaneously, illustrated by smaller and dark-
stained (hemoglobin containing) cells. In contrast, cytospin preparations from RTHα-derived HEPs show 
predominantly large, weakly stained cells that are still proliferating.
(B) FACS analysis of RTHα-derived and control HEPs after 2 weeks of proliferation (day 14). RTHα-derived 
HEPs had a larger mean size compared to control HEPs, illustrated by the percentage of cells with a forward 
scatter index large than 100K (41.7 % of cells in patients vs 23.6 % in controls, p < 0.001).
(C) FACS analysis of RTHα-derived and control HEPs during late proliferation (culture day ~ 14). RTHα-
derived HEPs express predominantly c-Kit, a proliferation cell surface marker (37.2 % of cells in patients vs 
74.5 % of cells in controls accumulate in the c-Kitnegative –subgate, p < 0.0001), while the majority of control 
HEPs express differentiation cell surface markers (CD71 and GPA) (29.6 % of cells in patients vs 59.7 % of cells 
in controls accumulate in the GPAhigh -subgate, p < 0.01) (D).
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expression increases during early differentiation, while Glycophorin A (GPA; CD235a) is 
a marker for mature erythroid cells.254,257 During the later stages of proliferation (culture 
day ~ 14), control HEPs (n = 11) were predominantly negative for c-Kit as illustrated by 
an accumulation of HEPs in the c-Kitnegative -subgate (Figure 2C). However, RTHα HEPs 
(n  =  11) accumulated less in the c-Kitnegative -subgate (37.2 % in patients vs 74.5 % in 
controls, p < 0.0001), corresponding to a delayed maturation stage. In addition, RTHα 
patients (n  =  9, due to insufficient cells in 2 samples for GPA staining) showed less 
HEPs in the GPAhigh -subgate compared to controls (n = 9) (29.6 % in patients vs 59.7 % 
in controls, p = 0.003), again indicating that RTHα HEPs display a reduced or delayed 
spontaneous differentiation rate compared to control HEPs (Figure 2D).
Despite similar culture conditions, the period in which cells could be maintained in 
culture varied slightly between different experiments. Nevertheless, for all experiments, 
the longer the cells were cultured, the more cells differentiated fully and then became 
apoptotic, reducing availability of cell samples for experiments focusing on later stages 
of maturation. No differences in the extent of apoptosis between patient and control 
HEPs were observed. Patient cells (n  =  7) and control samples (n  =  5) were further 
monitored during culture days ~15 to 20, still under proliferative conditions. The first 
signs of differentiation of RTHα cells were observed around day 16, ~2 days later than 
control cells. At this time point, the majority of the cells was reduced in size, but did 
not stain for hemoglobin (Figure 3A, top panel). After approximately 20 days of culture, 
apoptosis occurred in fully differentiated cells from most controls and RTHα patients, 
with no differences between cells with either frameshift/stop or missense mutations. 
Longer term observations were made with the samples that still contained viable 
cells. After ~20 days, the culture of control cells (n = 2) was terminated, as these cells 
were fully differentiated and started to disintegrate. In contrast, most RTHα cultures 
(n  =  3) contained 2 viable subpopulations: differentiated, hemoglobin-positive cells, 
and immature blasts (Figure  3A, lower panel). Although the number/percentage of 
blasts varied per patient/mutation, these immature cells could be maintained for an 
additional 5–7 days, followed by apoptosis. The differences in cell size between RTHα 
and control cultures during the different stages is shown in Figure 3B.
The delay in spontaneous differentiation of RTHα cells was also confirmed by FACS 
analysis. During differentiation, a large proportion of RTHα HEPs became negative for 
c-Kit and simultaneously increased the expression of GPA. Values for c-Kit and GPA ex-
pression in RTHα-derived cells reached levels comparable to controls, but with a delay 
of 4 days (Supplemental Figure 2). During this period, expression values of the different 
cell surface markers in the control cells did not change, as maximal levels were already 
reached.
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Taken together, these results show that onset of spontaneous differentiation is delayed 
in RTHα HEPs. However, when RTHα cells finally differentiate, differences between RTHα 
and control cells diminish, albeit with RTHα HEPs lagging behind control HEPs.
Induced differentiation proceeds similarly in RTHα and control HEPs
Optimal and synchronous differentiation of HEP cells can be induced by changing the 
culture conditions. To study optimal or ‘forced’ differentiation, HEPs were switched to 
StemSpan medium containing a high concentration of Epo (10 U/mL), human serum, 
and transferrin, whilst the proliferation factors (SCF and dexamethasone) were removed. 
After 6 days of induced differentiation, cell populations of the remaining RTHα patients 
(n = 3) and controls (n = 2) predominantly consisted of small, dark-stained and enucle-
Figure 3. Differences between differentiating RTHα-derived and control HEPs decrease wherein RTHα-
derived HEPs remain just behind control HEPs.
(A) Cytospin preparations of RTHα-derived (P5; A263S) and control HEPs at day 16 (early spontaneous dif-
ferentiation) and day 20 (late spontaneous differentiation).
(B) Differences in cell size between RTHα-derived and control cultures during the different stages of dif-
ferentiation, measured by flow cytometry analysis using forward scatter (FSC-A). To distinguish large cells 
from small cells a cut-off of ≥ 100K was used.
(C) Cytospin preparations of RTHα-derived (P1; F397fs406X) and control HEPs after 6 days of induced dif-
ferentiation, in which HEPs were cultured in StemSpan medium containing a high concentration of Epo, 
human serum and, transferrin.
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ated cells (Figure 3C). The expression of the different cell surface markers did not differ 
significantly between RTHα HEPs and control HEPs (Supplemental Figure 2).
In summary, under forced differentiation conditions, RTHα cells differentiate nearly as 
well as control cells.
T3 enhances spontaneous differentiation of RTHα HEPs
It has been shown that addition of T3 does improve the differentiation characteristics 
of erythroid progenitors when grown ex vivo.252 To investigate the effect of T3 on RTHα 
HEPs, we exposed part of the RTHα (n = 7) and control HEP cultures (n = 5), at later 
stages of proliferation (~ day 14), to 10 nM T3. After 2 days, this resulted in an increased 
proportion of differentiated HEPs when compared to HEPs cultured without T3, with 
a similar effect in RTHα and control samples. Cells in treated samples were smaller 
(Figure 4), stained less for c-Kit, and were more positive for GPA (Supplemental Figure 3).
Figure 4. Cytospin preparations of RTHα-derived (P4; C392X, P5; A263S) and control HEPs at day 16 cul-
tured with and without 10nM T3 for 2 days. Addition of T3 resulted in an increased proportion of morpho-
logically differentiated HEPs in both RTHα patients and controls. The decrease in cell size was significant in 
control HEPs.
Discussion
In the current study we show that inactivating mutations in TRα affect the balance 
between proliferation and differentiation in human erythroid progenitor cells (HEPs). Ex 
vivo studies show that RTHα HEPs have a reduced capacity to differentiate spontane-
ously in comparison to control HEPs.
Several studies in humans have documented an association between hypothyroidism 
and reduced red blood cell counts, identifying mild anemia in 20–60 % of hypothyroid 
patients.201,258 Studies in avian and murine models point towards involvement of TRα in 
later stages of erythropoiesis.203–206,259,260 However, it is important to point out that there 
are significant differences in the physiology of normal erythropoiesis between murine 
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and human contexts. For example, in mice, stress-induced erythropoiesis occurs in 
spleen, which is not the case in humans.203
Since (mild) anemia, mostly normocytic normochromic, is also a common character-
istic in RTHα patients,130,151,153,188,189,192,221,253 we decided to investigate if a defect in TRα 
affects the red cell maturation in RTHα patients. In this context, we sought to study 
whether tissue-specific hypothyroidism due to mutations in TRs affects erythropoiesis 
to a similar extent as primary hypothyroidism. The use of a well-validated cell culture 
protocol254,255 allowed us to expand the limited number of hematopoietic progenitors 
present in peripheral blood samples of both RTHα patients and healthy controls.
We were able to synchronize the development of HEPs at the pro-erythroblast stage, 
when cells show the first morphologically recognizable features of erythroid cells. From 
this stage, we studied the maturation of the HEPs using serum-free medium containing 
proliferation factors. Remarkably, RTHα HEPs continued to proliferate for a prolonged 
period whereas control HEPs started to differentiate spontaneously from day 14. This 
delay in maturation and development was evident from both morphological appear-
ance and expression of cell surface markers at this stage.242,254 The serum-free culture 
medium used in our experiments contained low levels of T3 (~0.5nM), which may have 
been sufficient to enhance differentiation in control HEPs by activation of wild-type 
TRα. However, in RTHα-derived HEPs such low T3 concentrations were probably unable 
to induce differentiation to a similar extent as these cells harbored mutant TRα with 
reduced T3 affinity, resulting in a prolonged proliferation phase.106
For efficient terminal maturation, proliferation factors in the medium need to be 
replaced by differentiation factors (higher concentration of Epo, transferrin, serum). Ad-
dition of serum is necessary for complete down-regulation of c-Kit and a further induc-
tion of GPA in human erythroblasts, both characteristics of terminal differentiation.255 
Under such optimal differentiation conditions, differences between RTHα-derived and 
control HEPs decreased. This suggests that TRα mutations most likely affect the timing 
of onset of differentiation, and influence the actual differentiation process itself to a 
lesser extent.
To investigate whether higher concentrations of T3 could overcome such delayed 
maturation dynamics, cultured HEPs during late proliferation were exposed to 10 nM T3. 
After 2 days, HEPs of both RTHα-derived and control T3-treated cells showed a modest 
decrease in cell size indicating an increased proportion of spontaneous differentiation. 
This observation is consistent with previous findings from Leberbauer et al,255 showing 
that proliferating HEPs treated with T3 have a gradual decrease in cell size, reduced 
proliferation rates and higher hemoglobin content.
Previous studies indicate that exposure of normal HEPs to T3 does not affect expres-
sion of differentiation cell surface markers255 and we confirmed these findings with 
control HEPs in this study. In contrast, RTHα HEPs exposed to 10 nM T3 showed a slight 
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increase in CD71 and GPA expression together with down regulation of c-Kit levels. 
One explanation for these findings is that levels of T3 present in normal medium are 
sufficient to permit differentiation of control HEPs with higher exogenous T3 concen-
trations following addition of exogenous hormone only shifting the balance of cells 
achieving terminal maturation. On the other hand, in RTHα-derived HEPs, harboring 
dysfunctional TRα, higher T3 concentrations could help overcome the TRα defect, 
thereby accelerating the onset of spontaneous differentiation. Previous characteriza-
tion130,151,153,188,189,192,193,221,253 of TRα mutations identified in RTHα cases indicates variable 
dysfunction with frame shift and nonsense mutations being markedly more deleterious 
than missense mutations (with some proximal receptor mutations also affecting TRα2). 
In this context, both in the current study and in reports of other published RTHα cases, 
there is no association between the degree of anemia and the severity of mutations in 
TRα. Furthermore, there is no relationship between hemoglobin concentrations or RBC 
number and TH levels in cases, all showing inherent variation among different subjects. 
Given these in vivo findings in RTHα, it is not surprising that the maturation dynamics 
of RTHα HEPs, harboring TRα mutations of varying severity, did not differ. Despite the 
anemia, the number of reticulocytes was not increased in RTHα patients, suggesting 
that the release of immature erythrocytes into the circulation is not altered. In addition, 
no major abnormalities in other blood cell lineages were detected. However, we were 
not able to measure the life span of erythrocytes in our patients in vivo; accordingly, 
we cannot discount the possibility that the life span of RTHα erythrocytes is altered 
compared to healthy controls.
Cultured, RTHα-derived HEPs responded to 10 nM T3 exposure, whereas LT4 treatment 
did not correct anemia in most patients with RTHα. One possible explanation for this 
discrepancy is that mutant TRα affects earlier phases of erythrocyte development in the 
bone marrow in RTHα patients, which we have not been able to examine in this study. 
In the current project we studied relatively late stages of erythrocyte maturation, in 
which T3 is known to favor differentiation of erythrocytes.261 In this phase, addition of 
higher T3 concentrations stimulated the onset of differentiation in both RTHα-derived 
and control HEPs. However, it remains unclear whether T3 via TRα similarly affects earlier 
stages of erythrocyte development and if so, whether LT4 treatment of RTHα patients 
can rescue mutant TRα function in this earlier phase.
In addition, we cannot discount the possibility that culture of isolated HEPs ex vivo 
enables different facets of the maturation process to be studied and regulated by 
exposure to T3, whereas it is more difficult to influence the likely complex interactions 
between HEPs with other cell types and factors that control the maturation process in 
vivo, with TH treatment. Thus, in addition to intrinsic differences between RTHα and 
normal erythrocyte progenitors, it is conceivable that such added interactions contrib-
ute to the anemia of RTHα patients.
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In conclusion, by studying erythroid progenitor cells from RTHα patients ex vivo, we 
have shown that both TH and TRα play a role in the later phases of human erythropoiesis. 
Erythrocyte progenitors from RTHα patients exhibit defective maturation capacity, with 
later onset of, and a slower progression through, the terminal differentiation program.
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Supplemental Figure 1. RNA expression of THRA and THRB in HEPs from a control during late proliferation.
Supplemental Figure 2. The expression of cell surface markers during different stages of HEP maturation. 
During spontaneous differentiation, values for c-Kit and GPA expression in RTHα-derived HEPs reached 
comparable levels as control samples with a delay of 4 days. During forced differentiation, the expression 
of the different cell surface markers did not significantly differ between RTHα-derived and control HEPs.
Supplemental Figure 3. 10nM T3 was added to part of the RTHα-derived and control HEP cultures at day 
14 (late proliferation). After 2 days, RTHα-derived HEPs cultured on T3 showed a decreased c-Kit expression 
and a mildly increased CD71 and GPA expression. This was less evident in (the yet more differentiated) 
control HEPs.
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Abstract
Background
Thyroid hormone (TH) acts via nuclear thyroid hormone receptors (TRs). TR isoforms 
(TRα1, TRα2, TRβ1, TRβ2) are encoded by distinct genes (THRA and THRB) and show 
differing tissue distributions. Patients with mutations in THRB, exhibiting resistance 
within the hypothalamic-pituitary-thyroid axis with elevated TH and non-suppressed 
TSH levels, were first described decades ago. In 2012, the first patients with mutations 
in THRA were identified.
Scope of this review
This review describes the clinical and biochemical characteristics of patients with 
Resistance to Thyroid Hormone alpha (RTHα) due to heterozygous mutations in THRA. 
The genetic basis and molecular pathogenesis of the disorder together with effects of 
levothyroxine treatment are discussed.
Conclusions
The severity of the clinical phenotype of RTHα patients seems to be associated with 
the location and type of mutation in THRA. The most frequent abnormalities observed 
include anaemia, constipation and growth and developmental delay. In addition, serum 
(F)T3 levels can be high-normal to high, (F)T4 and rT3 levels normal to low, whilst TSH 
is normal or mildly raised. Despite heterogeneous consequences of mutations in THRA, 
RTHα should be suspected in subjects with even mild clinical features of hypothyroid-
ism together with high/high-normal (F)T3, low/low-normal (F)T4, and normal TSH.
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Introduction
Thyroid hormone (TH) is essential for normal development, growth and cellular me-
tabolism. The importance of TH for the developing brain is exemplified by the severe 
defects in motor and mental development seen in patients with untreated congenital 
hypothyroidism.1,2
Serum TH levels are regulated by the hypothalamic-pituitary-thyroid (HPT) axis, where 
hypothalamic thyrotropin releasing hormone (TRH) stimulates the production of pitu-
itary thyroid-stimulating hormone (TSH), which in turn stimulates the thyroid gland to 
produce TH. The thyroid predominantly synthesises the prohormone T4, with only a 
small fraction of T3, the bioactive hormone, being produced.5,6 TRH and TSH synthesis is 
regulated by T3 and T4 as part of a negative feedback mechanism.
The intracellular availability of TH is dependent on transmembrane transport, medi-
ated by transporters such as monocarboxylate transporter 8 (MCT8). Intracellular TH 
concentrations are tightly regulated by three deiodinase enzymes (DIOs), mediating 
the conversion of T4 to T3 (DIO1 and DIO2) and of T3 and T4 into inactive metabolites 
(DIO3). In the nucleus, T3 binds to T3 receptors (TRs), which belong to the nuclear 
receptor superfamily of ligand-inducible transcription factors. TRs preferentially form 
heterodimers with retinoid X receptors (RXRs) and regulate target gene expression by 
binding to T3 response elements (TREs), usually located in their promoter region. In the 
absence of TH, unliganded TRs repress basal transcription of positively regulated genes 
by recruiting corepressors (e.g. nuclear receptor corepressor [NCoR], silencing mediator 
for retinoic acid and thyroid receptors [SMRT]) and histone deacetylase (HDAC). Bind-
ing of T3 to TRs results in dissociation of the corepressor complex and recruitment of 
coactivator proteins (e.g. steroid receptor coactivator 1 [SRC-1], and the histone acetyl 
transferase [HAT], CREB-binding protein [CBP] and CBP-associated factor [pCAF]), which 
induce transcriptional activation.7,105–107 TH also exerts non-genomic effects,262,263 but 
these are beyond the scope of this review.
In humans, TRs are encoded by two genes (THRA and THRB) on chromosomes 17 and 
3, respectively. Two receptor isoforms are generated from the THRA locus by alternative 
splicing: TRα1 is predominantly expressed in the central nervous system (CNS), bone, 
heart, skeletal muscle and gastrointestinal tract, whereas the non-T3 binding isoform 
TRα2 is expressed in various tissues (e.g. brain and testis). Two different isoforms TRβ1 
and TRβ2, which diverge in their amino-terminal regions, are generated from the THRB 
locus, TRβ1 is considered the major isoform in liver, kidney and thyroid. TRβ1 is also pre-
dominantly expressed in the brain, pituitary and inner ear, where it mediates overlap-
ping functions with TRβ2.264 TRβ2 has a more restricted expression pattern regulating 
neurosensory (hearing, vision) development as well as the HPT-axis.67,108,109
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Since 1986 it has been known that heterozygous mutations within three, CpG-rich, hot-
spots of the ligand-binding domain (LBD) of TRβ result in resistance to thyroid hormone 
β (RTHβ), a clinical syndrome of refractoriness to TH that was recognized two decades 
earlier.265 The incidence of RTHβ is ~ 1 in 40,000 and several hundred mutations have 
been identified so far.7,266 Patients with RTHβ are characterized by elevated serum TH 
levels with non-suppressed TSH, and a phenotype ranging from being asymptomatic 
to having clinical features of thyrotoxicosis (e.g. failure to thrive in infancy; tachycardia 
and cardiac arrhythmia, raised metabolic rate, anxiety in adulthood).7,110
Human TRα and TRβ are highly homologous, with the proteins showing 80 % amino 
acid identity. Taking into account the large number of different TRβ mutations associ-
ated with RTHβ, the identification of analogous mutations in human TRα had been 
anticipated. In an attempt to predict the clinical consequences of defective TRα, 
several knock-in and knock-out mouse models have been generated. Mice harboring 
different, heterozygous TRα mutations exhibit diverse phenotypes, depending on the 
severity and location of the mutations; however, all have near-normal thyroid function 
tests.111–114 Perhaps due to this lack of a clear biochemical thyroid phenotype, no muta-
tion in human THRA was reported until 2012.
In the last 4 years, 28 cases from 15 different families with mutations in THRA have 
been identified. In this review, we present an overview of the clinical features together 
with the underlying molecular mechanisms and effects of treatment in patients with 
Resistance to TH due to heterozygous mutations in TRα (RTHα).
Molecular mechanisms underlying RTHα
Table 1 shows all mutations in THRA identified in patients so far. Affected individuals are 
heterozygous for the mutations, which occurred de novo in 8 cases or were familial in 7 
cases. All mutations identified so far are localized in the ligand-binding domain (LBD) of 
THRA, as illustrated in Figure 1. Consistent with this, T3 binding by the mutant receptors 
is impaired whereas DNA binding is unaffected.
The mutations can be categorized into 3 classes of receptor defects: 1) frame shift / pre-
mature stop mutations, in which a deletion or insertion of one or several nucleotides re-
sults in a truncated receptor, 2) nonsense mutations, in which a nucleotide substitution 
results in a premature stop codon, and 3) missense mutations, in which a nucleotide 
substitution leads to an amino acid change without affecting protein length.
All patients are heterozygous, suggesting a dominant-negative effect of the mutant 
receptors on wild-type TRα. Indeed, when co-expressed the mutant receptors 
inhibit the function of their wild-type counterparts in a dominant-negative man-
ner,130,151,153,154,188,189,192,193,221 similar to what has been reported for TRβ mutations in 
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RTHβ. T3-induced dissociation of mutant TRα receptors from corepressors is retarded 
and ligand-dependent recruitment of coactivators impaired, likely contributing to the 
dominant-negative inhibition. Ex vivo analysis of mutation-containing, patient-derived, 
Table 1. Mutations in THRA identifi ed in patients. Mutations are organized by the type of mutation: frame 
shift, nonsense and missense.
Missense Nonsense Frame shift
G207E (unpublished)
♂ 15 mo + mother (26 yrs)
C392X
♂ 18 yrs
C380fs387X
♀ 12 yrs
D211G221
♀ 18 mo + father (30 yrs)
E403X
♀ 6 yrs
A382fs388X
♀ 45 yrs
A263V192
♀ 60 yrs + 2 sons (26/30 yrs)
E403X
♀ 15 yrs
F397fs406X,153
♀ 11 yrs + father (42 yrs)
A263S154
♂ 2.6 yrs + sister (7.4 yrs), mother (31 yrs), grandfather (55 
yrs), aunt (35 yrs), 2 cousins (17 / 8.8 yrs)
   
N359Y193
♀ 27 yrs
R384C284
R384H154
♂ 15 mo + mother (30 yrs)
E403K189
♀ 6 yrs + father (39 yrs)
P398R189
♀ 5 yrs
Figure 1. Localization of identifi ed mutations in THRA. Thyroid hormone receptor α1 (TRα1), the T3 recep-
tor encoded by the THRA gene and the splice variant TRα2, which does not bind T3 and does not act as a 
receptor, have identical aminoterminal and DNA binding domains. The non-homologous part of the ligand 
binding domains (LBD) is coloured in grey. The location of all known TRα mutations is indicated. G207E, 
D211G, A263S, A263V, and N359Y aff ect both TRα1 and α2 transcripts.
CHAPTER 8
122
cells showed reduced T3-mediated induction of target gene expression, consistent 
with dominant negative inhibition occurring in vivo.151,188,192
In 5 families, affected individuals harbored missense mutations, localized further 
upstream in THRA, thereby involving both TRα1 and TRα2 proteins. At low T3 con-
centrations such missense mutant receptors showed reduced transcriptional activity 
together with moderate dominant-negative inhibition of wild-type TRα1. Interestingly, 
at higher T3 concentrations, mutant receptors exhibited transcriptional activity similar 
to wild-type TRα1 with reversal of their dominant negative inhibitory activity.154,192,221 
These observations suggest that patients harbouring such milder, missense mutations 
may particularly benefit from TH treatment. Similar observations were made in mice 
with a missense mutation (R384C) in TRα1, with locomotor defects and behavioral 
abnormalities being alleviated by TH treatment.111,207,208
The phenotype of patients with a mutation in both TRα1/2 resembles the clinical 
characteristics of RTHα patients with a mutation in TRα1 alone.154,192,221 One exception 
to this is a patient with a mutation (N359Y) in TRα1/2 who showed a distinct clinical 
phenotype comprising skeletal malformations (clavicular agenesis, metacarpal fusion, 
syndactyly of digits), chronic diarrhoea, macrocytic anaemia, and hypercalcaemia.193 It 
remains uncertain whether these additional phenotypic characteristics are due solely 
to the mutation in THRA. In all other RTHα cases described to date, the mutation in TRα2 
does not seem to contribute to the phenotype, which is concordant with observations 
in TRα2KO mice. In these mice, phenotypic abnormalities are most probably not due 
to loss of TRα2, but are a consequence of compensatory overexpression of TRα1.209 In 
addition, previous studies have suggested that TRα2 is unable to heterodimerise with 
RXR, bind TREs or exert dominant-negative activity via corepressor recruitment.237,238,267
Noteworthy, the severity of the clinical RTHα phenotype appears to be associated with 
the type and localization of the mutation in TRα. In this, RTHα patients with frameshift 
and nonsense mutations show a more affected phenotype in comparison to RTHα 
patients with milder missense mutations.
Clinical phenotype
Appearance
Most patients were born at term after an eventless pregnancy and displayed no abnor-
mal characteristics, although recognized features of hypothyroidism (e.g. macroglossia, 
poor feeding, hoarse cry) were present in some cases at birth (Moran et al 2013; Moran 
et al 2014). Physical characteristics associated with hypothyroidism (e.g. macrocephaly, 
hypertelorism, a broad face and flattened nasal bridge) became more evident with 
time, together with poor linear growth, resulting in a dysmorphic appearance (see 
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Table  2).130,151,153,154,188,192,193,221 Several patients have numerous skin tags and moles, 
which seem to increase in number with age.151,188,192
Neurological and cognitive
In almost all index patients a delay in reaching developmental milestones was the 
prime reason for consultation. Childhood cases show a slow initiation of motor move-
ment together with impaired fine and gross motor coordination, resulting in dyspraxia 
and a broad-based ataxic gait. One young girl with a missense (D211G) mutation221 
initially presented with severe, predominantly axial, hypotonia. Two cases displayed 
childhood seizures.188,221 Several patients show mild to moderate/severe intellectual 
disability with a lower global IQ and reduced verbal and performance scores. A delay in 
speech development and dysarthric speech are consistent features in the majority of 
patients (see Table 2).130,151,153,154,188,189,192,221
Table 2. Clinical and biochemical characteristics of patients with resistance to thyroid hormone alpha.
System  Clinical / biochemical characteristics
Appearance:
Dysmorphic syndrome
•	 	Flat	nasal	bridge
•	 	Broad	face,	thickened	lips
•	 	Macroglossia
•	 	Coarse	facies
•	 	Skin	tags
Neurological and cognitive •	 	Delayed	developmental	milestones
•	 	Delayed	speech	development,	dysarthric	speech
•	 	Slow	initiation	of	movement
•	 	Fine	and	gross	motor	dyspraxia,	broad-based	ataxic	gait
•	 	Dysdiadochokinesis
•	 	Reduced	global	IQ,	reduced	verbal	and	performance	scores
Skeletal •	 	Disproportionate	short	stature:	reduced	total	height,	normal	sitting	
height, reduced subischial leg length.
•	 	Macrocephaly:	delayed	fontanelle	fusion,	thickened	calvarium,	wormian	
bones
•	 	Delayed	tooth	eruption
•	 	Delayed	ossification:	delayed	bone	age,	femoral	epiphyseal	dysgenesis
•	 	Cortical	hyperostosis	in	long	bones,	increased	bone	mineral	density
Cardiac •	 	Bradycardia
•	 	Low/low-normal	blood	pressure
Gastrointestinal •	 	Constipation:	decreased	peristalsis,	delayed	intestinal	transit,	bowel	
dilatation
Biochemical and metabolic •	 	Thyroid	function	tests:	normal	or	slightly	raised	TSH,	low/low-normal	(F)
T4, high/high-normal (F)T3, low/low-normal rT3, decreased (F)T4/(F)T3 
ratio and increased (F)T3/rT3 ratio
•	 	Hematological:	low	red	cell	mass	or	hematocrit	with	normal/raised	MCV,	
B12, folate and reticulocyte count
•	 	SHBG:	high/normal
•	 	IGF-1:	low/normal
•	 	Low	metabolic	rate
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Skeletal
Most, but not all, RTHα patients have short stature; some have a disproportionate 
reduction in subischial leg length.
Skull radiographs of RTHα patients in childhood show delayed fontanelle fusion 
together with excessively serpiginious skull sutures (wormian bone appearance). Re-
tarded ossification, resulting in delayed bone age or femoral epiphyseal dysgenesis, can 
be present. In addition, a thickened calvarium and a delayed tooth eruption have been 
observed in most cases.130,151,153,188,189,192,221 Especially in adults, cortical hyperostosis in 
long bones together with increased bone mineral density has been documented (see 
Table 2).
Cardiac and gastrointestinal
Blood pressure and resting heart rate are normal or low/low-normal in most RTHα 
patients, which is remarkable in view of the high serum T3 levels (see below).
In the majority of both childhood and adult patients, constipation is a persistent problem 
due to decreased frequency of bowel movements.130,151,153,154,188,189,192,221 When evaluated 
in patients, abdominal radiography shows a delayed intestinal transit together with 
bowel dilatation. In addition, reduced peristalsis is seen on colonic manometry (see 
Table 2).151,188 Only one adult case has chronic diarrhoea.193
Biochemical and metabolic
Thyroid function tests show a consistent pattern, albeit with significant variation 
between different cases. The thyroid biochemical phenotype not only varies between 
patients with different mutations but also between patients carrying the same muta-
tion. TSH levels are in the normal range in all patients, except for one adult female 
patient188 who showed a slightly raised TSH while off LT4 treatment. In almost all index 
cases, (F)T4 levels are initially low or low-normal. A rise in (F)T4 levels into the normal 
range is observed in some of the cases during follow-up, possibly indicating attenua-
tion of the biochemical phenotype with time. (F)T3 levels are high or high-normal in 
most patients, although normal (F)T3 levels have also been reported in several cases.154 
Nevertheless, an abnormally high T3/T4 ratio seems a consistent finding among all 
patients. Reverse T3 (rT3) levels are normal or subnormal, resulting in a higher serum 
T3/rT3 ratio (see Table 2).151,188,189,192,221
Other markers, reflecting TH action in peripheral tissues, can also be altered. A mild, 
usually normocytic normochromic, anaemia is an almost universal characteristic 
in RTHα patients. Serum muscle creatine kinase levels and sex hormone binding 
globulin (SHBG) levels may be raised, while circulating IGF-1 levels can be decreas
ed.130,151,153,154,188,189,192,193,221 Total and LDL cholesterol levels may be increased, in both 
childhood and adult cases.130,153 In several patients, a low basal metabolic rate (BMR), 
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measured by indirect calorimetry, was recorded (see Table  2).151,188,192,193 Overall, both 
clinical and biochemical abnormalities seen in RTHα are consonant with thyroid hor-
mone resistance in tissues expressing predominantly TRα1 (e.g. heart, bone, muscle, 
intestine, brain), while TRβ-expressing tissues (e.g. hypothalamus, pituitary, liver) remain 
sensitive to TH (Figure 2).
Figure 2. Cartoon showing the major tissue actions of thyroid hormone together with the predominant 
receptor subtypes mediating these eff ects. In RTHα, tissues expressing mainly TRα are resistant to thyroid 
hormone action (“impaired”) while TRβ-expressing tissues are sensitive (“not obviously impaired”).
Pathogenesis
Many clinical features in RTHα patients, such as delayed motor development, delayed 
cranial suture closure resulting in macrocephaly, delayed tooth eruption, developmen-
tal skeletal abnormalities (e.g. femoral epiphyseal dysgenesis, wormian bones), delayed 
bone age, and lower segment growth retardation, are characteristic of untreated hypo-
thyroidism.268,269 In addition, constipation due to decreased colonic motility and colonic 
dilatation is also clearly associated with hypothyroidism.270
Other characteristics of hypothyroidism, including slow speech, bradykinesia, dry skin 
and slow relaxing refl exes are also reported in RTHα cases. Interestingly, many of these 
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features (delayed growth, tooth eruption, fontanelle closure and endochondral and 
intramembranous ossification) are also present in different mouse models with frame-
shift mutations (TRα1-PV) or missense mutations in TRα1 (TRα1-R384C, TRα1-P398H, 
TRα1-L400R).111–114,212,271–274 Abnormal motor development in patients resembles the 
psychomotor phenotype of TRα1-R384C mice, which show reduced grip strength, poor 
limb coordination, and an abnormal gait.111,207
Several patients exhibit delayed mental development with cognitive deficits and two 
patients suffer from seizures, which have also been described in TRα1-R384C mice.207,208 
Constipation and bowel dilatation with reduced peristalsis that has been described in 
RTHα patients is very similar to the intestinal phenotype of TRα-/- mice.273,275
Despite the variation between patients, the biochemical abnormalities (increased 
T3/T4 and T3/rT3 ratios) found in most RTHα cases may reflect altered peripheral TH 
metabolism by deiodinases. As indicated by marked suppression of serum TSH by 
relatively small increases in serum (F)T4 in cases, central feedback regulation of the 
HPT-axis is preserved, favouring a minor contribution of TRα1 but predominant role for 
TRβ isoforms in regulation of the HPT-axis.153,200,264 Increased T3 and decreased rT3 levels 
could be due to up-regulation of hepatic DIO1 or reduced DIO3 activity as has been 
shown in studies with TRα mutant mice.112,276 DIO1 is expressed in liver, kidney, and 
thyroid and plays an important role in the production of the bioactive T3 from T4 and 
the clearance of rT3. DIO3 is present in brain, skin, placenta, and pregnant uterus where 
it inactivates T3 and T4 and hereby protects these tissues from excess active TH. T3/T4 
and T3/rT3 ratios are considered to be sensitive indicators of peripheral TH metabolism 
and are relatively independent of variations in serum binding proteins or thyroidal T4 
production.
The abnormalities in thyroid function seen in RTHα patients do not completely cor-
relate with observations made in different TRα mutant mouse models, since overt 
thyroid dysfunction was only documented in TRα1-PV and TRα1-P398H mice and not in 
TRα1-R384C and TRα1-L400R animals.111–114,207 It has been shown that TRα1-PV mutant 
mice have markedly increased levels of kidney and liver DIO1, while T3-induced DIO3 
expression in cortex is decreased, resulting in a decreased clearance of T3.277
Anaemia, with normal haematinics (iron, vitamin B12, folate) and haemolytic indices 
(reticulocyte count, circulating haptoglobin and lactate dehydrogenase), is a near-uni-
versal characteristic in RTHα. Usually a normocytic normochromic anaemia, although 
the mean corpuscular volume was raised in 3 cases.151,188,193 Several human studies have 
documented an association between hypothyroidism and anaemia.201,202 In addition, 
data from animal models support an important role for TRα in erythropoiesis.203–206 The 
molecular mechanisms underlying anaemia in RTHα patients remain to be elucidated.
Spontaneous conception and uneventful pregnancy has been observed in untreated 
females with RTHα, despite varying features of hypothyroidism.154 Maternal and paternal 
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inheritance of TRα mutations suggests that transmission of TRα mutations from parents 
to offspring is less impaired in humans than in mice.112
The observation that several affected relatives of RTHα index cases reached adulthood 
without identification of medical problems supports the mild character of these muta-
tions.154,221 Similar to RTHβ, individuals harbouring the same mutation can exhibit sig-
nificant variation in severity of clinical phenotypes and it is conceivable that additional 
variation (e.g. in genes encoding cofactors of TH action) could mediate this.7
Treatment
Several RTHα patients have been treated with LT4 and as yet, no other therapeutic 
approaches have been explored.151,153,154,188,192,193,221 Overall, 11 patients have been LT4-
treated: in 8 cases LT4 treatment was initiated from (early) childhood and in 3 cases LT4 
was started in adult life. The duration of LT4 treatment in childhood cases ranges from 
1 year in a girl with a D211G mutation to 5 and 6 years in girls with F397fs406X and 
E403X mutations in TRα, respectively, and 12 years in a girl with a C380fs388X muta-
tion.130,151,154,221 Adult cases have received LT4 supplementation for 1 month to over 40 
years.154,188,192,193 LT4 treatment had beneficial effects on several RTHα characteristics, as 
described below. In addition, initiation of LT4 therapy at a young age also had beneficial 
developmental effects in childhood cases.
LT4 treatment, even in typical physiological doses, resulted in suppressed TSH 
levels in all RTHα patients, implying an intact feedback mechanism within the HPT 
axis.151,154,188,192,193,221 In addition, serum (F)T4 and rT3 levels normalize while serum T3 
remains elevated. Some peripheral markers of TH action also responded to LT4 therapy, 
with a rise in serum SHBG and IGF1 levels together with a decrease in serum creatine 
kinase and LDL cholesterol levels.151,153,154,188,192,221 In most cases, LT4 therapy has a ben-
eficial effect on constipation but has no effect on anaemia and a blunted effect on 
cardiac function.
LT4 treatment initiated at young age resulted in a catch-up growth and improved 
overall height in several patients, and the addition of growth hormone did not further 
improve growth.151,153,221 Moreover, in one childhood case, harboring a TRα mutation 
whose dysfunction is reversible at higher TH levels, during LT4 treatment muscle 
hypotonia improved and motor development accelerated.221 LT4 treatment from early 
childhood in 3 related patients, with a relatively mild mutation (A263V) in TRα, may 
have ameliorated their phenotype and alleviated some symptoms (e.g. dyspraxia) in 
adulthood.192
In contrast, initiation of LT4 at the age of 2.5 years in a girl with the most upstream 
C380fs387X frameshift mutation did not ameliorate her growth retardation, and car-
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diac and renal problems, which may reflect ongoing tissue hypothyroidism, despite 
LT4 treatment. Concordant with this LT4 treatment of TRα1-PV mutant mice, harboring 
a deleterious frame-shift mutation, did not improve skeletal abnormalities or other 
abnormal phenotypes.212,278,279 In patients with frame-shift mutations involving the 
carboxyterminal region of TRα1, the severity of the clinical phenotype and also the 
effect of LT4 therapy may vary depending on the exact location of these mutations and 
the extent to which this domain is disrupted.153,154,188
Several affected relatives of RTHα index patients with missense mutations, who had 
only been diagnosed after screening of family members of the index case, showed 
an amelioration of clinical features with time. Similar observations have been made 
in TRα1-R384C mice, which showed severe but transient impairment of post-natal 
development and growth. Alterations in TH levels were also only evident in these mice 
during the juvenile period.111,207,208 The mechanisms underlying such age-dependent 
amelioration of phenotypes associated with some TRα1 mutations are unknown.
Overall, the effects observed with LT4 treatment of RTHα patients corresponds with the 
expected pattern, with TH resistance in organs predominantly expressing TRα1 (bone, 
skeletal muscle, gastrointestinal tract, myocardium, brain) and retention of TH sensitiv-
ity in TRβ-expressing tissues (hypothalamus, pituitary, liver). Indeed, chronic exposure 
to excess TH in LT4-treated RTHα patients could result in unwanted toxicities in TRβ-
expressing tissues. The observation that LT4 treatment in RTHα further raises SHBG and 
(F)T3 levels with suppression of TSH, supports this possibility.
In this regard, future therapies that could selectively target TRα1, e.g. high affinity 
TRα1-selective agonists, are of great interest. Such TRα1-specific thyromimetics could 
activate normal TRα1 and potentially, in higher dosages, overcome the impaired func-
tion of mutant TRα1. Alternative therapeutic strategies could involve targeting the 
dominant-negative effect of mutant TRα1 on its wild-type counterpart, either by in-
hibiting histone deacetylase activity or abrogating the interaction of mutant TRα1 with 
the corepressor complex. Studies in mice harbouring the TRα1-PV mutation showed 
that aberrant recruitment of NCoR by mutant TRα1 contributes to the phenotype and 
the severity of this can be partially reversed by introducing a mutation in NCoR that 
abrogates its interaction with TRα1.280 In an alternative approach, TRα1PV-mediated 
repression could be relieved by administration of suberoylanilide hydroxyamic acid 
(SAHA), a histone deacetylase inhibitor, also ameliorating the phenotypic abnormalities 
in these mice.281–283
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Conclusions
The clinical consequences of mutations in THRA are variable in extent and severity. This 
applies both to patients with different TRα mutations and to individuals in a family 
harbouring the same mutation. Similar to RTHβ, the observation that affected relatives 
with a relatively mild phenotype in some RTHα families were only diagnosed by genetic 
screening after initial diagnosis of the index cases supports the hypothesis that the 
incidence of RTHα could be much higher than currently estimated. Given the strong 
homology between the TRα1 and TRβ receptors and similar localization pattern of 
both TRα and TRβ mutations, the incidence of RTHα could correspond to that of RTHβ 
(1:40,000).
RTHα should be suspected in subjects when even mild clinical features of hypothyroid-
ism are present along with a normal TSH, a high serum T3/T4 or T3/rT3 ratio. RTHα 
patients, particularly those with mild mutations or diagnosed in early life, may benefit 
particularly from LT4 treatment. Further research to develop alternative treatment op-
tions and clinical biomarkers which better reflect the effects of LT4 treatment in both 
TRα- and TRβ-expressing tissues will be of great value.
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Introduction
Thyroid hormone (TH) is essential for normal development and function of all tissues 
in the human body. The intracellular TH availability is dependent on transmembrane 
transport proteins and deiodinating enzymes (DIOs) that mediate the conversion of 
T4 to T3 (DIO1 and DIO2) and the degradation of T3 and T4 into inactive metabolites 
(DIO3). TH action takes place in the nucleus, where the bioactive T3 binds to thyroid 
hormone receptors (TRs) and thereby modulates transcription of TH target genes. This 
thesis mainly focusses on two key players in TH homeostasis: TH transport and TH ac-
tion, in both health and disease.
First, we investigated whether the well-known TH transporters MCT8 and MCT10 in-
crease the availability of TH for the nuclear TRs rather than generate a rapid equilibrium 
between TH in- and efflux. Furthermore, we studied several liver-specific TH transport-
ers in their transport of both TH and TH analogs, such as eprotirome and GC-1.
Next, we identified a number of patients with mutations in the thyroid hormone recep-
tor alpha (TRα). We investigated the impact of the different mutations on TH action and 
made phenotype-genotype correlations. Finally, we studied the role of TH and TRα in 
human erythropoiesis.
In this chapter, the relevance of the performed studies is discussed in view of the cur-
rent literature and further research strategies are explored.
Thyroid hormone transport
Lack of thyroid hormone (TH) in early life results in severe developmental impair-
ment.1,115,116 To mediate its effects, TH must first be transported across the plasma mem-
brane by TH transporters. Several TH transporters from different families have been 
identified, such as monocarboxylate transporters (MCT), L-type amino acid transporters 
(LAT), organic anion transporting polypeptides (OATP), and bile acid transporters (such 
as the sodium taurocholate co-transporting polypeptide, NTCP)..117
MCT8 and MCT10
MCT8 and MCT10 are two highly homologous monocarboxylate transporters. Both 
transporters show high activity and specificity for TH transport, while MCT10 also 
transports aromatic amino acids. MCT8 is important for TH supply to the brain, since 
this transporter is expressed in endothelial cells of the blood-brain barrier (BBB) as well 
as in neurons.14,24,25,118
Apart from influx, MCT8 and MCT10 also facilitate efflux of TH.24,36 Therefore, it remained 
unclear whether MCT8 and MCT10 increase the availability of TH at the nuclear level 
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or merely establish a more rapid equilibrium between uptake and efflux at the plasma 
membrane. In chapter 2 we addressed this question, using cells transfected with MCT8 
or MCT10, together with TRβ1 and a T3 response element-driven luciferase construct 
to measure T3-dependent transcriptional activity. In addition, to study the effects of 
MCT8 and MCT10 on the metabolism of T3, cells were co-transfected with the type 3 
deiodinase (D3), which is a plasma membrane resident protein.127
Our results show that overexpression of MCT8 or MCT10 markedly stimulates T3 uptake, 
leading to an increased intracellular T3 concentration. However, the T3 availability for 
the nuclear TRs was only modestly increased, indicating a rapidly established equi-
librium between uptake and efflux of T3 at the plasma membrane. This was further 
supported by the fact that inhibition of T3 efflux by the intracellular binding protein 
CRYM137 resulted in an increased availability of T3 in the nucleus. It is likely that MCT8 
and MCT10 have a much greater effect on intracellular T3 availability at the cell periph-
ery than at the cell nucleus. This is supported by the observation that intracellular T3 
metabolism by D3 was greatly stimulated in cells co-transfected with MCT8 or MCT10, 
suggesting that the available T3 concentration at the D3 active center was much less 
affected by the rapid T3 efflux mediated by MCT8 or MCT10.
Mutations in MCT8 are associated with the Allan-Herndon-Dudley syndrome (AHDS), 
an X-linked disorder leading to severe psychomotor retardation due to a hypothyroid 
state in the brain during development.30,31 Interestingly, it has been demonstrated that 
MCT8 mutations may differentially affect cellular uptake and efflux of T3, leading to 
distinct neurological abnormalities in AHDS patients.285 In addition, studies in MCT8 
knock-out mice, which have similar abnormal thyroid function tests as AHDS patients, 
show that T3 efflux is not affected in these animals.26,39 These observations underscore 
the biological relevance of the efflux function of MCT8, which likely depends on the 
cellular context and may have different consequences in different tissues.286
MCT8 and MCT10 stimulate T3 metabolism by co-transfected D3, however, the rapid 
degradation by D3 also reduces the nuclear availability of T3. D3 is highly expressed in 
fetal tissues and the expression levels rapidly decrease after birth,133,134,176 suggesting 
that prevention of premature T3 action is important for developmental processes. This 
is supported by the observation that D3 KO mice show phenotypic abnormalities due 
to excessive T3 levels during fetal and early neonatal life.136,287 In addition, a more recent 
study showed that MCT8 deletion markedly improves the phenotype of D3 deficient 
mice, eliminating neonatal lethality and significantly ameliorating their growth retar-
dation. Altogether, this provides more evidence for the interdependent relationship 
between TH transport into cells by MCT8 and the deiodination process by D3.288
In humans, the strongest MCT10 expression was reported in pancreas and skeletal 
muscle, suggesting the need for TH and/or aromatic acids transport in this organ.29 
Human MCT10 prefers T3 over T4 uptake and appears to facilitate efflux less effectively 
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than MCT8.25 Interestingly, chicken MCT10 was a better T3 exporter than both chicken 
MCT8 and human MCT10.289 More studies into mechanisms of TH uptake and efflux 
regulation by MCT10 are required for a better understanding of its role in developmen-
tal processes and the possible consequences of mutations in this transporter.
Liver specific transporters
OATPs represent a large family of homologous proteins, many of which have been 
shown to transport iodothyronines and their sulfate conjugates.55,61,290,291 OATP1B1 and 
OATP1B3 are expressed specifically in the liver, while OATP1A2 is expressed in brain, 
liver and kidney. OATPs transport their substrates in a sodium-independent manner. 
This is in contrast to the bile acid transporter NTCP, which is also expressed in liver and 
facilitates TH uptake in a sodium-dependent manner.20,22,34,77
Besides their role in the enterohepatic circulation of bile salts, liver-specific transporters, 
such as OATPs and NTCP, are important in the maintenance of lipid and energy homeo-
stasis by TH.105,215,218 Dyslipidemia and metabolic syndrome are major health concerns 
and some aspects of these diseases can be ameliorated by manipulating TH signaling 
pathways.170,292,293 TH plays an important role in lipid metabolism, effects of which are 
mediated by stimulation of the TRβ1 receptor in liver by T3. In liver, TRβ1 has direct 
effects on bile acid and fatty acid synthesis by regulating the expression of important 
factors such as CYP7a1, acetyl CoA carboxylase, fatty acid synthase, and carbohydrate 
response element binding protein.215
Therefore, liver-specific TRβ-selective analogs can be ideal candidates to reduce serum 
cholesterol levels without adverse thyromimetic effects.145 To achieve this, it is neces-
sary to target lipid-lowering TH analogs to the liver through liver-specific transporters.
In chapter 3 and 4 we gained more insight in the characteristics of different TH 
transporters and their ability to transport the TH analogs eprotirome and GC-1. Epro-
tirome and GC-1 are thyromimetics that preferentially bind to TRβ and accumulate in 
the liver.170,172,294,295 In animals, both TH analogs show a reduction of LDL cholesterol, 
triglycerides and lipoprotein-a.296
Using transiently transfected COS1, JEG3 and HEK293 cells, we showed that eprotirome 
and GC-1 are effectively transported into the cells by the liver-specific transporters 
NTCP, OATP1B1, OATP1B3, but not by OATP1A2. In addition, these transporters induced 
TR-mediated action of both eprotirome and GC-1, indicating that cellular uptake of 
eprotirome and GC-1 by these transporters resulted in an increased nuclear availability 
of these TH analogs. However, when using JEG3 and HEK293 cells, a significant uptake 
of eprotirome and GC-1 was also seen in cells transfected with empty vector. This sug-
gests that other endogenous transporters can transport these TH analogs into other 
tissues, since JEG3 and HEK293 cells represent placenta and kidney cells, respectively.
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Remarkably, an earlier study with eprotirome in dogs was discontinued due to unwant-
ed side effects of eprotirome in cartilage (Karo Bio. Karo Bio terminates the eprotirome 
program. [Press release ]: www.karobio.com; 2012). One possible explanation for this 
could be that other transporters are expressed in cartilage, which are also involved in 
eprotirome (and possibly GC-1) uptake. The expression of the liver-specific transport-
ers NTCP, OATP1B1, and OATP1B3 is not reported in human cartilage,163 which might 
indeed point towards the involvement of other transporters in this tissue. However, it 
cannot be excluded that the expression of NTCP, OATP1B1 and OATP1B3 is different in 
dog cartilage compared to human cartilage.
In humans, short eprotirome treatment of patients with hypercholesterolemia showed 
promising results. However, it is possible that deleterious effects can emerge during 
longer treatment duration.146,162,297,298 Therefore, a better understanding of the adverse 
effects of eprotirome in the phase III trial in dogs must be obtained before more studies 
with lipid-lowering TH analogs in humans can be conducted. Was the cartilage damage 
a consequence of direct interactions between eprotirome and TRs or other proteins? 
Did eprotirome act on the HPT-axis and influenced cartilage indirectly by inducing mild 
hypothyroidism? Or did eprotirome have effects on cartilage via effects in the liver?
Nevertheless, our findings illustrate that TH analogs may be targeted to specific tissues, 
depending on the transporters they express. Still, it is important to gain further insight 
in the mechanisms of action of these transporters and their tissue specificity. In addi-
tion, it is necessary to investigate possible interactions between uptake of eprotirome, 
GC-1 and other substrates transported by these transporters, e.g. bile acids.
Thyroid hormone action
T3 has its action via nuclear TH receptors (TRs). TRs preferentially form heterodimers 
with retinoid X receptors (RXRs) and regulate target gene expression by binding to TH 
response elements (TREs) in target gene bodies.7,105
In humans, TR isoforms (TRα1, TRα2, TRβ1, TRβ2) are encoded by two genes (THRA and 
THRB) on chromosomes 17 and 3, respectively, and show differing tissue expression 
patterns.67,108,109
RTHβ
Since 1986 it has been known that heterozygous mutations in THRB result in Resistance 
to Thyroid Hormone β (RTHβ). Patients with RTHβ are characterized by elevated serum 
TH levels, a non-suppressed TSH, and a variable phenotype comprising goiter, tachycar-
dia and raised energy expenditure.7,110
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RTHα
Human TRα and TRβ are highly homologous, showing an overall 80 % amino acid iden-
tity. In an attempt to predict the clinical consequences of mutations in THRA, several 
knock-in and knock-out mouse models have been generated. However all mice lacked 
a clear biochemical thyroid phenotype.111–114 As a consequence, the first patients with 
mutations in THRA were only identified in 2012.
In chapters 5 and 6 we characterized 12 newly identified RTHα patients from 4 dif-
ferent families with 4 distinct THRA mutations.154,179 These mutations varied regarding 
severity, including missense mutations that led to a relatively mild phenotype in several 
RTHα patients. This enabled us to recognize the most frequent abnormalities, associ-
ated with THRA mutations, and thus allow easier identification of new patients. The 
characterization of a large family harboring the same mutation provided us with more 
insight into the variation of the RTHα phenotype. In addition, we studied the effects of 
levothyroxine treatment in patients with distinct mutations with different responses to 
therapy, depending on the severity of the mutation.
The severity of the clinical phenotype of RTHα patients seems to be associated with 
the location and type of mutation in THRA. The most frequent abnormalities observed 
include an abnormal combination of thyroid function tests, growth and developmental 
delay, constipation, and anaemia.
Several studies in humans and animal models have indicated an association between 
hypothyroidism and anaemia as well as an important role for TRα in erythropoiesis.201–206
Given the observations that RTHα patients have anaemia and that both T3 and TRα are 
important in the development of red blood cells, we hypothesized that mutations in 
TRα affect the fate decision between proliferation and differentiation of erythroblasts 
in human erythropoiesis. To investigate this, we studied the maturation of erythroid 
progenitor cells (HEPs) of RTHα patients with different TRα mutations ex vivo. In chapter 
7 we showed that both TH and TRα are involved in human erythropoiesis. Our results 
point towards a delay in developmental dynamics of RTHα HEPs, displaying sustained 
proliferation and delayed onset of spontaneous differentiation compared to control 
HEPs. This delay in development dynamics of RTHα HEPs was evident from both mor-
phological appearance and the expression of stage-specific cell surface markers. It is 
likely that the intrinsic difference between RTHα and control HEPs that we found, is only 
one of many molecular mechanisms underlying anaemia in RTHα patients.
Lastly, we present an overview of all RTHα patients identified so far (28 cases from 15 
different families) in chapter 8.151,153,154,178,179,188,189,192,193
In this chapter we discuss the heterogeneous clinical consequences of mutations in 
THRA. This applies to both patients with different TRα mutations and family members 
with the same mutation. The observation that, similar as for RTHβ, several relatives with 
a relatively mild phenotype were only diagnosed because of the initial diagnosis in 
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the index cases supports the hypothesis that the incidence of RTHα could be much 
higher than currently estimated. Given the strong homology between the TRα1 and 
TRβ1 receptors and a similar localization pattern of both TRα and TRβ mutations, the 
RTHα incidence could correspond to the incidence of RTHβ (1:40,000).7
RTHα should be suspected in subjects when even mild clinical features of hypothy-
roidism are present along with a normal TSH, a high serum T3/rT3 ratio, and anaemia. 
Especially RTHα patients with mild mutations and when diagnosed at young age 
seem to benefit from LT4 treatment. Further studies on treatment options and clinical 
biomarkers, which reflect the effects of LT4 treatment in both TRα- and TRβ-expressing 
tissues, will be of great value.
Concluding remarks
TH transport and action are two key players involved in TH homeostasis. In the last 
decades, research on normal thyroid physiology and molecular mechanisms underly-
ing thyroid diseases has provided crucial new insights into the role of this important 
hormone.
This thesis expands our knowledge on the molecular characteristics of the thyroid hor-
mone transporters MCT8 and MCT10, by showing that both transporters have a greater 
effect on intracellular T3 availability at the cell periphery than at the cell nucleus due to 
the rapidly established equilibrium between uptake and efflux of T3. This observation 
underscores the biological relevance of the efflux function of MCT8, which contributes 
to the understanding of the distinct phenotypes in AHDS patients.
Furthermore, this thesis describes the involvement of liver-specific transporters NTCP, 
OATP1B1 and OATP1B3 in targeting lipid-lowering TH analogs such as eprotirome and 
GC-1 to the liver. The fact that TH analogs may be targeted to particular tissues by usage 
of specific transporters provides new perspectives for future therapeutical purposes. 
Here, it remains important to exclude the possibility that the identified transporters are 
present in other tissues than the target tissue.
Lastly, this thesis describes both the phenotype and genotype of various RTHα patients 
in detail, including the effects of levothyroxine treatment in patients with different 
mutations. These studies facilitate the identification of other RTHα patients and thus 
contribute to the development of new treatment possibilities.
In the next years, more pieces will be added to the big puzzle, completing our knowl-
edge on thyroid function in health and disease including better therapeutic options for 
patient care.
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Thyroid hormone (TH) is important for normal development and cellular metabolism. 
The thyroid gland secretes predominantly the prohormone T4 ad to a lesser extent the 
bioactive hormone T3. Hypothyroidism, a deficiency of TH, may result to symptoms 
such as fatigue, constipation, cold intolerance and weight gain. Because of the impor-
tance of TH for the developing brain, hypothyroidism may lead to severe defects in 
motor and mental development as illustrated by patients with untreated congenital 
hypothyroidism. In contrast, an excess of thyroid hormone (hyperthyroidism) can cause 
agitation, heat intolerance and weight loss.
Cellular TH homeostasis is regulated at different levels: 1) TH transporters mediate 
transport of the hormones across the plasma membrane, 2) different deiodinating 
enzymes in the cytoplasm activate the prohormone T4 to the bioactive T3 (deiodinases 
type 1 and 2) and inactivate T4 and T3 by the conversion to the inactive metabolites 
rT3 and T2 (deiodinase type 3), 3) T3 binds to TH receptors (TRs) in the nucleus, which 
modulate the expression of T3-target genes. The intracellular availability of TH is depen-
dent on adequate function of transporter proteins and deiodinating enzymes, while 
TRs mediate TH action. Under physiological conditions, these different levels of control 
can precisely modify TH cellular content and action. Changes in any of these key players 
of peripheral TH regulation can alter TH signaling, for example as a consequence of 
altered cellular circumstances. However, defects in these key players of local TH homeo-
stasis may cause disease. This thesis presents studies in which TH regulation has been 
investigated under both normal and pathological conditions, with the main focus on 
TH transport and action.
Chapter 1 provides a general background of normal TH physiology. The synthesis and 
importance of TH are further elucidated. Particular attention is paid to cellular transport 
of TH by different TH transporters, TH metabolism by different deiodinases and TH ac-
tion via TRs. Lastly, the general aims and outline of this theses are presented.
Chapter 2 reports on the well known TH transporters MCT8 and MCT10, which mediate 
TH transport across the plasma membrane but also facilitate TH efflux out of cells. The 
objective of this study was to investigate if MCT8 and MCT10 increase the availability 
of TH for the nuclear TRs rather than generate a rapid equilibrium between TH in- and 
efflux across the plasma membrane. The results suggest that MCT8 and MT10, by virtue 
of their bidirectional TH transport, have less effect on steady-state nuclear TH levels 
than on TH levels at the cell periphery where D3 is located. The presence of MCT8 and 
MCT10 increase TH metabolism by D3 without increasing TH action in the nucleus. By 
preventing cellar efflux, the TH binding protein CRYM appears to increase the nuclear 
availability of TH.
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In chapter 3 and 4 the characteristics of different human TH transporters in liver (OATPs 
and NTCPs) are explored. In chapter 3 we demonstrate that human NTCP is a highly ef-
fective transporter of the TH analog eprotirome. In mice, eprotirome is also transported 
by mouse Ntcp, however the pharmacokinetics of eprotirome were not affected by 
Ntcp deficiency.
In chapter 4 we extend the repertoire of liver transporters and show that the transport-
ers OATP1A2, OATP1B1, OATP1B3, and NTCP can transport the TH analog GC-1, but also 
T3 and T4, across the plasma membrane and thus enable the activation of the nuclear 
TRβ1 receptor. This may explain the liver-selective action of these TH analogs. In addi-
tion, these findings provide insights into how TH analogs may be targeted to different 
tissues depending on the presence of specific transporters in these tissues.
In chapter 5 we describe the youngest patient identified with resistance to TH (RTHα) 
due to a D211G missense mutation in both TRα1 and TRα2, together with her father 
who is also affected. In 2012, the first patients with RTHα due to inactivating mutations 
in TRα were identified. These patients are characterized by growth retardation, variable 
motor and cognitive defects, macrocephaly and abnormal thyroid function tests. In ad-
dition to these symptoms, this very young girl (18 months) with the D211G mutation in 
TRα1 and TRα2 displayed severe axial hypotonia. Early levothyroxine (LT4) treatment dit 
not only ameliorate her muscle tone, but also improved her growth and development. 
In addition, we studied the consequences of the mutation for TRα1/2 receptor function 
in vitro. The missense mutation led to a decreased transcriptional activity of TRα1, which 
could be overcome by higher T3 levels. The mutation did not affect the function of 
TRα2, which already in normal conditions can not bind T3.
Chapter 6 describes a total of 10 RTHα patients with three different mutations in TRα 
(C380fs387X, R384H, A263S). This large case series enables us to report on the diver-
sity in the RTHα phenotype and compare the phenotypes of both affected and non-
affected individuals from a family with the same mutation. The most frequent RTHα 
characteristics within this group of patients were anemia, constipation and a delay in 
reaching one or more developmental milestones. In addition, patients showed high/
high-normal (F)T3 and low/normal (F)T4 and rT3 levels with a normal TSH. Furthermore, 
we studied the effects of the mutations on the TRα1/2 receptor function in vitro.
In chapter 7 we report on the role of TH and TRα in human erythropoiesis. Animal 
studies suggest an important role for TH and TRα in the maturation of erythroid pro-
genitor cells. In addition, almost all RTHα patients have mild anemia, the pathogenesis 
of which is unknown. We show that different TRα mutations affect the balane between 
proliferation and differentiation of erythroid prgenitor cells in human erythropoiesis, 
which likely contributes to the anemia seen in RTHα patients.
In chapter 8 we present an overview of all RTHα patients identified so far (28 cases 
from 15 different families). We discuss the variation in phenotypes of the different RTHα 
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patients and describe the consequences of the different mutations on the receptor 
function in vitro. Hereby, we try to establish phenotyope-genotype correlations and we 
report on the association of the severity of the phenoytpe with the location and type of 
mutation in THRA. Lastly, we describe the effects of levothyroxine treatment in patients 
with distinct mutations with different responses to therapy, depending on the severity 
of the mutation.
In chapter 9 the results presented in this thesis are discussed in view of the current 
literature. The possible implications ot the findings are explored and further directions 
for future research in the light of this thesis are provided.
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Schildklierhormoon (SKH) wordt geproduceerd door de schildklier, een vlindervormig 
orgaan gelegen in de hals dat voornamelijk het prohormoon T4 en in mindere mate 
het bioactieve hormoon T3 afscheidt. SKH is cruciaal voor de normale ontwikkeling van 
vrijwel alle weefsels in het lichaam. Een tekort aan SKH (hypothyreoïdie) resulteert in 
klinische symptomen als moeheid, obstipatie, koude-intolerantie en gewichtstoename. 
Daarentegen leidt een overschot aan SKH (hyperthyreoïdie) juist tot gejaagdheid, 
warmte-intolerantie en gewichtsverlies. Het belang van SKH voor de hersenontwikke-
ling van de foetus wordt tevens benadrukt door patiënten met onbehandelde conge-
nitale hypothyreoïdie, die zich presenteren met ernstige verstandelijke en motorische 
beperkingen.
De werking van SKH wordt in de cel op verschillende niveaus gereguleerd: 1) in de 
celwand zorgen SKH transporters voor de beschikbaarheid van SKH in de cel, 2) in de 
cel zorgen verschillende enzymen (dejodases) voor de omzetting van het prohormoon 
T4 naar het bioactieve hormoon T3 (dejodase type 1 en 2) en de omzetting van T4 en 
T3 naar de inactieve metabolieten rT3 en T2 (dejodase type 3), 3) in de celkern bindt 
T3 aan SKH receptoren (TRs), die fungeren als transcriptiefactoren en de expressie van 
T3-gevoelige genen activeren of onderdrukken. Binnen de SKH homeostase reguleren 
transporters en dejodases dus de SKH concentratie in de cel terwijl de SKH receptoren 
van belang zijn bij de uiteindelijke SKH actie. Een goede interactie tussen SKH trans-
porters, dejodases en kernreceptoren zorgt in normale omstandigheden voor een 
nauwkeurige SKH concentratie in de cel, aangepast naar de behoefte van het lichaam. 
Veranderingen in de activiteit van één of meerdere van deze schakels kunnen onder-
deel zijn van aanpassingsmechanismen, ten gevolge van gewijzigde omstandigheden. 
Wanneer dit niet het geval is en er sprake is van een defect in één van deze schakels, 
kan dit resulteren in verschillende ziekteprocessen. In dit proefschrift worden studies 
beschreven waarin de verschillende niveaus van SKH homeostase onder normale en 
abnormale omstandigheden zijn onderzocht, met de nadruk op SKH transport en actie.
In hoofdstuk 1 wordt een algemene achtergrond van de SKH fysiologie beschreven. 
De productie van SKH door de schildklier en het belang van SKH worden nader toe-
gelicht. Vervolgens wordt er dieper ingegaan op het cellulaire transport van SKH door 
verschillende SKH transporters, het SKH metabolisme door de dejodases en de SKH 
actie via de kernreceptoren. Het hoofdstuk wordt afgesloten met de hoofdlijnen en 
doelstellingen van dit proefschrift.
Hoofdstuk 2 beschrijft een studie met de bekende SKH transporters MCT8 en MCT10. 
De in de celmembraan gelegen MCT8 en MCT10 zorgen voor SKH transport vanuit 
het bloed naar de cellen. Echter faciliteren deze transporters ook SKH efflux uit de 
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cellen. Het doel van deze studie was daarom te onderzoeken of MCT8 en MCT10 
de beschikbaarheid van SKH voor de kernreceptoren verhogen of dat er eerder een 
equilibrium wordt bereikt tussen SKH in- en efflux. De resultaten suggereren dat MCT8 
en MCT10, vanwege hun bidirectionele SKH transport, meer invloed uitoefenen op de 
SKH concentratie in het cytoplasma dan in de celkern, waar de SKH receptoren zich 
bevinden. Aanwezigheid van MCT8 en MCT10 zorgt voor een toegenomen SKH me-
tabolisme door het type 3 dejodase in het cytoplasma maar niet voor meer SKH actie 
in de celkern. Echter, wanneer de SKH efflux wordt tegengegaan door toevoeging van 
CRYM (een SKH bindend eiwit in het cytoplasma), neemt de SKH concentratie in de 
kern wel toe.
In de hoofdstukken 3 en 4 worden de kenmerken van verschillende humane SKH 
transporters (OATPs en NTCPs) in de lever bestudeerd en onderling vergeleken. In 
hoofdstuk 3 laten we zien dat de humane NTCP het SKH analogon eprotirome ef-
fectief transporteert. In muizen wordt eprotirome ook door muis Ntcp getransporteerd, 
echter wordt de farmacokinetiek van eprotirome niet beïnvloed door afwezigheid van 
Ntcp. In hoofdstuk 4 breiden we het repertoire aan levertransporters uit en laten we 
zien dat de transporters OATP1A2, OATP1B1, OATP1B3, en NTCP in staat zijn om het 
SKH analogon GC-1, maar ook T3 en T4, over het plasmamembraan te transporteren en 
vervolgens de SKH receptor TRβ1 te activeren. Dit kan de leverselectiviteit van deze SKH 
analoga verklaren. Deze bevindingen geven tevens inzicht in hoe SKH analoga gericht 
gebruikt kunnen worden voor verschillende weefsels, op basis van de aanwezigheid 
van specifieke transporters in deze weefsels.
In hoofdstuk 5 beschrijven we de jongste patiënt met schildklierhormoonresistentie 
(RTHα) door een D211G puntmutatie in de SKH receptoren TRα1 en TRα2 samen met 
haar vader, die dezelfde mutatie heeft. In 2012 zijn de eerste patiënten met RTHα 
geïdentificeerd. Deze patiënten worden gekenmerkt door groeiachterstand, mentale 
en motorische beperkingen, een vergrote schedelomtrek (macrocefalie) en abnormale 
SKH waarden in het bloed. Dit 18 maanden oude meisje, met de D211G mutatie in TRα1 
en TRα2, had naast bovengenoemde symptomen voornamelijk last van spierzwakte 
(hypotonie) in haar ledematen. Behandeling met SKH (levothyroxine) verbeterde niet 
alleen deze spierzwakte maar versnelde ook haar groei en ontwikkeling. Tevens onder-
zochten we de gevolgen van deze mutatie voor de functie van TRα1 en TRα2 in vitro. De 
resultaten laten zien dat de gemuteerde receptor D211G-TRα1 in mindere mate T3 kan 
binden, wat overkomen kan worden door de T3 concentratie te verhogen. De mutatie 
had geen invloed op de functie van TRα2, die in normale omstandigheden al geen T3 
kan binden.
Hoofdstuk 6 omvat een gedetailleerde fenotypering van 10 RTHα patiënten met 3 
verschillende mutaties in TRα (C380fs387X, R384H, A263S). Dit grote aantal patiënten 
stelde ons in staat om de diversiteit binnen het RTHα fenotype te bestuderen en bin-
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nen één familie met dezelfde mutatie de aangedane individuen te vergelijken met 
hun niet-aangedane familieleden. De meest voorkomende RTHα kenmerken binnen 
deze patiëntengroep waren bloedarmoede (anemie), obstipatie en vertraging in het 
bereiken van één of meer ontwikkelingsmijlpalen. Daarbij hadden de patiënten hoog/
hoog-normale (F)T3 en laag/normale (F)T4 en rT3 concentraties bij een normaal TSH. 
Eveneens hebben we de effecten van de mutaties op de functie van TRα1 en TRα2 in 
vitro bestudeerd.
In hoofdstuk 7 onderzoeken we de rol van SKH en de SKH receptor TRα in de aanmaak 
van rode bloedcellen (erytropoëse) bij mensen. Verschillende muizenstudies suggere-
ren immers dat SKH en TRα een belangrijke rol spelen bij de rijping van rode bloedcel-
len (erytrocyten). Bovendien hebben bijna alle patiënten met RTHα een milde anemie, 
waarvan de oorzaak onbekend is. In deze studie tonen we aan dat verschillende TRα 
mutaties het rijpingsproces van erytrocyt voorlopercellen beïnvloeden, waarbij de 
balans tussen proliferatie en differentiatie van deze voorlopercellen verstoord is.
In hoofdstuk 8 presenteren we een overzicht van alle tot op heden geïdentificeerde 
RTHα patiënten (28 patiënten uit 15 verschillende families). We beschrijven de vari-
atie in het fenotype van de verschillende patiënten samen met de gevolgen van de 
verschillende mutaties voor de receptorfunctie in vitro. Hierbij proberen we fenotype-
genotype correlaties te maken en beschrijven we de associatie tussen de ernst van het 
fenotype en de locatie en type van de mutatie in THRA. Tenslotte beschrijven we de 
verschillen in respons op levothyroxine therapie in patiënten met diverse TRα mutaties 
en de samenhang met de ernst van de mutaties.
In hoofdstuk 9 worden de resultaten van dit proefschrift bediscussieerd en in een 
breder perspectief geplaatst aan de hand van de huidige literatuur. De mogelijke impli-
caties van de bevindingen worden verkend en suggesties voor verder onderzoek naar 
aanleiding van dit proefschrift worden aangedragen.
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